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Introduction
InTRoDUCTIon
Despite its natural appearance, pregnancy remains a formidable challenge to a woman's 
body. Most organs undergo substantial changes, in order to permit the growth of life 
inside her womb. These changes are particularly pronounced in the circulatory system. 
Vascular resistance falls early in pregnancy and triggers a rapid increase in blood volume 
and cardiac output up to 50% of pre-pregnancy values. The woman enters a state which 
is comparable to a continuous cardiovascular aerobic exercise of several months. It 
results in cardiac structural remodeling. This hemodynamic adaptation is essential to 
cope with the demands of a growing fetus.
Many complications in pregnancy either relate to or affect the cardiovascular system. 
The circulatory system is involved in most causes of both maternal and fetal mortal-
ity and severe morbidity. Hemodynamic maladaptation often results in hypertensive 
complications like pre-eclampsia and/or fetal growth restriction. In women with heart 
disease, a reduced cardiac reserve can compromise the ability to achieve or cope with 
the necessary changes. Other complications like postpartum hemorrhage and puerperal 
sepsis put a serious strain on the cardiovascular system. Even in preterm labor, a compli-
cation without apparent cardiovascular implications, tocolytic therapy has a substantial 
impact on the maternal hemodynamics.
The cardiovascular system can be considered as a closed circuit with the heart function-
ing as driving pump. On a macrocirculatory level, blood is distributed through elastic 
arteries to the organs. Exchange of nutrients and oxygen for carbon dioxide and waste 
products between cells and capillaries occurs at the microcirculatory level. Blood then 
returns to the heart trough the venous system. While blood is essentially circulating 
within this one continuous system, interactions between the different levels can be 
complex. As in many other conditions, discrepancies can be observed between changes 
in cardiac, macrovascular and microvascular function.
Given the importance of the circulatory system in normal and complicated pregnan-
cies, the potential for hemodynamic monitoring seems evident. This is best achieved 
using non-invasive methods and by assessing several component of the cardiovascular 
system enabling a total overview. Initial studies using right heart catheterization and 
cardiac ultrasound learned us a lot about the hemodynamics in both healthy and com-
plicated pregnancies. The invasive nature of the former limited its use in obstetrics. Fur-
thermore, lack of validation, availability and experience in pregnancy initially prevented 
widespread use by obstetricians of this technique. Nowadays, evolutions in ultrasound 
technology permit the combined installation of obstetric, cardiac and vascular software 
on the same devices. It provides the opportunity to simultaneously study the maternal, 
uteroplacental and fetal circulation. The intense multidisciplinary collaboration with 
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anesthesiologist and cardiologist within perinatal teams, enabling obstetric critical care, 
also increased the interest and knowledge in hemodynamics of obstetricians. Together 
it provided a new boost for hemodynamic research in pregnancy.
Recent technological developments also made non-invasive bedside analysis of 
the microcirculation feasible. This has led to some innovative insights in other hemo-
dynamic conditions like sepsis and shock. Coupling microvascular to macrovascular 
findings potentially provides a more complete overview and offers new perspectives 
in understanding the pathophysiology of complex hemodynamics of pregnant women.
The focus of this thesis is to address the hemodynamics in several pregnancy complica-
tions. The specific aims of the thesis can be summarized as follows;
1. to validate transthoracic echocardiography for cardiac output measurements in 
pregnant women
2. to evaluate the feasibility of microvascular perfusion assessment with Sidestream 
Darkfield Imaging (SDF) in pregnancy
3. to evaluate the potential of non-invasive hemodynamic profiling in various 
important pregnancy issues like
 a.  tocolysis
 b. pre-eclampsia
 c.  cardiac disease
After the introduction (chapter 1), we start by providing a general overview (chapter 2) 
of normal hemodynamic adaptation (chapter 2.1) and the microcirculation (chapter 2.2) 
in pregnant women.
Subsequently several techniques of non-invasive cardiovascular monitoring are ad-
dressed (chapter 3) with the validation of transthoracic echocardiography in pregnant 
women (chapter 3.1) and the use of cardiovascular magnetic resonance for accurate 
analysis of the effects of maternal positioning during each trimester of pregnancy 
(chapter 3.2).
We then describe the potential of cardiovascular monitoring in several pregnancy 
complications (chapter 4). The hemodynamic effects on mother and fetus of nifedip-
ine for tocolysis (chapter 4.1) and nicardipine for hypertensive crisis (chapter 4.2) are 
observed in respectively normotensive and severe pre-eclamptic pregnant women. 
Microcirculatory perfusion using SDF is assessed in women with severe pre-eclampsia 
with and without HELLP syndrome (chapter 4.3).
In the fifth chapter we focus on women with cardiac disease (chapter 5). With improve-
ments in medical and surgical care, women with heart disease often reach reproductive 
age. We provide an overview of the management of pregnancy in women with cardiac 
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disease (chapter 5.1) and pregnancy outcomes of women with aortic valves substitutes 
are presented (chapter 5.2). Maternal hemodynamic adaptation to pregnancy (chapter 
5.3) and uteroplacental perfusion (chapter 5.4) are then analyzed in women with heart 
disease. We also address the issue of contraception in this population (chapter 5.5).
Chapter 6 contains a general discussion with reflections on further research.
Finally the results of the thesis are summarized in chapter 7.

Chapter 2.1
Normal cardiovascular  
adaptation to pregnancy
J Cornette
JW Roos-Hesselink
Book chapter in: Evidence-Based Cardiology Consult. London: Springer; 2014. 423-32.
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absTRaCT
Normal pregnancy is characterized by profound hemodynamic changes. These begin 
early in pregnancy and include a fall in vascular resistance which induces an increase in 
blood volume and stroke volume. Heart rate and cardiac output also rise. Arterial blood 
pressure is reduced. The adaptation is most prominent in the first half of pregnancy. 
To cope with these hemodynamic challenges, the left ventricle hypertrophies, thereby 
preserving systolic and diastolic function. Peripheral arterial resistance is decreased and 
compliance and distensibility are increased. Venous capacitance is greatly enhanced.
Uteroplacental blood flow augments with gestation to meet the increased needs of a 
growing fetus. Maternal cerebral blood flow is reduced. The influence of these major 
macrovascular changes on microvascular perfusion remains to be elucidated. During 
labor and delivery, cardiac output further rises. Postpartum, most hemodynamic pa-
rameters are rapidly reversed within weeks. Structural changes normalize within several 
months.
19
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InTRoDUCTIon
Normal pregnancy is a unique physiological state. It imposes a profound challenge to the 
cardiovascular system in a relatively short period of time. These changes are necessary 
to meet the increased demands of a rapidly growing feto-placental unit. Fortunately, 
most young women have sufficient cardiovascular reserve. However, failure to achieve 
these adaptations is associated with maternal and fetal complications like hypertensive 
disorders and fetal growth restriction 1-6. In women with preexisting heart disease, the 
work and volume load can cause deterioration in cardiac function 7-9.
The cardiovascular system can be viewed as a closed circuit. The heart is the central 
core organ directing flow between the venous and arterial systems. Exchange of 
oxygen, carbon dioxide, and nutrients, the final goal of the circulation, takes place on a 
microcirculatory level in the capillaries. While central hemodynamics have been mostly 
studied due to the prominence and accessibility of the heart and large artery systems, 
knowledge about the venous compartment, local organ perfusion systems, and the 
microcirculation are equally essential for a complete understanding of the normal physi-
ology of pregnancy. In this chapter we will discuss normal adaptation to pregnancy of 
the various components of the cardiovascular system.
MeTHoDs of CaRDIoVasCUlaR MonIToRIng
Hemodynamic monitoring is of clinical importance in the management of women with 
cardiovascular disease or severe hemodynamic complications like preeclampsia 10-13.
Secondly, it can be of scientific interest in both healthy pregnant women and various 
other pregnancy complications 14, 15. The ideal tool would be noninvasive, cheap, reliable, 
and easy to use at the bedside and offer a broad range of information. While different 
methods exist, experience and validation during pregnancy remain questionable for 
most of them 16, 17.
The pulmonary artery catheter (PAC) was often used in the 1980s and 1990s for the 
management of severe preeclampsia 10-13, 18-26. As it measures both cardiac output and 
filling pressures, it contributed to the pathophysiological knowledge of the condition 
10, 12, 23, 26. Its invasive nature along with controversy about clinical benefit has abated 
the enthusiasm for this method such that it is now rarely used in pregnant women 27, 28. 
However, it remains the gold standard for hemodynamic monitoring. Ideally, alterna-
tive methods should be validated in pregnancy against PAC 16. Experience with pulse 
contour analysis in pregnancy (PiCCO®, LIDCOTMplus, FloTracTM/VigileoTM) is limited 14, 29, 30.
Thoracic bioimpedance has mainly been used for longitudinal hemodynamic cardiac 
output measurements in research settings 31-35. While the method is simple, safe, and easy 
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to use, there are some serious concerns about its accuracy, reliability, and validation 16, 36. 
Thoracic bioreactance has been developed to overcome the limitations of impedance 
cardiography. It is based on changes in frequency rather than amplitude and therefore 
less susceptible to interference. Bioreactance holds promise but has not been validated 
and is rarely used in pregnancy 16, 17, 37. Esophageal Doppler output measurements in 
pregnancy have shown poor agreements with thermodilution, and the method is not 
well tolerated by all women 38.
Transthoracic echocardiography has become a preferential method for the hemody-
namic assessment of both ill and healthy pregnant women 39. Its noninvasive nature 
allows bedside measurements, including structural and functional information. Most 
advanced obstetric ultrasound devices can be equipped with supplemental car-
diac modules. As such, the method is accessible and can relatively easily be learned 
by caregivers with prior ultrasound experience. The Doppler method for cardiac output 
measurements has been validated in pregnancy against both thermodilution and Fick’s 
method 40-46. Additionally, ultrasound permits the investigation of peripheral arterial 
systems by the assessment of resistance and pulsatility indexes.
Finally cardiac MRI can be used in pregnancy 47. Although expensive, it offers accurate 
structural and hemodynamic information and can be of great benefit in women with 
structural heart disease with suboptimal ultrasound image resolution 48. While experi-
ence in pregnancy is limited, the technique is considered safe after the first trimester. 
Gadolinium contrast is best avoided 49.
CenTRal HeMoDynaMICs
Initiating Mechanisms
Cardiovascular adaptation starts very early in pregnancy. A primary fall in systemic and 
renal vascular tone induces an increase in the renal blood flow and glomerular filtration 
resulting in plasma volume expansion 50-54. This is accompanied by a further reduction in 
systemic vascular resistance (SVR) and arterial pressure as well as an increase in stroke 
volume (SV) and cardiac output (CO) 39, 51, 55-60.
A substantial part of the adaptation occurs before the placenta becomes functional at 
around 8–12 weeks. In fact, similar changes as in early pregnancy have been observed in 
the luteal phase of the menstrual cycle 61. It means that adaptation to pregnancy starts 
soon after ovulation and is probably triggered by substances produced by the corpus 
luteum. The exact mechanisms that initiate and sustain the primary fall in vascular re-
sistance and subsequent hemodynamic adaptations remain to be elucidated. Reduced 
responsiveness to vasopressors such as angiotensin 2, thromboxane, and norepineph-
rine and increased sensitivity and production of vasodilators like prostacyclin and nitric 
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oxide have been well described 62-65. There are some indications that relaxin, a hormone 
structurally related to insulin, might be a key factor in initiating and sustaining the 
changes in pregnancy 63. It is produced by the corpus luteum and, later, by the placenta 
and decidua and acts as a potent vasodilator through various nitric oxide pathways.
As mentioned before, the primary trigger is a fall in arterial and venous tone 50, 52, 66. This 
leads to a rise in CO, a decrease in SVR, and reduction in mean arterial pressure 39, 50, 60, 67. 
These changes are most prominent during the first trimester and reach a maximum in 
the second trimester when, remarkably, the nutritive requirements of the feto-placental 
unit still remain relatively small (Fig. 1).
blood Volume
The expansion of blood volume is triggered by the state of vascular underfilling and the 
increased renal perfusion 50, 52-54, 68. It rises gradually until 28–34 weeks and then plateaus 
until delivery 51. The increase in plasma volume is more important as compared to the 
increase in red cell volume leading to a physiologic hemodilution 58, 69. The total blood 
volume increases 50 % above nonpregnant values. Along with the drop in SVR, it allows 
high-flow low-resistance perfusion in order to meet the increased oxygen demands of 
the feto-placental unit and several maternal organs including the kidneys, skin, and 
heart 70. Secondly, it forms a protective reserve for maternal blood loss around parturi-
tion.
Vascular Resistance
Vascular resistance initially drops in the first and second trimester by 30–50 %, reaching 
its nadir by the end of the second trimester 39, 58-60, 67. It then remains stable until the end 
of the third trimester to slightly rise again towards term. Plasma renin is increased and 
atrial natriuretic peptide (ANP) levels are reduced, indicating that volume expansion is 
proportional and in reaction to the vasodilatation and increased vascular capacitance 
66, 68.
Cardiac output, stroke Volume, and Heart Rate
The increase in CO of 30–50 % mirrors the reduction in SVR. It is initiated by a rise in heart 
rate (HR) and subsequently accompanied by an increase in SV as soon as plasma volume 
expansion occurs 39, 50-53, 67. After a rapid climb in the first half of pregnancy, it reaches a 
plateau in the second trimester after which it remains constant until the end of preg-
nancy 35, 39, 56, 60, 67, 71-73. Towards term there is a slight reduction in SV which is probably 
compensated by an elevation in HR 39, 60, 67, 71, 72. Some studies indicate a slight reduction 
in CO towards term due to this fall in SV 56, 74, 75. This discrepancy probably reflects the 
large interpersonal variation between subjects and the limitations of the methods used 
to determine CO 39, 73. The factors contributing to an elevation in SV during pregnancy 
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are the increasing preload due to a rising blood volume and a reduction in afterload due 
to the decline in SVR.
More important than the slight variations between studies is the effect of maternal 
position on CO. As from 20 weeks gestation, supine position directly reduces maternal 
CO through aortocaval compression by the gravid uterus, thereby reducing preload and 
increasing afterload 47, 76. Therefore, output should be measured in a left lateral position 
from as soon as 20 weeks gestation. Also in case of fetal or maternal distress, left lateral 
tilt is critical in enhancing output in the second half of pregnancy 77.
blood Pressure
Both systolic and diastolic pressure fall early in gestation as a result of the reduction 
in SVR, reaching a nadir in the second trimester of 5–10 mmHg below values prior to 
pregnancy 67, 78-80. In the third trimester, blood pressure gradually returns towards non-
pregnant values.
systemic Pressures
Central venous pressure remains within the normal nonpregnant range. The increased 
right ventricular preload, associated with volume expansion, is compensated for by 
afterload reduction through a decrease in pulmonary vascular resistance 18, 21, 52. Left 
ventricular filling pressures (invasively reflected by pulmonary capillary wedge pressure) 
and pulmonary artery pressures, whether measured invasively or noninvasively, remain 
within normal nonpregnant ranges 21, 67.
CaRDIaC aDaPTaTIon
left Ventricular systolic function and Mass
Assessment of left ventricular systolic function during pregnancy is mostly performed 
by ultrasound. It is complicated by the inherent limitations of the ultrasound technique 
as well as by the major fluctuation in loading conditions during pregnancy. As such, 
most standard indices are relatively indirect and only partly reflect different aspects 
of ventricular function. A good and complete denominator of global systolic function 
independent of loading conditions is still lacking. Newer techniques like tissue Doppler, 
strain analysis and speckle tracking are promising, as they offer additional information 
on left ventricular function.
Ejection fraction (EF) and fractional shortening (FS) are the most classic indices of left 
ventricular systolic function. They primarily reflect the function of the circumferential 
fibers of the myocardium. Both EF and FS probably slightly increase early in pregnancy, 
then remain constant until 30 weeks and subsequently slightly decrease towards term 
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25, 39, 56, 60, 67, 81. The increase early in pregnancy suggests increased myocardial contractil-
ity. Still, there is discrepancy between several studies concerning the changes in EF and 
FS 72, 82. It is probably due to the fact that the left ventricular volumes, used to calculate 
these parameters, are most often derived from the Teichholz formula, which is based 
on geometrical assumptions that are probably not met during pregnancy. While the 
Simpson methods of discs summation as well as 3D echocardiography are probably 
more accurate, they can be hampered by decreased echogenicity due to the cardiac axis 
displacement as well as engorgement of breast tissue during pregnancy.
Assessment of myocardial contractility using the less load-dependent ventricular end-
systolic stress (ESS) and mean velocity of circumferential fiber thickening (Vcfc) relation-
ship also offers conflicting results, although it seems that myocardial contractility is at 
least continuously preserved during pregnancy 67, 81, 83-85.
Analysis of left ventricular long axis function offers information on subendocardial 
longitudinally arranged fibers which are more prone to reflect subtle myocardial impair-
ment. Apical M-mode measurements through the mitral annulus show an increase in 
left ventricular long axis displacement with gestation until 23 weeks with a subsequent 
decrease reaching values below preconceptional readings towards term 56. Long axis 
shortening decreases significantly with gestation 71, 86. Tissue Doppler of the mitral an-
nulus, which is less load dependent, does not show any changes in S’ velocity during 
pregnancy71. These findings also suggest that contractility and systolic function are 
preserved throughout pregnancy and might even be slightly enhanced in the first half 
of pregnancy.
The recent introduction of strain, strain rate analysis, as well as speckle tracking 
permits investigation of myocardial deformation and left ventricular twist (torsion) and 
untwist. A higher deformation rate in the first trimester suggests a state of increased 
contractility in response to the hemodynamic changes of early pregnancy 72. In the third 
trimester, a small but significant reduction in longitudinal deformation and deformation 
rate is observed, without changes in circumferential and radial strain 72. This reduction 
in longitudinal strain occurs despite an increase in global ventricular performance, 
reflected by left ventricular stroke work, suggesting that strain and strain rate are also 
influenced by loading conditions and chamber geometry. As such, they cannot be used 
as a surrogate for global myocardial function, but they are more sensitive than other 
conventional parameters in reflecting subtle changes in ventricular function.
Speckle tracking analysis shows that pregnancy is accompanied by an increase in left 
ventricular twist and twist velocity due to increased apical rotation without changes in 
untwist and untwist velocity 87, 88.
Structurally, pregnancy is characterized by a proportional increase of both chamber 
size and wall dimensions. This leads to an eccentric hypertrophy which is characteristic 
of volume loading conditions 5, 72. Left atrial and ventricular diameters augment with 
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increasing gestational age, reaching peaks at around 34 weeks 52, 57, 60, 67, 72, 89. By term, 
left ventricular mass exceeds nonpregnant values by 50 % 57, 60, 67, 72. This physiologic 
and reversible hypertrophy is similar to the one observed in endurance athletes. It is a 
compensatory mechanism, reducing wall stress by increasing wall thickness. As such, 
the necessary stroke volume can be achieved despite increases in both preload and 
afterload and reduced diastolic filling time 57.
In conclusion myocardial performance is increased during pregnancy. However, this is 
not uniformly reflected in all different markers of systolic function. This is probably related 
to the complex interaction between changes in left ventricular geometry, loading condi-
tions, and limitations of the investigational methods. Globally one can conclude that myo-
cardial function is preserved or slightly increased in normal healthy pregnancy, and the 
changes in left ventricular morphology and structure can be regarded as a physiological 
adaptation to the changes in loading conditions in order to preserve myocardial function.
Diastolic function
As with left ventricular systolic function, the assessment of diastolic function is greatly 
influenced by the alterations in loading conditions during pregnancy. Pulsed wave Dop-
pler analysis of the mitral valve shows an initial increase in E-wave (E) and A-wave (A) 
velocities as compared to prepregnancy values 57. While early filling slightly diminishes 
with gestational age, the atrial contribution to ventricular filling increases leading to 
an increased A and decreased E/A ratio towards term 71, 90. Doppler of the pulmonary 
venous flow shows a transient peak in systolic forward flow velocity in the second tri-
mester, a gradual slight decrease in pulmonary venous diastolic velocity, and increase 
in pulmonary venous reversed flow at atrial contraction along with gestation 90. With 
increasing myocardial hypertrophy, ventricular compliance and hence E-wave velocity 
diminishes, which partly explains this pattern of impaired relaxation. Nevertheless, the 
observed changes in pulsed wave Doppler of the mitral annulus mostly remain a reflec-
tion of changing loading conditions during pregnancy.
Load-independent tissue Doppler of the mitral annulus better demonstrate changes 
in diastolic function during pregnancy. There are no significant changes in either sep-
tal or lateral peak E’ and A’ velocities during normal gestation 71, 86. However, E/E’ ratio 
reaches the upper end of normality with a broadening of the range in the late third 
trimester, possibly reflecting a marginal increase in left ventricular filling pressure 71. A 
slight increase in A’ with subsequent decrease in E’/A’  ratio is consistent with enhanced 
left atrial contraction 71. The Tei index, which is a global measure for both left ventricular 
systolic and diastolic function, is characterized by a broader range during pregnancy 
compared to nonpregnant controls 71. The absence of changes in untwist parameters 
using speckle tracking echocardiography further suggests normal diastolic function 
during pregnancy despite the volume overload 88.
25
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In conclusion normal pregnancy is associated with normal diastolic function. Analysis 
of diastolic function best includes load-independent methods like tissue Doppler or 
speckle tracking in order to differentiate changing loading conditions from real diastolic 
dysfunction.
laboR anD DelIVeRy
During labor and delivery, maternal hemodynamics are influenced by several factors like 
anxiety, analgesia, uterine contractions, Valsalva maneuver, blood loss, and maternal posi-
tion. An increase in SV and CO is observed from the beginning of the first stage of labor 
which further augments as dilation progresses 91-93. During each contraction, 300–500 ml 
of blood from the uterine sinusoids is forced again in the systemic circulation thereby in-
creasing preload 94. Maternal discomfort and exertion can further increase the HR thereby 
augmenting CO 50% above pre-labor values. Arterial pressure also increases during each 
contraction by about 15–20 mmHg (see Fig. 1). The changes can be more prominent in 
recumbent as compared to left lateral position due to caval compression as well as to 
occlusion of the distal aorta during contraction with redistribution of the stroke volume in 
the upper half of the body 58, 95. It is evident that the abrupt onset and magnitude of these 
changes can pose a serious challenge to patients with cardiovascular disease.
Epidural analgesia also influences the hemodynamic changes during labor. Pain and 
anxiety are often reduced and both the fluid challenge and reactive vasodilatation can 
also influence loading conditions 96. In controlled circumstances, the severe hemody-
namic changes due to labor are often attenuated by epidural anesthesia.
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39 ,  58 – 60 ,  67 ]. It then remains stable until 
 Blood Pressure 
 Both systolic and diastolic pressure fall early in gestation as 
a result of the reduction in SVR, reaching a nadir in the sec-
ond trimester of 5–10 mmHg below values prior to preg-
nancy [ 67 ,  78 – 80 ]. In the third trimester, blood pressure 
gradually returns towards nonpregnant values. 
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figure 1. Hemodynamic changes in pregnancy, during labor, and postpartum. CO cardiac output, SVR sys-
temic vascular resistance, MAP mean arterial pressure, pp postpartum
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PosTPaRTUM
The gradual hemodynamic adaptation to pregnancy is rapidly reversed after delivery. 
Immediately postpartum, CO and SV are still elevated compared to pre-labor values 
58, 91-93. The massive autotransfusion from the uterine blood volume and relief of caval 
obstruction compensate for postpartum blood loss 97. Both SV and CO remain elevated 
for the first 24 h after which they gradually decline. The reduction is most prominent 
within the first 2 weeks postpartum but can continue until 6 months postpartum before 
reaching prepregnancy values 78, 97-99 (see Fig. 1). Heart rate falls rapidly after delivery. 
Mean arterial pressure initially drops immediately postpartum but returns to pre-labor 
levels on the second day postpartum. It then gradually declines over the following 2 
weeks 97. Left atrial dimensions normalize within the first 2 weeks, reflecting the rapid 
normalization of blood volume in the puerperium 100. While most cardiac adaptations 
progressively return to normal values within 6 months after delivery, some minor 
structural changes can remain longer or even become permanent 39, 55, 67, 78, 101, 102. In sub-
sequent pregnancies, hemodynamic adaptation is often more prompt and pronounced. 
The latter suggests that pregnancy induces some form of cardiovascular imprinting 
which is protective in further pregnancies and possibly later life.
PeRIPHeRal sysTeMs
arterial system
Changes in the systemic arterial circulation in normal pregnancy are characterized by 
a decreased peripheral resistance and increased arterial compliance and distensibility 
103, 104. The latter is mainly achieved by a reduction in smooth muscle tone, although 
there are some indications that some degree of structural vessel wall remodeling during 
pregnancy could also play a role.
Aortic valve cross-sectional area slightly increases between the first and third trimester 
67, 83, 103. Therefore, left ventricular outflow tract diameter should always be determined 
simultaneously with the velocity time integral, when assessing stroke volume by ultra-
sound at different gestational ages.
Global arterial compliance increases in the first trimester and remains elevated 
thereafter. The magnitude of peripheral wave reflection at the aorta is reduced 104, 105. 
Noninvasive assessment of arterial stiffness by applanation tonometry, using pulse 
wave analysis and velocity, showed a transient decrease in augmentation index, with a 
nadir by the end of the second trimester. The reduction in central aortic blood pressure 
is more pronounced than the decline in peripheral blood pressure 105, 106.
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Venous Hemodynamics
While the scientific interest in venous (patho) physiology is certainly less than their 
arterial and cardiac counterparts, the venous compartment nevertheless is important 
as it serves as a large volume reservoir storing approximately two thirds of total blood 
volume. In a state of extensive vascular expansion, it becomes even more prominent as 
it greatly contributes to the regulation of cardiac output. The splanchnic veins in par-
ticular serve as a major storage pool where much of the unstressed blood volume can 
remain and be mobilized when necessary 107. In pregnancy, venous distensibility and 
capacitance are greatly increased. They return to prepregnancy values within 3 months 
postpartum 107–109. Investigation of the venous hemodynamics can be performed nonin-
vasively using Doppler ultrasound which also has a role in pathophysiological research 
of complicated hemodynamic syndromes such as preeclampsia 110.
RegIonal blooD flows
Uterine blood flow
With increasing demands of nutrition and oxygen from the rapidly growing products of 
conception, several adaptations take place in the uterine circulation. From early gesta-
tion, uterine artery diameter progressively increases, while pulsatility and resistance in-
dices decrease 31, 111–117. Uterine blood flow increases from 50 ml/min in the first trimester 
to 500–750 ml/min at term 114, 116, 117. The increase in uterine blood flow is not only in 
absolute terms but also in proportion to the total cardiac output 118.
The trophoblast invasion with arterial remodeling of spiral arteries allows appropriate 
uteroplacental exchange but also contributes to the reduction of arterial resistance 116.
Renal blood flow
It is very clear that renal hemodynamics play a major role in normal adaptation to 
pregnancy 54, 115. Renal blood flow increases during pregnancy. While the results are less 
conclusive, renal artery resistance index probably rises during pregnancy, reaching a 
peak by the end of the second trimester and then slowly returning to normal values 
postpartum.
Cerebral blood flow
The cerebral circulation can be analyzed by noninvasive transcranial Doppler and MRI. 
Both Doppler technique and MRI technique show a decrease in middle cerebral artery 
velocity as well as a 20 % reduction in total cerebral blood flow at term 119–121.
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THe MICRoCIRCUlaTIon
The microcirculation is the site of exchange of oxygen and nutrients 122. The impor-
tance of microcirculatory dysfunction, independent from macrocirculatory changes, is 
emerging in several pathological conditions such as sepsis and shock 123–125. Research 
on microvascular parameters has mainly been hampered by technical difficulties. The 
gold standard, intravital microscopy, remains difficult outside the laboratory setting. 
Capillaroscopy, plethysmography, and laser Doppler have been used in pregnancy but 
are each hampered by several limitations 126–130. More recent technical innovations like 
Orthogonal Polarization Spectral (OPS) imaging and Sidestream Dark Field (SDF) imag-
ing are promising 131, 132. They allow a combination of microvascular vessel density and 
flow velocity measurements at the bedside.
Thus far, microvascular research in pregnancy remains limited and mostly focused on 
pathological conditions like preeclampsia. Information on normal pregnancy is scarce 
and is mainly derived from healthy pregnant control groups. As such, it offers little 
information regarding the longitudinal adaptation to normal pregnancy. Anim-Nyame 
et al. showed a reduction in isovolumetric venous pressure as compared to nonpregnant 
controls 126. Hassan et al. showed increased skin capillary density in pregnancy, reach-
ing a peak by the end of the second trimester with subsequent gradual reduction to 
nonpregnant values 6 weeks postpartum 127.
Key PoInTs
– Normal pregnancy is characterized by profound hemodynamic changes.
– A marked decline in systemic vascular resistance occurs early in pregnancy.
– Cardiac output rises dramatically, especially in the first half of pregnancy.
– To cope with these hemodynamic challenges, the left ventricle hypertrophies, 
thereby preserving systolic and diastolic function.
– During labor and delivery, cardiac output further rises. Postpartum, most hemody-
namic parameters are rapidly reversed within weeks.
– Structural changes normalize within several months.
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absTRaCT
The microcirculation is the largest component of the cardiovascular system. It is the site 
where the ultimate goal of circulation, the exchange of oxygen and nutrients for carbon 
dioxide and waste products with tissues takes place. The microcirculation consists of 
blood vessels with a diameter below 100 micrometre (µm). Arterioles regulate blood 
flow to the capillaries, where the exchange takes place, after which blood is drained 
by venules. Several non-invasive methods. have recently been developed to assess the 
microcirculation. Video-capillaroscopy, orthogonal polarization spectral imaging(OPS), 
sidestream dark field imaging (SDF), incident dark field imaging (IDF), laser Doppler im-
aging, O2C and retinal vessel analysis each use different techniques to investigate spe-
cific aspects in distinct microvascular beds. Which method and site are most appropriate 
depends on what information is required. In conditions with substantial haemodynamic 
disturbances, parameters of microcirculatory perfusion appear to be independently as-
sociated with outcome, prognosis and response to treatment. Inclusion of microvascular 
parameters in a haemodynamic profile can optimise haemodynamic management. 
Knowledge about microvascular function in pregnancy is very limited. Considering 
the haemodynamic changes that accompany both normal pregnancy and most severe 
pregnancy complications as well as the recent availability of non-invasive techniques, 
there certainly is an indication for more microcirculatory research in pregnant women.
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anaToMy anD PHysIology
The circulatory system can be viewed as a closed circuit where the heart functions as 
central pump. With each beat, blood is driven through large elastic capacitance arteries 
and is then directed into more muscular arteries that distribute the flow to the organs 
according to their needs. In these tissues smaller arterioles further branch down into 
capillaries. Here, exchange of oxygen and nutrients for carbon dioxide and waste prod-
ucts takes place with tissue cells, which is in essence the primary function and ultimate 
goal of the circulation. Blood is then drained by venules into the venous system and 
returns to the heart.
The microcirculation includes vessels with a diameter (Ø) below 100 micrometre (µm) 
and mainly consist of the arterioles, capillaries and venules 1, 2. It is by far the largest com-
partment of the circulatory system. Arterioles have a thin muscular layer and, along with 
precapillary sphincters, they regulate the blood flow towards the capillaries according to 
the tissues` needs on a microvascular level 2, 3. Capillaries have a Ø below 20 µm allowing 
erythrocytes to flow through them in a single column 4. They consist of a layer of endothe-
lial cells with a basal membrane. Three different types of capillaries can be distinguished 
based on the connection between the endothelial cells 2, 5, 6. Continuous capillaries are 
the most commonly found type (e.g. nervous system, muscle, lung). They are character-
ized by narrow intercellular clefts where one cell directly connects to the next through 
tight junctions. Fenestrated capillaries have pores (transcellular cytoplasmatic holes) and 
are found in organs where more exchange between the intra- and extravascular compart-
ment is required (e.g. endocrine glands, gastrointestinal tract and kidneys). Discontinu-
ous capillaries are sometimes referred to as sinusoids and can be found in e.g. the liver, 
spleen and bone marrow. They have more significant gaps between adjacent cells and a 
discontinuous basal membrane. While exchange of gasses and small molecules mainly 
occurs though diffusion and pinocytosis, gaps in or between the endothelial cells allow 
easier exchange of fluids and larger molecules. On the inside (lumen), the endothelial 
cells are covered with a gel-like structure called the glycocalyx 5-7. It mainly consists of 
glycoproteins and soluble components and is sometimes referred to as the endothelial 
surface layer (ESL). It forms a film between the blood cells and the endothelium and im-
proves rheology by preventing unnecessary interaction and adhesion of the erythrocytes, 
leucocytes and platelets with endothelial cells. The glycocalyx also plays an essential role 
in regulating the exchange of fluids and solutes (flux) between the intravascular com-
partment and the interstitium 8. The classic Starling`s principle, where exchange is driven 
by the opposing hydrostatic and oncotic forces was revised as recent evidence suggest 
that the glycocalix reflects albumin into the intravascular compartments and creates a 
hypoalbuminamic space between the glycocalix and the endothelium 5, 6. The inward 
flux created by the oncotic difference is not as large as previously assumed and most 
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of the fluid returning from the interstitial space back into the circulatory system occurs 
through lymphatic drainage. Damage to the endothelial glycocalyx induces proteinuria 
in glomeruli and impaired permeability in systemic blood vessels 5.
Delivery of oxygen and nutrients to the tissues is essential to maintain cellular homeo-
stasis and function but the required amounts are not constant. The circulatory system 
has several mechanisms to regulate the supply according to the specific needs and situ-
ations. Cardiac output can be adapted by modifying stroke volume and heart rate. Blood 
flow can be redirected to central organs or specific tissue areas and bypass others, by 
regulating the muscular tone of arteries and arterioles. In severe haemodynamic condi-
tions like septic shock, this redistribution might result in increased core organ perfusion 
on a macrovascular level but heterogeneous perfusion on microvascular level which can 
be detrimental for the tissues 1, 9, 10.
Delivering oxygen from the microvascular level to the cells occurs trough two main 
mechanisms. The first is convective oxygen transports which is dependent on the red 
blood cell velocity and the capacity of the red blood cell to carry oxygen. The second is 
diffusion which is dependent of the pressure gradients between the red blood cell and 
the tissues and is inversely related to the distance between the capillary and the cell 
11, 12. With homogeneous capillary flow, tissues are steadily perfused in a continuous and 
equally distributed manner allowing optimal exchange between the capillaries and the 
cells. During heterogeneous tissue perfusion the total amount of flow may be similar, 
but some parts closer to the capillaries are hyper perfused, while others cells further 
away receive less resulting in suboptimal exchange and tissue dysfunction 1.
MeTHoDs of assessIng THe MICRoCIRCUlaTIon
The study of the microcirculation has mainly been limited by technical difficulties. Major 
advances in the last 2 decades have permitted more rapid, easier and non-invasive as-
sessment of microvascular beds of various organs with several different techniques. The 
microcirculation can either be assessed morphologically by looking at the diameter or at 
the number of capillaries (capillary density (CD)), the appearance of capillaries or integrity 
of the glycocalyx layer. Alternatively one can assess microcirculatory perfusion by looking 
at red blood cell velocity in the microcirculation (Microvascular flow index (MFI)) and/or 
heterogeneity of microvascular perfusion (heterogeneity index (HI)). Finally, the endothe-
lial function in the microcirculation can be assessed by assessing the response to specific 
challenges like drugs, flickering light, post ischemic (occlusive) vasodilatation or thermal 
stimuli.
Which technique, site or parameter of microvascular assessment is most appropriate 
in a specific circumstance can be answered by addressing the four W questions.
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Who:  who is going to assess the microcirculation (e.g. a highly dedicated and skilled 
investigator for research purpose or a medical worker as part of routine clinical 
observations) and who is going to be assessed (e.g a neonate or an adult, a 
patient with chronic rheumatologic disease or patient with septic shock).
Why:  does one intents to assess morphology, perfusion or endothelial function (e.g. 
in order to understand pathophysiology or to monitor treatment).
Where:  refers to which microvascular bed is best assessed (e.g., sublingual, skin, nail-
fold, retina, gut, brain, vaginal mucosa) and in which setting (e.g. in a laboratory 
setting, outpatient clinic, at the bed side or during surgery)
When:  is one interested in single measurements, repeated intermitted or continuous 
measurements.
Video capillaroscopy
Video capillaroscopy uses an intravital microscope coupled to a video camera to study 
the microcirculation in vivo 13-17. The initial devices were quite bulky and cumbersome, 
limiting their use to research setting. Current video capillaroscopes are small hand held 
devices that couple a microscope to a digital video camera 14, 16, 17. They allow direct 
visualization of moving erythrocytes in the capillaries. The vessel wall is not visualized 
and as such only perfused capillaries can be investigated. In the nail fold, capillaries 
run parallel to the skin and the technique can be used to assess the morphology of 
capillaries and estimate red cell velocities. It is used in rheumatic and skin conditions like 
systemic sclerosis and Raynaud disease 15. In the skin, the capillaries run perpendicular 
to the to surface. They are observed as small red dots and the technique can merely be 
used to assess capillary density (basal capillary density (BCD)) and capillary recruitment 
(maximal capillary density (MCD)) after certain stimuli like venous congestion, post-
occlusive reactive hyperaemia and thermal challenges 17, 18. Still one has to bare it mind 
that skin perfusion is very heterogeneous and several sampling sites must be assessed 
and averaged in order to have reproducible measurements.
orthogonal Polarization spectral imaging (oPs), sidestream Dark field 
Imaging (sDf) and Incident Dark field Imaging (IDf).
These three types of handheld videomicroscopes use green light (wave length of +- 530 
nm), which penetrates the surfaces of organs to a depth of approximately 3 mm, to 
allow direct visualization of the superficial microcirculation. Green light of this wave 
length allows optimal absorption by hemoglobin in red blood cells. The surrounding tis-
sues mostly reflect the light which creates contrast. This is captured by a video camera, 
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which allows visualization in high contrast images of flowing red blood cells as little 
black moving targets in the superficial microcirculation. Here again the vessel walls 
are not visualized 19-22. Depending of the size of the moving red blood cell column and 
direction of flow one can discern arterioles from capillaries and venules. Tissues with a 
thin epithelial layer are most easily studied. The sublingual mucosa is often used as it 
is easily accessible, located in close proximity of the brain and from the same embryo-
logic origin as the gastrointestinal system, which is often substantially involved in the 
pathophysiology of conditions like shock and sepsis 1, 10. Nevertheless other sites like the 
vaginal mucosa, cervix, skin, or the microcirculation of internal organs like bowel and 
brain during surgery can be examined 23-27. As such these techniques allow immediate 
non-invasive visualization of the microcirculation at the bedside. They can be used in 
adults, children and even preterm neonates 28-30.
The recorded images need to be analyzed with specific software. These allow semiau-
tomatic analysis and still require a substantial human input. Analysis is therefore often 
performed off line and can be time consuming 31, 32. Several aspects of the microcircula-
tory perfusion can be examined 4. Vessels are divided according to their size into small 
(capillaries, Ø < 20µm) and non-small vessels (arterioles and venules, Ø 20-100 µm). For 
both groups vessel density (VD) and perfused vessel density (PVD) can be assessed. The 
MFI describes the predominant flow pattern in a semiquantiative score of 0-4 (0 =absent, 
1 = intermittent, 2 = sluggish, 3 = normal or 4 = hyperdynamic flow) of both vessel types. 
The HI is an important parameter of microvascular tissue perfusion and is calculated from 
the MFI scores by subtracting the lowest score from the highest score divided by the 
mean score. The integrity of the glycocalyx can also be assessed with specific software 
by analysing the dimensions of the red blood cell perfused boundary regions (PBR) 8, 33.
Usually 3-5 video clips are recorded and analyzed for the measurements. These are 
performed according to consensus recommendations of an international round table 
conference for standardization purpose and the validation and reliability has been 
demonstrated in non-pregnant adults, pregnant women and neonates 29, 30, 34-37.
Orthogonal polarization spectral (OPS) (cytoscan cytometrics, Philadelphia, USA) 
was developed in the late 1990`s and can be considered as the first generation of these 
handheld video microscopes which opened the field of bedside study of the superficial 
microcirculation 21, 22. Further developments resulted in the second generation side-
stream dark field imaging technique (SDF) (MicroScan Video Microscope, MicroVision 
Medical, Amsterdam, the Netherlands) with improved image contrast and quality 
(Figure 1 a,c) 20. The mobility and ease of use at the bedside was improved by allowing 
battery depend operation. This device of approximatively 320 grams still contains an 
analogue video camera necessitating conversion to digital images for time consuming 
off line analysis 29, 31, 32, 38.
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Recently a third generation camera was developed using incident dark field (IDF) il-
lumination technique (cytocam Braedius medical, Huizen, The Netherlands) (Figure 1 
b,d) 19, 36. It weighs around 120 gram. Image quality was again substantially improved by 
the use of high-resolution optics, computer controlled illumination units and a digital 
camera with computer controlled high resolution sensors. Image collection is further 
facilitated by a quantitative focus mechanism which determines and remembers an 
individual’s characteristic focus depth for serial measurements.
The device also includes an improved automatic analysis software which substantially 
quickens and facilitates analysis of several parameters and promises complete instant 
bed side analysis in a nearby future 19, 39. This will permit the incorporation of microvas-
cular measurements as independent parameters in a haemodynamic profile for immedi-
ate clinical decision making at the bedside.
laser Doppler imaging
With Laser Doppler imaging, a beam of laser light is directed on the skin with a 
wavelength that penetrates to a depth of approximatively 1mm and reflected light is 
measured. The principle is based on the wavelength change (Doppler shift) the light 
undergoes when hitting moving red blood cells in the superficial microcirculation of the 
dermis. This Doppler shift is related to the number and velocities of the blood cells. It 
provides an index of skin perfusion called flux, expressed in arbitrary units (AU), which is 
the product of average red blood cell velocity and concentration 13, 17, 40-43.
figure 1 Sidestream dark field (SDF) (a-c) and incident dark field (IDF) (b-d) probes with respective snap-
shot images of movies obtained from the sublingual microcirculation.
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Initially the technique was developed as laser Doppler flowmetry (LDF) or Laser Dop-
pler perfusion monitoring (LDPM) assessing blood flow in a single area of less than 1 
mm3. High sampling frequencies allowed good temporal variability making LDF inter-
esting for the assessment of rapid changes in blood flow as a response to a stimulus 
42. Nevertheless, spatial variability and therefore reproducibility are limited due to the 
important heterogeneity in skin perfusion 44.
With Laser Doppler Imaging (LDI) or laser Doppler perfusion imaging (LDPI), all indi-
vidual single measurement points are combined and a large area of interest is scanned 
by the laser beam (up to 50 x 50 cm2) 13, 17, 44-47. The backscattered light is analyzed and a 
2-D color coded image is created with each pixel representing a perfusion value.
This overcomes the problem of spatial resolution and reproducibility encountered 
with LDF but at the cost of reduced temporal resolution. As such it cannot be used to 
assess rapid changes in microcirculatory perfusion. Nevertheless, recent developments 
in high speed cameras, multichannel lasers and mapping algorithms permit much faster 
scanning 46, 47.
A latest technique is called laser speckle contrast imaging (LSCI)48-50. The laser light 
penetrates tissue to a depth of 300 µm and induces a phenomenon called laser speckle. 
This is the irregular backscattering pattern of the light created by irregularities in the 
tissue structure. This pattern is influenced by movements in the tissue, such as by blood 
flow, creating a blurring of this pattern. Speckle contrast is a quantification of this blur-
ring 45. It allows instant scanning of lager areas combining the advantages of LDF with 
LDPI but measures in a more superficial layer of the skin 51-53.
All these techniques are mostly used to assess microvascular skin reactivity to certain 
challenges like iontophoresis of vasoactive drugs, post occlusive reactive hyperaemia 
and thermal challenges 17, 42-44, 54.
With iontophoresis a low intensity current is used to deliver charged molecules in 
the dermis. Acetylcholine (Ach) and nitroprusside (SNP) are the most commonly used 
drugs, respectively eliciting an endothelial dependent and endothelial independent 
vasodilatation. In post occlusive reactive hyperaemia, the increase in skin blood flow is 
analyzed after the relieve of a temporary arterial occlusion. Alternatively, the effect on 
skin perfusion of local heat or cold stimuli can also be analyzed. Nevertheless the exact 
underlying biological mechanisms of all these reactions remain complex. As such rather 
than specifically assessing distinct pathways, these tests merely reflect microvascular 
reactivity and function 17, 42-44. Standardization remains essential in order to allow com-
parison between studies as many variables may influence the response and reproduc-
ibility of these tests.
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o2C
The O2C device (Lea Medizintechnik, Gieβen, Germany) combines laser Doppler 
flowmetry with tissue spectrophotometry. It consist of a small glass fiber probe that 
can be attached to the skin, tongue or internal organs during surgery (Figure 2). The 
spectrophotometer transmits continuous wave laser light and white light into the tissue 
and the reflected light is split into its spectral components by charge-coupled device 
array and converted into an electrical signal. It allows simultaneous, continuous (beat 
to beat) and operator independent measurements of relative blood flow (in Arbitrary 
Units (AU), blood flow velocity (in AU), capillary-venous oxygen saturation (in %, which 
reflects the oxygen reserve after extraction of oxygen by tissues) and relative amount of 
haemoglobin (in AU) in the microcirculation55-60.
Retinal vessel analysis
With a non-mydriatic or mydriatic fundus camera retinal arterioles and venules can be 
non-invasively and directly visualized. Static imaging analysis of retinal vessels is the 
automatic measurement of the mean arteriolar and venular diameter, expressed as cen-
tral retinal arteriolar equivalent (CRAE) and central retinal venular equivalent (CRVE)61. 
figure 2 O2C monitoring device with glass fibre probe measuring microvascular perfusion on a hand 
palm.
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Therefor the largest arterioles and venules within the superior temporal region are simply 
marked, using a Retinal Vessel Analyzer (eg. RVA, Imedos, Jena, Germany) (Figure 3). The 
superior temporal region represents a circular area of 0.5-2 disk diameters from the optic 
disc margin. Whereas arteriolar constriction is often accompanied by venular dilatation, 
the arteriolar to venular ratio (AVR) is commonly used instead. Hence a reduced AVR 
indicates arteriolar narrowing as a sign of hypertensive retinopathy, which is frequently 
seen in hypertension and even associated with 5-year incident severe hypertension62.
The dynamic behavior of retinal vessels can be solely assessed with a mydriatic 
fundus camera, which is part of the Dynamic Vessel Analyzer (eg. DVA, Imedos, Jena, 
Germany)63. After 1% tropicamide administration to reach mydriasis, this device mea-
sures the arteriolar and venular diameter continuously, under the influence of flicker-
ing light stimulation. Retinal flicker response is a function of neurovascular coupling, 
caused by enhanced retinal ganglioneuronal activity, which primarily dilates capillaries. 
The secondary increase in blood flow thereby induces an NO-mediated dilatation of 
larger arterioles and venules, independently of perfusion pressure, with a physiological 
subsequent arteriolar constriction64. Therefore the resulting sum curve of flicker analysis 
consists of a baseline diameter, flicker-induced dilatation (FID) and maximum arteriolar 
constriction component (MAC). The arteriolar amplitude is the percentage change from 
peak FID to MAC (Figure 4) 65. Endothelium-dependent retinal flicker response, which 
includes FID and MAC, is impaired in chronic hypertension and aging, indicating pre-
aged and stiffened retinal vessels with dysfunctional endothelium66, 67.
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figure 3 This retinal vessel imaging, recorded with a fundus camera (Retinal Vessel Analyzer, Imedos, Jena, 
Germany), demonstrates the direct measurement of retinal arterioles (red marks) and venules (blue marks) .
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PoTenTIal anD IMPoRTanCe of MICRoVasCUlaR MeasUReMenTs
With the recent developments of new techniques allowing direct visualization, the im-
portance and potential of microvascular assessment for understanding the pathophysi-
ology, predicting prognosis and directing therapy in conditions with haemodynamic 
imbalance is emerging. It is well known that macrocirculatory parameters like cardiac 
output, blood pressure and fi lling pressures are poorly performing as predictors of out-
come or end-points for guiding therapy in conditions like sepsis and cardiac shock 68-71. 
In pregnancy, discordance between macrovascular and microvascular parameters was 
demonstrated in women with severe pre-eclampsia and changes in capillary perfusion 
were observed in women with HELLP syndrome 29, 72-74. Parameters of microcirculatory 
perfusion are independently associated with outcome and can be better predictors 
of prognosis and response to treatment 10, 75-83. Several experiments have shown that 
improving microcirculatory perfusion results in better outcome. If available at the bed-
side, microvascular assessment can become an important extension of conventional 
macrovascular haemodynamic monitoring in managing complex conditions with car-
diovascular imbalance 11.
Even in normal pregnancy the cardiovascular system is severely challenged 84-86. 
Most complications in pregnancy and causes of adverse maternal or fetal outcome like 
pre-eclampsia, growth restriction, cardiac disease, sepsis, diabetes, post-partum haem-
orrhage and thrombotic disease result in or from substantial haemodynamic dysregula-
tion and endothelial dysfunction which suggest an involvement of the microcirculatory 
compartment 87-90. Many of these complications are still poorly understood and major 
improvements are still to be achieved in their management. The advent of improved 
bedside techniques holds promise for research and clinical implications as it did in other 
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figure 4. This sum curve of a dynamic retinal fl icker analysis of a women with normal pregnancy outcome 
at 34 weeks gestation demonstrates the arteriolar fl icker-induced dilatation (second black arrowhead), the 
physiologic maximum arteriolar constriction (asterisk) and the resulting arteriolar amplitude (blue double-
headed arrow) along a normal distribution curve (dashed green lines).
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conditions like sepsis and shock. Along with new non-invasive techniques assessing the 
macrocirculation and uteroplacental Dopplers, a concept of global foetomateral hae-
modynamic monitoring or cardiovascular profiling can be developed to unravel many 
issues of these complex disease states72.
As an example for the potential of microcirculatory assessment we will discuss fluid 
management, which is one of the most common therapeutic interventions performed 
in medicine for a variety of indications and disciplines including obstetrics. In the lit-
erature large scientific debates have been held on which type of fluid, either colloids 
or crystalloids, to use in case of shock 91-93. However, on even more fundamental issues 
like when to start , how much to give and when to stop this common therapeutic act 
that is performed countless times on a daily base, one can hardly find any evidence or 
guidance. Clinical signs (eg. hypotension, capillary refill test, decreased urinary produc-
tion or consciousness), laboratory finding (lactate levels) and dynamic indices (CO, CVP, 
PCWP) are often arbitrary and do not offer information on how much to give and when 
to stop. The main goal of fluid managements is to enhance oxygen delivery to the cells. 
As discussed previously there are 2 main determinants of oxygen transport to the cells. 
Convective transport and passive diffusion. The former is dependent of the RBC veloc-
ity and oxygen carrying capacity. Diffusion is dependent of the pressure gradient and 
inversely related to the distance between the RBC and tissue. While colloids and crystal-
loids in themselves contain little components that might actually improve cellular func-
tion , they do so by increasing red cell velocity (thereby enhancing convective transport) 
and opening previously closed capillaries (thereby reducing diffusion distance between 
RBC and tissue). However, too much fluid will result in oedema which will increase dif-
fusion distance. Despite increased perfusion this would lead to a reduction in cellular 
function. Finding the balance between knowing when to start and how much to give in 
order to improve tissue perfusion, but knowing when to stop before side effects prevail, 
can be helped by direct assessment of the microcirculation using OPS, SDF or IDF where 
convective transport is reflected by the MFI and the diffusion distance by functional 
capillary density (FCD). Fluid administration can be monitored and directed according 
to specific predefined MFI and FCD values. This concept is called functional microcircula-
tory haemodynamics 11, 12, 94.
noRMal PRegnanCy
Pregnancy is characterized by a major cardiovascular adaptation to meet the needs of 
growing a foetus. Early in pregnancy vascular resistance starts to fall and cardiac output 
rises. RBC mass is increased but not as much as plasma volume resulting in a physi-
ologic haemodilution 84, 85. In fact perfusion of nearly all organs undergo major changes. 
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It is therefore likely that the microcirculatory compartment, which is the largest of the 
cardiovascular tree, is equally involved. Still, mainly hampered by technical limitations, 
very little is known about the microcirculation in normal pregnancy.
Using nailfold capillaroscopy 2 different groups showed a substantial increase in 
erythrocyte velocity during pregnancy and reduced vasodilatatory response after 
ischemia, which was attributed to the normal physiologic vasodilatation occurring in 
pregnancy 95, 96. Recently, George et al. compared the sublingual microcirculatory perfu-
sion between third trimester healthy pregnant women and non-pregnant controls using 
SDF 97. They found significant increase in MFI reflecting increased RBC velocity. There 
were no changes in PVD. These values were similar to those of third trimester healthy 
pregnant controls from another study assessing sublingual capillary perfusion in severe 
pre-eclamptic women, equally showing a PVD within normal non pregnant reference 
ranges and a hyperdynamic capillary flow (MFI) 29. Hasan et al. used intravital microscopy 
on the finger skin in 22 healthy pregnant women 98. They initially showed an increase in 
BCD and MCD after venous congestion reaching a peak at mid gestation and mirroring a 
decrease in blood pressure. In a later study in 225 healthy primigravid caucasian women, 
the same group using the same technique found opposite results with a reduction in 
BCD and MCD but these changes also mirrored the rise in blood pressure with advanc-
ing gestation that was now observed in the population 99. While these findings suggest 
that, as in other disease states, the microcirculation partly contributes to the regulation 
of blood pressure, it does not offer an explanation for the discrepancy in both microvas-
cular and macrovascular findings between these 2 studies. Moreover, these findings of 
capillary rarefaction were not observed in the sublingual or nailfold microcirculation in 
other studies.
Knowledge about the effects of Ach and SNP challenges on microvascular forearm 
flow measured with laser Doppler during normal pregnancy is very limited and mainly 
derived from small control groups and the results are not equivocal. Ramsay et al. found 
an increased dose dependent vascular responsiveness to Ach and SNP during the third 
trimester as compared to several months postpartum 100. Khan et al. observed a similar 
response for Ach but no difference for SNP 101. In the same study there were no dif-
ferences in vascular reactivity to Ach or SNP between 22-26 or 34 weeks of gestation, 
suggesting a steady increase in endothelium-dependent dilatation during normal 
pregnancy with return to normal values postpartum. The same group also showed an 
association between birth weight, augmentation index and endothelial function during 
pregnancy, suggesting microvascular involvement in the adaptation of cardiovascular 
system to normal pregnancy 102. Eneroth-Grimfors et al. could not find difference be-
tween pregnant and non-pregnant woman but they only used one charge stimulus and 
may not have reached a plateau level 103.
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Physiological changes in the microcirculation can be visualized using static image 
analysis of retinal vessels, which provides insights into vascular tone and periph-
eral resistance. Similar to capillary density of the finger skin, the retinal arteriolar and 
venular diameter mirrored the fall and rise in blood pressure throughout pregnancy. 
The maximum retinal vascular diameter was reached at 19 weeks gestation, the nadir at 
delivery and baseline values 6 months postpartum, which reflects a decreased vascular 
resistance at mid-gestation as one of the cardiovascular adaptions that occur during 
healthy pregnancy104.
From this overview is clear that knowledge about microvascular function in normal 
pregnancy is very limited. There certainly is a necessity for further assessment, in order 
increase insights and to determine normal values as it is definitely different from the 
non-pregnant state. This would best be achieved longitudinally in a large population, 
preferably using the latest techniques and in conjunction with macrovascular haemody-
namic parameters. We would suggest that this would be done using different techniques 
but in a standardized manner as to allow comparison with other studies and/or with 
other health and disease states. We would also suggest to assess the microcirculation 
of several organ systems as to discover which are most affected and which would best 
represent global microvascular function in pregnancy in future studies. Only when 
including the microcirculation into the concept of global foetomaternal haemodynamic 
profiling, will we be able to better understand the complex cardiovascular adaptation to 
pregnancy and its disturbances that occur in many complications.
Key PoInTs
-  The microcirculation includes vessels with a diameter below 100 micrometer (µm) 
and mainly consist of the arterioles, capillaries and venules.
- Exchange of oxygen and nutrients for carbon dioxide and waste products occurs at 
a capillary level.
- Several techniques allow non-invasive assessment of the microcirculation at the 
bedside.
- Microcirculatory perfusion can predict outcome and response to treatment inde-
pendent from macrovascular haemodynamic parameters.
- Inclusion of microvascular parameters completes the haemodynamic profile.
- Knowledge about microvascular function in pregnancy is limited and more research 
in this area is required.
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absTRaCT
Introduction
Most severe pregnancy complications are characterized by profound hemodynamic dis-
turbances. There is a need for validated hemodynamic monitoring systems in pregnant 
women. Pulmonary artery catheterization (PAC) using thermodilution is the clinical gold 
standard for CO measurements. However this reference methods is nowadays rarely 
performed due to its invasive nature. Transthoracic echocardiography (TTE) allows non-
invasive determination of the cardiac output (CO). We aimed to validate TTE against PAC 
for CO determination in pregnant women.
Methods
This study consist of a meta-analysis combining data from a prospective study and a 
systematic review. Simultaneous CO measurements by TTE and PAC were compared. 
The prospective arm was conducted in Pretoria (South Africa) in 2003. Women with 
severe pregnancy complications requiring invasive monitoring with PAC according to 
contemporary guidelines were included. Comparative measurements were extracted 
from similar studies retrieved from a systematic review of literature and added to a 
database. Agreement between both methods was assessed with Bland-Altman statistics 
and intraclass correlation.
Results
Thirty-four comparative measurements were obtained in the meta-analysis.
Mean CO obtained by PAC and TTE were 7.39 l/min and 7.18 l/min respectively. The bias 
was 0.21 l/min with lower and upper limits of agreement of -1.18l/min and 1.60 l/min 
and percentage error of 19.1% . Intraclass correlation coefficient was 0.94.
Conclusion
CO measurements by TTE show excellent agreement with PAC measurements in preg-
nant women. Given its non-invasive nature and availability it could be considered as a 
reference for the validation of other CO techniques in pregnant women.
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InTRoDUCTIon
Pregnancy induces a substantial challenge on the maternal cardiovascular system1, 2. 
Complications like pre-eclampsia, cardiac disease, sepsis, hemorrhage and pulmonary 
embolism that account for the majority of severe maternal morbidity and mortality are 
characterized by profound hemodynamic disturbances3-6. Maternal pulse and blood 
pressure are easily obtained and are often solely used as indirect surrogates of maternal 
cardiovascular function. Nevertheless, knowledge about the cardiac output (CO) can be 
important when managing hemodynamic compromised pregnant women or studying 
(patho)physiological conditions in pregnancy3, 4, 7-12. Thermodilution by pulmonary ar-
tery catheter (PAC), often referred to as Swan-Ganz catheter, is considered to be the clini-
cal gold standard for CO measurements13. Until the beginning of the previous decade, 
it was commonly used for hemodynamic monitoring and guiding therapy in intensive 
care settings14, 15. In pregnancy, critically ill and severe pre-eclamptic pregnant women 
were also managed with PAC16-25. Still, this invasive technique requires right heart cath-
eterization with inherent procedure related risks26-29. Controversy started after several 
reports failed to show the benefits or even suggested increased mortality with the use 
PAC’s in various critical conditions 13, 30-36. The initial enthusiasm for this technique faded 
in the intensive care and subsequently in the obstetric community, leaving a gap for 
hemodynamic monitoring which has not yet been replaced by newly emerged minimal 
or non-invasive alternatives as validation of these methods remains of concern.
Transthoracic echocardiography (TTE) using 2-D and pulsed wave (PW) Doppler of 
the left ventricular outflow tract (LVOT) is commonly used to determine CO both in 
and outside pregnancy. The technique is non-invasive, safe and accessible to pregnant 
women as many obstetric ultrasound devices allow upgrading with cardiac software 
and probes. Nevertheless, validation in pregnancy against the clinical gold standard, be-
ing PAC has not been adequately performed. As indications for PAC in pregnancy were 
limited to severely ill women, comparative studies included limited number of subjects 
and were often performed using statistical methods that are nowadays considered 
suboptimal or inappropriate. By combining data from a single center comparative study 
and systematic review, our aim was to validate CO determination using TTE against PAC 
in pregnant women.
MeTHoDs
A meta-analysis combining data from a prospective study and from a systematic review 
of literature was performed using appropriate statistical methods according to current 
standards in order to compare CO measurements obtained by TTE with PAC.
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Prospective study
The prospective comparative trial was conducted at the Kalafong Hospital, which is a 
tertiary care referral center for the University of Pretoria in South-Africa, from May 2003 
until October 2003. Severe pre-eclamptic women, admitted to the obstetric high care 
unit and requiring PAC for their clinical management, were included in the study after 
informed consent. The study was approved by the medical ethical board of the Uni-
versity of Pretoria (40-2003). Indications for PAC were according to the contemporary 
guidelines16, 18, 21, 25. These recommended to consider PAC in severe pre-eclampsia com-
plicated by either oliguria (not responding to fluid challenge), severe hypertension (not 
controlled by a combination of 3 different antihypertensive drugs), pulmonary edema or 
by clinical or echocardiographic signs of cardiac dysfunction. A triple lumen continuous 
CO PAC catheter (7.5F) (Edwards Life Sciences) was inserted via internal jugular vein ap-
proach. Correct position was confirmed by waveform analysis and chest X-ray. This type 
of catheter allows both intermittent and continuous CO determination using a vigilant 
CO computer (Edwards Life Sciences).
Intermittent CO determination obtained by bolus thermodilution is considered the 
clinical gold standard and was used for comparison. Measurements were performed af-
ter inclusion and insertion of the pulmonary artery catheter. CO was calculated from the 
mean of three consecutive thermodilution curves using 10 ml physiological saline room 
temperature injectates at different phases of the respiratory cycle. Subsequent CO mea-
surements were performed with the CCO module. For the latter a 10 cm thermal filament 
is incorporated into the pulmonary artery catheter 15-25 cm proximal of the catheter 
tip which emits pulses of energy and thereby heats blood in a repetitive intermittent 
sequence. Differences in temperature measured by thermistor at the catheter tip are 
correlated with the emitted signal. CO is determined by a similar equation as for thermal 
dilution without the need of repetitive fluid injections. A continuous output is deduced 
which is an average of the CO measured over the previous 5 to 15 minutes13, 37. Clinical 
management was based on continuous CO measurements and cardiac and pulmonary 
pressure readings.
Subsequently transthoracic echocardiography was performed by the principal inves-
tigator using an obstetrics ultrasound system with appropriate cardiac transducer and 
software package (Siemens sonoline ominia). The left ventricular outflow tract diameter 
(LVOTd) was measured at the base of the aortic leaflets from a parasternal long window 
from which the left ventricular outflow tract cross sectional area (LVOTcsa) was calcu-
lated (0.7854 x LVOTd2). The left ventricular outflow tract velocity time integral (LVOTvti) 
was obtained by pulsed wave Doppler from an apical 5 chamber view and stroke vol-
ume (SV) computed as LVOTcsa x LVOTvti. CO was calculated by multiplying SV with 
the corresponding heart rate (HR) derived from the simultaneous electrocardiography 
recordings. The mean of three measurements were taken into account. Measurements 
63
Cardiac output in pregnancy, TTE vs PAC
were recorded and calculations of the LVOTcsa, SV and CO were performed off-line after 
completion of the TTE exam.
Both pulmonary artery thermodilution and echo Doppler measurements were per-
formed in a 15° left lateral tilt to limit the possible interference of aortocaval compres-
sion. PAC and TTE measurements were performed within 15 minutes from one another 
without the occurrence of new therapeutic interventions or major clinical changes be-
tween the 2 measurements.
The investigator performing the ultrasound measurements was blinded for the ther-
modilution measurements.
systematic review
A systematic review of the literature was performed. We searched Embase, Medline, 
Web-of-Science, Scopus, Cochrane, Cinahl, Pubmed publisher and Google Scolar with 
search headings such as pulmonary artery catheter, echocardiography, Doppler and 
pregnancy. A list of the search strategy for each database is included in appendix 1. 
Reference lists of relevant articles were screened for potential additional hits not discov-
ered by the search strategy.
Articles in English language describing direct comparison during or immediately 
after pregnancy of CO determined by TTE using 2-D and PW at the LVOT with PAC using 
bolus thermodilution were included. Studies using a different reference method (e.g. 
Fick method) or different ultrasound method (e.g., CW Doppler in the aortic, mitral or 
pulmonary position) were excluded. The methodology employed was in accordance 
with the PRISMA statements. The titles and abstracts obtained from the search and full 
text reports were obtained and analyzed from the studies that seemed to be relevant. 
Individual comparisons between both methods were extracted from the manuscripts 
that met the predefined criteria.
Meta-analysis
A database was created containing direct comparisons between TTE and PAC obtained 
during the prospective arm of the study combined with data obtained from the sys-
temic review. Agreement between both methods of CO measurement was evaluated 
with Bland-Altman plots and statistics as appropriate for both the prospective arm of 
the study and the combined database. Mean CO, bias, standard deviation around the 
bias, limits of agreement (mean CO +-1.96 standard deviation around the bias) and 
percentage error ((1.96 standard deviation around the bias / mean CO) x 100% ) were 
determined. Agreement was considered to be good if bias would be low and percentage 
error below 30% as proposed by Chritchley et al38. Absolute agreement in ratings was 
evaluated using intraclass correlation.
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ResUlTs
Prospective study
Seven severe pre-eclamptic women were included in the prospective arm of this study. 
Demographics, indications for right heart catheterisation and time of measurement (an-
tepartum or postpartum) are represented in table 1 for the three studies. No maternal 
mortality occurred. One neonate born at 25 weeks died immediately postpartum after 
comfort care was offered, as this gestational age was considered non-viable in the South 
African context. No clinically relevant complication related to the pulmonary artery 
catheterisation occurred, with exception of a balloon rupture in one woman. The prob-
lem was suspected rapidly after insufflation of the balloon with air failed to produce a 
typical wedged waveform. Replacement of the catheter over a guidewire confirmed the 
suspicion. Close observation could not reveal any clinical sign of air embolism. Mean CO 
obtained by thermodilution and Doppler echocardiography was 6,89 l/min (+-2.17) and 
6.46 l/min (+-1.84) respectively. Mean CO was 6.67 l/min (+-1.99) with a bias of 0.43 l/min 
and standard deviation around the bias of 0.63 l/min. The limits of agreement were 0.43 
+- 1.23 l/min (-0.8 – 1.66). Percentage error was 18.4% .Intraclass correlation coefficient 
was 0.97 (95% CI .0.79 - 0.99).
Table 1. Gestational and maternal age, indications for right heart catheterisation and time of measure-
ment are represented for each of the three individual included studies as well as for the combined popula-
tion.
Cornette (n = 7) lee (n = 16) belfort (n = 11) Meta-analysis (n = 34)
gestational age 29* (25-31) 34,9+ +-1.2 33* (17 - 39) na
Maternal age 24* (18 - 37) 21+ +- 1 23* (17 - 36) na
Indication
Preeclampsia 7 14 2 23
Oliguria 3
Pulmonary edema 1
Cardiac dysfunction 3
Hypertension 0
Sepsis 0 4 4
Hemorrhage 0 1 0 1
Cardiac 0 0 3 3
Pulmonary embolus 0 0 1 1
Renal 0 1 1 1
Time
Antepartum 6 8 10 24
Postpartum 1 8 1 10
*expressed as median with rage, + Expressed as mean with SD
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systematic review
The search revealed a total of 366 hits; one additional record was identified through 
reference list reviews. 220 records remained after duplicates removed, which were 
screened on title and abstract. Twenty five full text articles were assessed for eligibility. 
Of these 10 included a direct comparison between pulmonary artery catheter measure-
ments and echocardiographic measurements in general during pregnancy39-48. Seven 
described comparative measurements of CO in specific of which four were excluded as 
methods of CO determination were different from our predefined methods. Finally three 
articles, including an abstract of the current study, were retained for direct comparison 
and meta-analysis (figure 1)39, 40, 43. One study by Lee et al. included 16 subjects43. One 
woman had been excluded from the study due to a technical difficulty resulting from 
a faulty pulmonary artery catheter. The manuscript included a table with comparative 
measurements in each subject from which the data was extracted. The other study by 
Belfort et al included eleven women39. No complications related to the right heart cath-
eterisation were reported. Data points were derived from the regression lines presented 
in the manuscript.
figure 1 PRISMA flow diagram representing the results of the systematic review
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Meta-analysis
Measurements comparing TTE with TD from our study were added to data retrieved 
from the systematic review. All three studies contained one single paired measurement 
per subject.
In total 34 subjects are included in the meta-analysis of which 24 were measured 
antepartum and 10 postpartum. The Bland-Altman plot represented in figure 2 suggests 
good agreement between both methods over a wide range of CO measurements (3.95 
– 11.40 l/min). Mean CO obtained by thermodilution and Doppler echocardiography 
was 7.39 l/min (+-2.09) and 7.18 l/min (+-2.10) respectively. Mean CO was 7.28 l/min (+-
2.07) with a bias of 0.21 l/min and standard deviation around the bias of 0.71 l/min. The 
limits of agreement were 0.21 +- 1.39 l/min (-1.18 – 1.60). Percentage error was 19.1%. 
Intraclass correlation coefficient was 0.94 (95% CI 0.88 - 0.97).
figure 2 Bland & Altman Plot showing agreement between CO measurements obtained by PAC and TTE. 
The differences between both methods of CO measurements are plotted against the respective means. The 
circles correspond with the measurements reported by Belfort et al., the triangles with the measurements 
reported by Lee et al, and the crosses with the measurements obtained by Cornette et al.. The continuous 
lines represent the bias and limits of agreement, each with their respective upper and lower 95% CI ( dot-
ted lines).
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DIsCUssIon
Maternal CO is an important hemodynamic parameter which is subjective to substan-
tial changes in pregnant women1, 49. TTE using PW Doppler ultrasound from the LVOT 
position is commonly used for CO measurements2, 3, 8, 12, 50. Still, our systematic review 
revealed only three validation studies of limited size against the clinical gold standard, 
including our own prospective study39, 40, 43. By combining them we were able to analyse 
34 paired measurements using the appropriate statistics. These data covered a wide 
range of CO, gestational and maternal ages, both during pregnancy and immediately 
postpartum, in different pathological conditions and in three independent research 
groups. Our results show excellent agreement with a small bias, limits of agreements 
and percentage error well within our predefined margins and an excellent intraclass 
correlation coefficient. When a new method to assess a clinical variable is introduced it 
is usually compared against an established reference technique. Adoption of this new 
method usually depends on the degree of agreement with the reference technique and 
other potential benefits51.
PAC remains an invasive technique with inherent risks that have been well described 
both in and outside pregnancy26-29, 52, 53. In our systematic review, we encountered 2 
complications related to the procedure. TTE is non-invasive and increasingly acces-
sible as many obstetrics ultrasound devices allow upgrading with cardiac software and 
probes. It can be used in all pregnant women ranging from healthy to critically ill at the 
bedside. As fetal and adult echocardiography are in essence very similar, it would take 
most feto-maternal medicine specialist little effort to learn the appropriate planes. In 
analogy with its homonyms in other critical circumstances (FAST, BLEEP, FATE or HART) a 
ROSE ( rapid obstetric screening echocardiography) scan can be developed along with 
obstetric anaesthesiologist and congenital cardiologist for rapid, accessible and now 
reliable bedside hemodynamic monitoring in pregnant women9.
Agreement between two different techniques depends on the accuracy and precision 
of the new method. Accuracy describes how close the measurement is to the reference 
value and precision how close the values of repeated measurements are. Cecconi et al. 
nicely visualised it by comparing it to target shooting, where accuracy is the characteris-
tic of being able to shoot close to the bullseye and precision is how close repeated shots 
are close to each other54. Most studies outside pregnancy and the 2 studies included in 
our meta-analysis compared both techniques by correlation and regression. However 
these merely reflect the strength of a relation and not the agreement. If for example 
each CO determined by TTE would be exactly 5 l/min higher than the one determined 
by TD, the standard Pearson coefficient would still show perfect correlation despite 
substantial differences between the 2 techniques. By centering and scaling data using 
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a pooled mean and standard deviation, the intraclass correlation coefficients is more 
appropriate to reflect the variance and agreement between 2 methods of measurement.
In their reference paper Bland and Altman proposed bias and precision statistics 
to analyse agreement between 2 methods where the differences (bias) are plotted 
against the means of each pair of measurements55, 56. This is now considered the gold 
standard for comparison between 2 techniques of CO measurements. The bias, reflect-
ing accuracy, and the standard deviation around the bias as well as limits of agreement 
(limits in which 95% of points fall on each side of the bias), estimating precision, can 
be calculated. In order to conclude that agreement between 2 methods is acceptable, 
it should be defined beforehand wherein the limits of agreement should fall. It is often 
difficult to determine which limits are clinically acceptable. The reference method of 
thermodilution is merely the clinical standard and does not reflect the true CO. It carries 
some inherent errors in accuracy and precision (10-20%) due to fluctuations in CO with 
respiration and technical limitations13, 37. Also it is evident that a bias of 1 l/min is more 
significant at a low CO (e.g. 3 l/min) than in a high output state (e.g.10l/min). To overcome 
these problems Chitchley et all. proposed that a new method should be accepted if the 
level of accuracy and precision is at least equal to that of the reference. They proposed 
the percentage error of the limits of agreement as compared to the mean to be used to 
assess agreement between 2 methods of CO determination with a cut-off of 30%38, 51, 57. 
Studies comparing both methods of CO determination in non-pregnant adults using the 
appropriate Bland-Altman statistics are equally rare. They are approximatively of similar 
size and suggest a similar degree of agreement58-60.
The importance of CO measurements in obstetrics is highlighted by the emergence 
of multitude of new techniques assessing CO in a minimally or non-invasive way. Sev-
eral devices calculate CO using pulse contour analysis (LidCO®, Nexfin®,…), impedance 
cardiography ( Niccomo®, Physioflow®, NICOM®,…) or continuous wave ultrasound (Us-
com®)7, 61-64. Some of these allow continuous measurements, some require only a limited 
amount of training and skill making them more operator independent. Nevertheless 
validation of these devices, especially in pregnancy, remains an major issue, mainly by 
the lack of a gold standard65.
PAC is still considered the clinical gold standard but indications for its use in obstet-
rics became extremely rare. Our study nicely showed that TTE is equivalent to PAC in 
pregnant women and besides for clinical use it can be considered as a surrogate gold 
standard to validate other techniques.
The strength of this study lies in the fact that by the systematic review approach we 
were able gather a maximal amount of cases for analysis using the appropriate statistics. 
The main limitations are that 34 comparisons remain modest and, while obvious given 
the invasiveness, our study does not include healthy pregnant women.
69
Cardiac output in pregnancy, TTE vs PAC
In conclusion our data indicated that CO measurements by TTE agree with PAC mea-
surements in severely ill pregnant women. Given its non-invasive nature and availability 
it could be considered as a reference for the validation of other techniques in pregnant 
women.
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absTRaCT
background
There are physiological reasons for the effects of positioning on hemodynamic variables 
and cardiac dimensions related to altered intra-abdominal and intra-thoracic pressures. 
This problem is especially evident in pregnant women due to the additional aorto-caval 
compression by the enlarged uterus. The purpose of this study was to investigate the 
effect of postural changes on cardiac dimensions and function during mid and late 
pregnancy using cardiovascular magnetic resonance (CMR).
Methods
Healthy non-pregnant women, pregnant women at 20th week of gestation and at 32nd 
week of gestation without history of cardiac disease were recruited to the study and 
underwent CMR in supine and left lateral positions. Cardiac hemodynamic parameters 
and dimensions were measured and compared between both positions.
Results
Five non-pregnant women, 6 healthy pregnant women at mid pregnancy and 8 healthy 
pregnant women at late pregnancy were enrolled in the study. In the group of non-
pregnant women left ventricular (LV) cardiac output (CO ) significantly decreased by 9% 
(p=0.043) and right ventricular (RV) end-diastolic volume (EDV) significantly increased 
by 5% (p=0.043) from the supine to the left lateral position. During mid pregnancy LV 
ejection fraction (EF), stroke volume (SV), left atrium lateral diameter and left atrial 
supero-inferior diameter increased significantly from the supine position to the left 
lateral position: 8%, 27%, 5% and 11%, respectively (p<0.05). RV EDV, SV and right 
atrium supero-inferior diameter significantly increased from the supine to the left lateral 
position: 25%, 31% and 13% (p<0.05), respectively. During late pregnancy a significant 
increment of LV EF, EDV, SV and CO was observed in the left lateral position: 11%, 21%, 
35% and 24% (p<0.05), respectively. Left atrial diameters were significantly larger in the 
left lateral position compared to the supine position (p<0.05). RV CO was significantly 
increased in the left lateral position compared to the supine position (p<0.05).
Conclusions
During pregnancy positional changes affect significantly cardiac hemodynamic pa-
rameters and dimensions. Pregnant women who need serial studies by CMR should be 
imaged in a consistent position. From as early as 20 weeks the left lateral position should 
be preferred on the supine position because it positively affects venous return, SV and 
CO.
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baCKgRoUnD
Increasing numbers of women with pre-existing heart disease are reaching childbearing 
age and are deciding to become pregnant 1. Pregnancy induces marked physiological 
changes in cardiac parameters, with a 30-50% increase in cardiac output, through an 
increase both in stroke volume and heart rate 2. While usually well tolerated in healthy 
pregnant women, these changes can induce adverse effect in women with pre-existing 
heart disease on both right and left-sided lesions 3, 4. Therefore, heart function should 
be closely monitored during pregnancy in these patients. Echocardiography has been 
used for many years but cardiovascular magnetic resonance (CMR) is more reliable in 
the context of congenital heart disease 5. To date, most data have been derived using 
echocardiography with the patients in lateral position 6, while CMR is usually performed 
in supine position. As aortocaval compression is important in advanced pregnancy 
7, 8 data of both techniques can not be compared. Many women with complex cardiac 
conditions will require CMR during pregnancy, however there is relatively little data 
regarding both the use of CMR during pregnancy and of the impact of supine and 
lateral positions on cardiac parameters. The purpose of this study was to investigate the 
impact of maternal position on cardiac parameters derived from CMR during 2nd and 3rd 
trimesters of pregnancy in normal women.
MeTHoDs
Patient selection
Healthy non-pregnant women, pregnant women at 20th week of gestation and at 32nd 
week of gestation with no history of cardiac disease were recruited to the study be-
tween June 2009 and January 2010. Study participants underwent CMR in supine and 
left lateral positions. Exclusion criteria were the common contraindications for CMR 
studies (pacemaker, cochlea implants and claustrophobia). The study was approved by 
the institutional review board and each subject gave informed consent.
CMR protocol
CMR was performed using a 1.5T scanner (Signa CV/I, GE Medical System, Milwaukee, 
WI). Firstly the patient was placed in the supine position and entered feet first into the 
magnet. A dedicated cardiac 8 channels coil was placed on the thorax of the subject and 
used for the acquisition of the images. CMR cines were obtained using a breath-holding 
ECG triggered balanced steady state free precession sequence. Imaging parameters 
were as follows: FOV 36-40 x 28-32 cm; matrix 224 x 196; TR: 3.4 milliseconds; TE: 1.5 
milliseconds; flip angle 45 degrees; 12 views per segment. Slice thickness was 8 mm 
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with a gap of 2 mm. These parameters resulted in a temporal resolution per image of 
41 milliseconds. At first, three rapid surveys were obtained for the determination of the 
cardiac position and orientation; two- and four-chamber cine MR images were then 
obtained. The series of short axis (SA) images were obtained from the reference images 
provided by the two- and four- chamber end-diastolic images at the end of expiration. 
Approximately 10 to 12 slices were acquired to cover the entire length of the heart. 
Directly after the first CMR study, the subject was repositioned on the left lateral side 
position for the second examination. The acquisition of images was performed by the 
same operator.
Image analysis
All the studies were analysed on a remote workstation using the CAAS-MRV (version 3.2; 
Pie Medical Imaging, Maastricht, The Netherlands).
Left end-diastolic volume (EDV) and end-systolic volume (ESV) were calculated using 
a combination of classic SA and long-axis images. The long-axis view was used to limit 
the extend of volumes at the base and at the apex of the heart. The Simpson rule was 
used to calculate volumes based on the SA images where the first basal and the last api-
cal were only partially included relating to the area outlined on two- and four- chamber 
images. More details about this approach have been previously reported 9. The papillary 
muscles were considered as being part of the blood pool shortening the analysis time 
without compromising the accuracy of LV volumes compared to standard short-axis 
technique 10. Ejection fraction (EF) was calculated as (EDV – ESV)/EDV. Cardiac output 
(CO) was calculated from stroke volume (SV) and heart rate (HR). Left atrium volume 
(LAvol) was measured using a combination of the two- and four chamber views in the 
diastolic phase of the atria. Lateral (LAlat) and supero-inferior (LAsi) left atrial diameters 
were measured on a four-chamber view during the phase of cardiac cycle with the 
largest left atrium (Figure 1). The lateral diameter was taken from the perpendicular 
constructed from the midpoint of the LAsi diameter extending to the atrial borders. The 
LAsi dimension corresponds to a line bisecting the left atrium and extending from the 
midpoint of the mitral annulus to the midpoint of the superior left atrium.
Right EF, EDV, ESV, SV and CO were calculated using cine images acquired in SA 
view, parallel to the tricuspid valve annulus and applying the same methods of the left 
ventricular hemodynamic measurements without long-axis corrections. In addition, 
lateral (RAlat) and supero-inferior (RAsi) right atrium diameters were taken during the 
phase of the cardiac cycle with the largest right atrium, on a four-chamber view (Figure 
1). The RAlat diameter corresponds to the line extending from the atrial borders and 
perpendicular to the RAsi diameter. The RAsi diameter is the line from the midpoint of 
the tricuspid valve to the midpoint of the superior right atrium.
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Due to the low inter-observer variability reported in a previous study 11 image analysis 
was performed by one operator with 3 years-experience in CMR. The operator was 
blinded to the same patient at the other position. CMR analyses were performed in a 
random order at different days.
analysis by gestational week
The patients were categorized into 3 groups according to gestational age. The first group 
consists of non-pregnant controls, the second group of women in the 20th gestational 
week and the third group of women in the 32nd gestational week.
statistical analysis
All analyses were done using SPSS 15 (SPSS Inc.) software. Parametric data were re-
ported as mean ± standard deviation. For each gestational group mean values of HR, 
EDV, ESV, EF, SV, CO, left and right atrium diameters of supine and left lateral positions 
were tested for significance, using Wilcoxon’s two sample test. A p-value <0.05 was con-
figure 1 Cardiac dimensions: four-chamber end-systolic view:
lalat: left atrium lateral diameter; LAsi: left atrium supero-inferior diameter; RAlat: right atrium lateral di-
ameter: RAsi: right atrium supero-inferior diameter.
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sidered significant. The percentage of change in the measure of left ventricle (LV) and 
right ventricle (RV) parameters (X) and left atrium (LA) and right atrium (RA) parameters 
(X) between supine and left lateral position was calculated using the following formula:
percentage change in X = [(Xlateral – Xsupine)/Xsupine] x100.
ResUlTs
A total of 14 healthy women with singleton pregnancies (30.3±5.2 years) were included 
in the study. Five non-pregnant women (29.4±5.7 years) were recruited as controls. The 
time interval between the examinations in supine and left lateral position ranged be-
tween 8 and 12 minutes. Table 1 gives the data regarding hemodynamic parameters and 
cardiac dimensions as related to gestational week and maternal posture. Percentage 
differences of cardiac volumes between supine and left lateral position are graphically 
reported in Figure 2 and 3 and will be reported in more detail below.
Table 1. Influence of position related to gestational weeksTable 1 Influence of position related to gestational weeks
Pre pregnancy (N = 5) T20 (N = 6) T32 (N = 8)
Supine
position
Mean (SD)
Left lateral
position
Mean (SD)
p-value Supine
position
Mean (SD)
Left lateral
position
Mean (SD)
p-value Supine
position
Mean (SD)
Left lateral
position
Mean (SD)
p-value
LEFT ATRIUM AND LEFT VENTRICLE
HR 78.2 (12.7) 73.0 (12.1) 0.180 80.5 (11.3) 72.3 (5.3) 0.104 80.8 (15.7) 75.2 (10.6) 0.237
EF (%) 56.2 (3.5) 55.9 (4.3) 0.686 53.8 (4.4) 57.8 (4.6) 0.046 51.8 (7.2) 57.7 (8.0) 0.012
EDV (ml) 156.5 (23.3) 153.5 (24.7) 0.686 140.8 (37.1) 157.4 (20.7) 0.115 138.4 (22.1) 166.1 (25.6) 0.012
ESV (ml) 68.6 (12.7) 67.8 (14.1) 0.893 64.6 (17.9) 66.5 (11.8) 0.917 67.1 (16.4) 71.4 (22.3) 0.484
SV (ml) 87.8 (12.9) 85.7 (13.4) 0.223 76.0 (21.1) 90.9 (13.4) 0.028 71.2 (12.2) 94.8 (13.1) 0.012
CO (L/min) 6.8 (0.8) 6.2 (1.2) 0.043 6.5 (1.1) 6.5 (1.6) 0.917 5.6 (0.7) 6.9 (0.9) 0.012
LA vol (ml) 65.5 (13.3) 57.1 (15.8) 0.068 51.8 (12.7) 60.8 (10.3) 0.028 49.0 (20.9) 68.6 (15.7) 0.012
LA lat (mm) 39.7 (2.8) 37.8 (3.3) 0.080 35.0 (3.9) 36.7 (3.7) 0.028 35.4 (2.4) 40.7 (3.7) 0.012
LA si (mm) 45.1 (6.7) 43.7 (3.4) 0.500 40.3 (3.9) 44.9 (3.2) 0.027 39.7 (6.3) 44.7 (8.2) 0.025
RIGHT ATRIUM AND RIGHT VENTRICLE
EF (%) 51.5 (5.5) 46.4 (4.0) 0.225 50.5 (3.4) 52.9 (4.7) 0.249 53.2 (6.8) 54.6 (6.6) 0.575
EDV (ml) 161.0 (24.8) 168.6 (29.2) 0.043 132.0 (34.6) 156.1 (22.3) 0.028 138.8 (37.3) 155.9 (22.6) 0.161
ESV (ml) 78.7 (18.8) 90.5 (17.6) 0.080 65.1 (16.5) 73.1 (8.9) 0.463 65.7 (22.6) 71.8 (18.7) 0.484
SV (ml) 82.3 (10.7) 78.1 (14.1) 0.345 66.9 (19.3) 84.1 (16.9) 0.028 73.1 (17.2) 84.1 (7.9) 0.050
CO (L/min) 6.4 (1.0) 5.6 (1.1) 0.138 5.3 (1.5) 5.9 (1.8) 0.075 5.6 (0.6) 6.3 (0.7) 0.025
RA lat (mm) 34.4 (5.0) 33.5 (5.2) 0.345 32.4 (4.0) 33.2 (5.2) 0.500 33.9 (6.2) 36.2 (7.1) 0.484
RA si (mm) 47.5 (2.8) 45.9 (4.4) 0.345 40.4 (4.4) 45.1 (5.6) 0.042 44.5 (6.0) 45.2 (7.8) 0.889
T20: 20th gestational week; T32: 32nd gestational week.
EF (ejection fraction), EDV (end-diastolic volume), ESV (end-systolic volume), SV (stroke volume), CO (cardiac output), LAvol (left atrium volume), LAlat (left atrium
lateral diameter), LAsi (left atrium supero-inferior diameter), RAlat (right atrium lateral diameter), RAsi (right atrium supero-inferior diameter)
Rossi et al. Journal f Cardiovascular Magnetic Re onance 2011, 13:31
http://www.jcmr-online.com/content/13/1/31
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Pre pregnancy
HR did show a slight although not significantly decrease between supine and left lateral 
position: 78±12 versus 73±12. Left CO significantly decreased by 9% (p=0.043) and right 
EDV significantly increased by 5% (p=0.043). There were no other significant changes of 
hemodynamic parameters and cardiac dimensions between the two recumbent posi-
tions.
20 gestational weeks
Six pregnant women were in the 20th gestational week. HR was 80±11 bpm in the supine 
position and 72±5 in the left lateral position (p=0.15). A significant increment of EF and 
SV of the left ventricle was observed between the supine and the left lateral position: 8% 
(p=0.046) and 27% (p=0.028), respectively. Left atrial dimensions increased significantly 
between the supine and the left lateral position by 5% for LAlat (p=0.028) and by 11% 
for LAsi (p=0.027). Regarding the right side of the heart, EDV increased by 25% (0.028) 
and SV increased by 31% (0.028) between the supine and the left lateral position. RAsi 
significantly increased by 13% (p=0.042) between the supine and the left lateral posi-
tion.
figure 2 Percentage differences of hemodynamic parameters of left side of the heart.
ef (ejection fraction: %), EDV (end-diastolic volume: ml), ESV (end-systolic volume: ml), SV (stroke volume: 
ml), CO (cardiac output: L/min), LAvol (left atrium volume: ml)
Percentage difference from supine to left lateral position is calculated with the following formula:
x (%) = [(Xlateral – Xsupine)/(Xsupine)] x100 where X is a cardiac parameter.
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32 gestational weeks
Eight pregnant women were in the 32nd gestational week. HR did not significantly change 
between the supine and the left lateral position: 81±16 versus 75±8 bpm (p=0.237). A 
significant increment of EF, EDV, SV and CO was observed between the supine and the 
left lateral position: 11% (p=0.012), 21% (p=0.012), 35% (p=0.012) and 24% (p=0.012), 
respectively. Left atrial dimensions increased significantly between the supine and 
the left lateral position by 15% for LAlat (p=0.012) and by 13% for LAsi (p=0.025). No 
significant changes of right hemodynamic parameters and dimensions were observed 
between the two recumbent positions with the only exception of CO (p=0.025).
Impact of gestational age
A progressive increase of percentage changes of hemodynamic parameters and cardiac 
dimensions of the left side of the heart was found throughout gestation. The only excep-
tion was the percentage change of ESV which substantially did not change between 20 
and 32 weeks of gestation. During late pregnancy left ventricle CO significantly increased 
between supine and left lateral position; the percentage of increment at 32 weeks 
was 24%. This was associated to an increase of 21% of left ventricle EDV. A significant 
figure 3 Percentage differences of hemodynamic parameters of right side of the heart.
ef (ejection fraction: %), EDV (end-diastolic volume: ml), ESV (end-systolic volume: ml), SV (stroke volume: 
ml), CO (cardiac output: L/min), LAvol (left atrium volume: ml)
Percentage difference from supine to left lateral position is calculated with the following formula:
x (%) = [(Xlateral – Xsupine)/(Xsupine)] x100 where X is a cardiac parameter.
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increase in LA dimensions was also found. The difference between the two recumbent 
positions was less clear at 20th gestational week with an increase of left ventricle EDV 
and LA dimensions but with no clear impact on CO. For the right side of the heart we 
observed a similar trend of increment of ventricular and atrial dimensions at 20 weeks 
but no further increase during late pregnancy.
DIsCUssIon
This study investigated how the supine and the left lateral positions during CMR af-
fects heart rate, cardiac volumes and dimensions at different gestational ages. To our 
knowledge this is the first study investigating the effect of two recumbent positions on 
cardiovascular hemodynamic measurements and changes in cardiac dimensions dur-
ing pregnancy using CMR. The data show a clear difference between the two positions, 
which become more marked as pregnancy advances but are significant from as early as 
20 weeks. There were minimal changes in the non-pregnant subjects. The existing data 
from non-pregnant humans with regards to the effect of different positions on hemo-
dynamic parameters are limited and sometimes conflicting. Some report that cardiac 
output is higher in the supine position compared to the right or left lateral position 12, 13, 
while others have shown that cardiac output is higher in the left lateral position than in 
the supine position 14 and still others that there is no difference in either position 15, 16. In 
our series, we found that there was no significant effect on hemodynamic parameters 
and cardiac dimensions of moving from the supine to the left lateral position in non-
pregnant women. However, we did observe a non significant decline in both heart rate 
and stroke volume leading to a borderline significant reduction in cardiac output.
Pregnancy itself is a circulatory burden with a significant impact on the cardiovascular 
system. Cardiac output increases 30-50% above pre-pregnancy levels. In addition, when 
a pregnant woman lies flat on her back, the gravid uterus partially compresses the infe-
rior vena cava with the consequent reduction of venous filling load and cardiac output 
2, 17. From our data it appears that the increase of left atrial volume accounts for the 
majority in increase in stroke volume. As such it seems that the relief of caval obstruction 
(preload) is far more important that the relief of aortic compression (afterload) for the 
increase in cardiac output. In our series the significant increase in LA dimensions and 
the trend to increase EDV in the left lateral position suggest an increased venous return 
in this position which is already present at 20 gestational weeks. The effect of the gravid 
uterus compressing the abdominal vessels might be enforced by the increase in plasma 
volume even as early as 20 weeks of pregnancy 2. An increase of right atrial pressure 
18 and left and right ventricular peak systolic and end-diastolic pressures 19 in the left 
lateral position can also help to explain the increased venous return. It is of interest to 
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observe that the heart rate was higher in the supine position compensating for the fall 
in stroke volume in this position 16 in an attempt to recover cardiac output. This could be 
partly explained by the fact that during mid-late pregnancy the suppression of cardiac 
vagal activity and the enhancement of cardiac sympathetic activity are greater in the 
supine position 20 than in the lateral position. In this series left ventricle EDV, EF, CO and 
SV increase significantly from the supine to left lateral position. These findings are easily 
explained: the change from the supine to the lateral position relieves the compression on 
the vena cava from the gravid uterus. The increasing venous return leads to an increased 
SV and so CO. Ueland et al 16 demonstrated that a change in position from the supine to 
the left lateral side produced a rise in CO by 8% at 20 to 24 weeks gestation, 13.6% at 28 
to 32 weeks gestation and 28.5% at term in a group of eleven healthy pregnant women. 
We observed that the SV increased by approximately 27% at 20 weeks gestation. At 32 
weeks gestation SV increased significantly by 35%. In our series turning to the left lateral 
position we observed an increment of the SV of the right ventricle which is more evident 
in the mid than in the late pregnancy. More studies are needed to better explain the 
consistency of this finding.
Some concerns may develop regarding the use of CMR in pregnant patients. Most 
studies evaluating MR safety during pregnancy do not show ill effects on the fetus 21-23. 
It is anyway good practice to avoid MR studies during the first trimester of pregnancy 
although it can be used if clinical indicated. All our patients were studied during the 
second or third trimester of pregnancy.
Several limitations of this study should be highlighted. First, our results should be 
tested in a larger sample of women including women with cardiac disease. Indeed the 
normal physiological respond to pregnancy could be different in patients with congeni-
tal or acquired cardiovascular diseases. In addition, the small sample size may justify the 
large standard deviation in our series. Second, because the interval between each MR 
acquisition was between 8 and 12 minutes it is possible that cardiac parameters had not 
returned to baseline. Additional studies using more time points and also investigating 
the reverse change from lateral to supine could clarify this interesting subject. Third, 
this study is a cross-sectional study. The effects of the position on cardiac hemodynamic 
should preferably be studied in a prospective-longitudinal study investigating the same 
population at different gestational times.
ConClUsIon
In the non-pregnant state, turning from supine to left lateral position have minimal ef-
fect on cardiac parameters. During pregnancy, from as early as 20 weeks, turning to the 
left lateral position has positive effects on cardiac hemodynamics inducing a significant 
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increase of venous return, SV and CO. Pregnant women requiring CMR should be studied 
in a consistent position for serial studies and the left lateral position is preferred from 
early pregnancy onwards, also to limit uteroplacental hypoperfusion.
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absTRaCT
While nifedipine is commonly used for tocolysis, the controversy on its safety remains. 
So far, the haemodynamic effects on maternal and fetal circulations have not been 
well documented. Fifteen normotensive women who received 20 mg nifedipine were 
included in this prospective observational study. The maternal and fetal haemodynamic 
effects were analysed using maternal echocardiography and fetal Doppler ultrasonog-
raphy. Nifedipine induced a significant afterload reduction in all women. It triggered 
a compensatory increase in cardiac output, which maintained blood pressure. These 
maternal changes had no influence on the uteroplacental and fetal circulations.
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InTRoDUCTIon
Nifedipine is a potent cardiovascular drug, registered for the treatment of ischaemic 
heart disease and hypertension. This calcium channel blocker is also commonly used 
for tocolysis in preterm labour. It was found to be superior to β-agonists with a better 
cardiovascular safety profile.1 Nifedipine does not seem to affect blood pressure signifi-
cantly in normotensive pregnant women, despite high-dose regimens.1–4 Nevertheless, 
there are some concerns on its safety.5,6 Rare but serious maternal cardiopulmonary and 
fetal complications have been reported in both humans and animals after tocolysis with 
calcium channel blockers. Nifedipine is not licensed for tocolysis and has not been sub-
jected to specific safety assessments for this indication. With the availability of atosiban, 
a registered alternative in Europe, the controversy on the use of nifedipine tocolysis has 
increased.6
Most adverse events can be explained by the cardiovascular profile of the drug, which 
is more extensive than a mere antihypertensive effect.4 By blocking calcium influx, 
nifedipine diminishes smooth muscle and myocardial contractility. In vascular tissue it 
results in an arterial relaxation with afterload reduction and increased coronary perfu-
sion. On cardiac function, nifedipine has a negative inotropic potential, which may result 
in an undesirable myocardial depression and pump failure. However, the peripheral va-
sodilatation can induce a baroreceptor-mediated increase in sympathetic tonus, leading 
to a compensatory cardiostimulation by increasing the heart rate.4
Despite the large-scale and off-label use of nifedipine in pregnancy, data on maternal 
haemodynamic effects of nifedipine in women are limited to maternal heart rate and 
blood pressure recordings. The effects on uteroplacental and fetal circulation are also 
largely unknown.
In this prospective observational study, we investigated the effects of nifedipine to-
colysis on maternal, fetal and uteroplacental haemodynamics in normotensive pregnant 
women.
MeTHoDs
The study was conducted from September 2007 to October 2008 at the Department of 
Obstetrics of the Erasmus Medical Centre of the University of Rotterdam. To selectively 
assess the influence of nifedipine and avoid interference from labour-induced changes, 
we investigated women who received tocolysis for external cephalic version.
Informed consent was obtained from 15 healthy normotensive pregnant women 
with an uncomplicated singleton pregnancy between 35 and 37 weeks. Women with 
a complicated cardiovascular history or signs of uteroplacental insufficiency were 
Chapter 4.1
94
excluded. The study protocol was approved by the local medical ethical committee. 
After confirmation of the breech presentation and 15 minutes of bed rest, baseline 
measurements for blood pressure as well as maternal haemodynamics (trans-thoracic 
echocardiography) and fetal and uteroplacental haemodynamics (Doppler ultrasound) 
were obtained. Then, one 10 mg capsule of nifedipine was administered twice with a 
20-minute interval. Women were instructed to swallow the whole capsule with a little 
water. Sixty minutes after the administration of the first capsule, all measurements 
were repeated. Finally, external cephalic version was attempted. The fetal condition 
was monitored by cardiotocography, in between ultrasound measurements and for 45 
minutes after the external cephalic version.
Systolic and diastolic blood pressure were measured by sphygmomanometry and 
mean arterial pressure was calculated. All ultrasound measurements were performed 
using a commercially available ultrasound device (iU22; Philips Ultrasound, Bothell, 
WA, USA), with cardiac and obstetric software packages. A 1–3-MHz sector probe 
transducer was employed for trans-thoracic echocardiography and a 2–5- MHz curved 
array transducer was used for the obstetric Dopplers. All measurements were obtained 
in a 15° left lateral tilt by one investigator (JC). Two-dimensional, M-mode and Doppler 
waveform images were digitally stored. Tracing and analysis were performed off site. For 
each variable the mean of three measurements was taken. The examination was usually 
completed within 30–45 minutes.
During maternal echocardiography, determinants of systolic and diastolic function 
were assessed. Left atrial diameter, aortic diameter and left ventricular end-diastolic and 
end-systolic diameters were obtained by M-mode. Left ventricular end-diastolic and 
end-systolic volumes were derived according to Teichholz formula and ejection fraction 
and fractional shortening were calculated.
The left ventricular outflow tract diameter was measured at the base of the aortic 
leaflets. The ventricular outflow tract velocity time integral (LVOTvti) was obtained by 
pulsed wave Doppler from an apical window and the corresponding heart rate (HR) was 
derived from the simultaneous electrocardiography (ECG) recording.
Stroke volume (SV), cardiac output (CO) and total vascular resistance (TVR) in dynes x 
s/cm5 were calculated accordingly.
Diastolic function was assessed by pulsed wave Doppler analysis of mitral and right 
superior pulmonary vein inflow signals. Mitral valve peak velocities in early diastole (E-
wave), during atrial contraction (A-wave) and the E/A ratio, as well as the deceleration 
time and isovolumetric relaxation time, were measured. Pulmonary vein peak systolic, 
diastolic and atrial reversal flow velocities were recorded. The maximum and minimum 
left atrial area were traced and the left atrial fractional area change was calculated. Peak 
regurgitation velocities over the pulmonary and tricuspid valves were determined by 
continuous wave Doppler.
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All uteroplacental and fetal Doppler measurements were obtained using colour-di-
rected pulsed wave Doppler. Pulsatility indices and time-averaged maximum velocities 
of the uterine arteries, umbilical artery, middle cerebral artery and ductus venosus were 
calculated.
Statistics were performed with the SPSS 15.0 software package (SPSS Inc., Chicago, IL, 
USA). Variables were tested for normality and measurements before and after nifedipine 
were compared with a student’s t test for paired samples or the nonparametric Wilcoxon 
signed ranks test as appropriate. In view of the number of parameters evaluated, we set 
P ≤ 0.01 (two-sided) as the limit of significance.
ResUlTs
Mean maternal age was 33 years. The external cephalic version was performed at a mean 
gestational age of 364/7 weeks and was successful in a third of the women (5 of 15). All 
women received a total of 20 mg nifedipine and no major maternal or fetal complica-
tions occurred. One woman reported minimal nausea, one a sensation of lighthead-
edness and another reported minor flushes after nifedipine administration. All these 
adverse effects were transient. None of them was accompanied by a significant change 
in blood pressure, or required additional treatment. Paired measurements of all major 
parameters of systolic and diastolic function as well as uteroplacental and fetal Dopplers 
were obtained in most women. The results for all parameters are depicted in Table 1.
Nifedipine did not cause a change in arterial blood pressure but induced a significant 
increase in maternal CO (15.5%) and a decrease in TVR (13.8%). Moreover, this pattern of 
reduced afterload and raised output was consistent in all women (except in one woman 
where the CO remained unchanged). Both significant increases in maternal HR (7.4%) 
as well as in LVOTvti (7.7%) and SV (6.7%) contributed equally to the increased output.
There were no significant changes in cardiac dimensions, other determinants of sys-
tolic or diastolic function or in uteroplacental and fetal Dopplers.
DIsCUssIon
This is the first study investigating the effects of nifedipine tocolysis on central maternal 
haemodynamics in combination with fetal and uteroplacental haemodynamics. Our 
results clearly indicate that nifedipine systematically induces a vascular relaxation 
with a significant reduction in TVR in normotensive pregnant women. It is masked by a 
constant blood pressure, as the fall in peripheral resistance is balanced by a compensa-
tory rise in CO. Our observations are in accordance with the findings of invasive stud-
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Table 1. Parameters of maternal, fetal and uteroplacental haemodynamics divided into determinants of 
maternal systolic function, maternal diastolic function and uteroplacental and fetal Doppler results
balanced by a compensatory rise in CO. Our observations
are in accordance with the findings of invasive studies on
nifedipine using right heart catheterisation, although most
were performed in nonpregnant individuals suffering from
cardiac disease or hypertension.4 These studies showed a
decrease in vascular resistance and BP, which led to both a
compensatory rise in HR as well as to an improved ventric-
ular emptying with increased SV and CO and decreased
ventricular filling pressure. As the magnitude of the changes,
especially in BP, was dependent on the pre-treatment
Table 1. Parameters of maternal, fetal and uteroplacental haemodynamics divided into determinants of maternal systolic function, maternal
diastolic function and uteroplacental and fetal Doppler results
Parameter* No. of
pairs
Mean before
nifedipine
Mean after
nifedipine
Mean difference
(95% CI)
P-value
Maternal systolic function
SBP (mmHg) 15 110 111 1 ()2 to 4) 0.364
DBP (mmHg) 15 71 70 )1 ()4 to 1) 0.253
MAP (mmHg) 15 84 84 0 ()2 to 1) 0.657
LVEDd (cm) 15 4.75 4.85 0.10 ()0.02 to 0.22) 0.087
LVESd (cm) 15 2.89 2.73 )0.16 ()0.48 to 0.16) 0.296
EDV (ml) 15 106 111 5 ()1 to 12) 0.085
ESV (ml) 15 33 33 0 ()3 to 3) 0.883
EF (%) 15 69 71 2 ()1 to 5) 0.234
FS (%) 15 39 41 2 ()1 to 4) 0.144
Ao (cm) 15 2.39 2.42 0.03 ()0.13 to 0.20) 0.670
LVOTd (cm) 15 2.02 2.01 )0.01 ()0.03 to 0.02) 0.582
LVOTcsa (cm2) 15 3.23 3.21 )0.02 ()0.10 to 0.06) 0.565
LVOTvti (cm) 15 22.4 24.1 1.7 (0.7 to 2.8) 0.003
HR (bpm) 15 80 86 6 (2 to 10) 0.005
SV (ml) 15 72 77 5 (1 to 9) 0.015
CO (l/min) 15 5.7 6.6 0.9 (0.5 to 1.2) < 0.001
TVR (dyne s/cm)5) 15 1247 1075 )172 ()239 to )105) < 0.001
Maternal diastolic function
E (cm/s) 15 87 90 3 ()4 to 10) 0.420
A (cm/s) 15 59 64 5 ()1 to 11) 0.112
E/A 15 1.5 1.4 )0.1 ()0.2 to 0) 0.155
Adur (ms) 15 125 122 )3 ()11 to 4) 0.324
DT (ms) 15 178 170 )8 ()22 to 7) 0.262
IVRT (ms) 15 74 72 )2 ()7 to 3) 0.375
Pvs (cm/s) 12 50 49 )1 ()8 to 5) 0.610
Pvd (cm/s) 12 45 42 )3 ()7 to 2) 0.221
Pva (cm/s) 12 31 32 1 ()3 to 4) 0.746
Pvadur (ms) 12 111 116 5 ()7 to 17) 0.352
LA (cm) 15 3.59 3.69 0.10 ()0.11 to 0.31) 0.325
LAmax (cm
2) 15 15.25 15.56 0.31 ()1.14 to 1.77) 0.646
LAmin (cm
2) 15 6.62 6.54 0.08 ()1.06 to 0.88) 0.848
LAFAC (%) 15 57 58 1 ()3 to 6) 0.561
TR (cm/s) 11 132 140 8 ()18 to 35) 0.500
PR (cm/s) 12 139 149 10 ()5 to 25) 0.178
Uteroplacental and fetal Doppler
PIruter 14 0.68 0.69 0.01 ()0.06 to 0.07) 0.862
TAMVruter (cm/s) 14 102 101 1 ()15 to 16) 0.924
PIluter 15 0.73 0.77 0.04 ()0.05 to 0.13) 0.379
TAMVluter (cm/s) 15 114 96 18 ()1 to 37) 0.061
PIuter 14 0.71 0.74 0.03 ()0.04 to 0.09) 0.387
TAMVuter (cm/s) 14 109 97 12 ()3 to 28) 0.119
PIumb 15 0.91 0.98 0.07 ()0.01 to 0.15) 0.069
TAMVumb (cm/s) 15 32 34 )2 ()7 to 3) 0.337
PImca 15 1.80 1.76 )0.04 ()0.22 to 0.14) 0.635
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degree of cardiac dysfunction and hypertension, it is often
stated that vascular relaxation does not occur in nor-
motensive people. However, invasive measurements in nor-
motensive volunteers and in pregnant ewes given
equivalent doses of nifedipine showed a similar pattern of
significant decrease in systemic vascular resistance which
triggered an increase in HR and CO but without changes
in blood pressure.7,8
The capacity to further reduce TVR is remarkable as
peripheral resistance is already largely decreased during
This study objectifies the pharmacodynamic profile of
nifedipine in normotensive pregnant women. Our results
show that two 10-mg capsules of nifedipine induce signifi-
cant but hidden changes in maternal central haemodynam-
ics 1 hour after administration. The balance between these
opposite effects on TVR and CO is probably the reason
why high doses of this potent drug can be used for toco-
lysis without complications in most people.
However, these findings cannot automatically be extrap-
olated to the longer treatment schedules or higher doses
Table 1. (Continued)
Parameter* No. of
pairs
Mean before
nifedipine
Mean after
nifedipine
Mean difference
(95% CI)
P-value
TAMVmca (cm/s) 15 26 28 )2 ()6 to 2) 0.311
PIVdv 12 0.57 0.57 0.00 ()0.10 to 0.1) 0.985
TAMVdv (cm/s) 12 64 54 10 ()5.8 to 25.8) 0.191
*A, mitral valve peak velocity during atrial contraction; Adur, duration of the A wave; Ao, aortic diameter; CO, cardiac output; DBP, diastolic
blood pressure; DT, deceleration time; E, mitral valve peak velocity during early diastole; E/A, E/A ratio; EDV, left ventricular end-diastolic volume;
EF%, ejection fraction; ESV, left ventricular end-systolic volume; FS%, fractional shorteni ; HR, heart rate; IVRT, isovolumetric relaxation time;
LA, left atrial diameter; LAFAC, left atrial fractional area change; LAmax, maximal left atrial area; LAmin, minimal left atrial area; LVEDd, left ventri-
cular end-diastolic diameter; LVESd, left ventricular end-systolic diameter; LVOTcsa, left ventricular outflow tract cross sectional area; LVOTd, left
ventricular outflow tract diameter; LVOTvti, left ventricular outflow tract velocity time integral; MAP, mean arterial pressure; PIluter, left uterine
artery pulsatility index; PImca, middle cerebral artery pulsatility index; PIruter, right uterine artery pulsatility index; PIumb, umbilical artery pulsatility
index; PIuter, mean uterine artery pulsatility index; PIVdv, ductus venosus pulsatility index for veins; PR, pulmonary valve regurgitation; Pva, pul-
monary vein peak atrial reversal velocity; Pvadur, pulmonary vein atrial reversal duration; Pvd, pulmonary vein peak diastolic velocity; Pvs, pulmon-
ary vein peak systolic velocity; SBP, systolic blood pressure; SV, stroke volume; TAMVdv, ductus venosus time-averaged maximum velocity;
TAMVluter, left uterine artery time-averaged maximum velocity; TAMVmca, middle cerebral artery time-averaged maximum velocity; TAMVruter,
right uterine artery time-averaged maximum velocity; TAMVumb, umbilical artery time-averaged maximum velocity; TAMVuter, mean uterine
artery time-averaged maximum velocity; TR, tricuspidal regurgitation; TVR, total vascular resistance.
P-values were calculated using student’s t test.
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*a, mitral valve peak velocity during atrial contraction; Adur, duration of the A wave; Ao, aortic diameter; CO, cardiac out-
put; DBP, diastolic blood pressure; DT, deceleration time; E, mitral valve peak velocity during early diastole; E/A, E/A ratio; 
EDV, l  ventr cular end-diastolic volume; EF%, ejection fraction; ESV, left ventricular e d-sys olic volume; FS%, frac ional 
shortening; HR, heart rate; IVRT, isovolumetric relaxation time; LA, left atrial diameter; LAFAC, left atrial fractional area 
change; LAmax, maximal left atrial area; LAmin, minimal left atrial area; LVEDd, left ventricular end-diastolic diameter; LVESd, 
left ventricular e d-systolic diameter; LVOTcsa, left ventric lar outflow tract cross sectional area; LVOTd, left ventricular 
outflow tract diamete ; LVOT ti, left entric lar outflow ct locity ime integral; MAP, mean arterial pressure; PIluter, left 
uterine artery pulsatility index; PImca, middle cerebral artery pulsatility index; PIrut , right uterine artery pulsatility index; 
PIumb, umbilical artery pulsatility index; PIuter, mean uterine artery pulsatility index; PIVdv, ductus venosus pulsatility in-
dex for veins; PR, pulmonary valve regurgitation; Pva, pulmonary vein peak atrial reversal velocity; Pvadur, pulmonary vein 
atrial reversal duration; Pvd, pulmonary vein peak diastolic velocity; Pvs, pulmonary vein peak systolic velocity; SBP, sys-
tolic blood pressure; SV, stroke volume; TAMVdv, ductus venosus time-averaged maximum velocity; TAMVluter, left uterine 
artery time-averaged maximum velocity; TAMVmca, middle cerebral artery time-averaged maximum velocity; TAMVruter, 
right uterine artery time-averaged maximum velocity; TAMVumb, umbilical artery time-averaged maximum velocity; TAM-
Vuter, mean uterine artery time-averaged maximum velocity; TR, tricuspidal regurgitation; TVR, total vascular resistance.
P-values were calculated using student’s t test.
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ies on nifedipine using right heart catheterisation, although most were performed in 
nonpregnant individuals suffering from cardiac disease or hypertension.4 These studies 
showed a decrease in vascular resistance and BP, which led to both a compensatory 
rise in HR as well as to an improved ventricular emptying with increased SV and CO and 
decreased ventricular filling pressure. As the magnitude of the changes, especially in 
BP, was dependent on the pre-treatment degree of cardiac dysfunction and hyperten-
sion, it is often stated that vascular relaxation does not occur in normotensive people. 
However, invasive measurements in normotensive volunteers and in pregnant ewes 
given equivalent doses of nifedipine showed a similar pattern of significant decrease 
in systemic vascular resistance which triggered an increase in HR and CO but without 
changes in blood pressure.7,8
The capacity to further reduce TVR is remarkable as peripheral resistance is already 
largely decreased during pregnancy as an adaptive mechanism initiating plasma vol-
ume expansion. Despite this, there still seems to be a reserve for further reduction in 
the healthy pregnant woman. One could argue that our study was performed near term 
when peripheral resistance has already slightly risen from its nadir, but the magnitude of 
the changes indicates that this could only offer a partial explanation.
Both a rise in HR as well as in SV equally contributed to the elevation in CO in the women 
in this study. Although the increased HR reflects sympathetic stimulation, the increase in 
SV is interesting. Apparently, a further afterload reduction, on top of the already lowered 
TVR can still induce a more efficient myocardial contraction with improved ventricular 
emptying, which is superior to the negative inotropic effect of nifedipine, and results 
in an increased SV. It reflects myocardial reserve in a normal healthy pregnant woman.
The absence of effects on diastolic function resembles the findings in invasive studies, 
where changes in filling pressures were limited to people with impaired systolic func-
tion.4 This study objectifies the pharmacodynamic profile of nifedipine in normotensive 
pregnant women. Our results show that two 10 mg capsules of nifedipine induce signifi-
cant but hidden changes in maternal central haemodynamics 1 hour after administra-
tion. The balance between these opposite effects on TVR and CO is probably the reason 
why high doses of this potent drug can be used for tocolysis without complications in 
most people.
However, these findings cannot automatically be extrapolated to the longer treat-
ment schedules or higher doses that are common for tocolysis.
Our results may also explain the observation that major maternal cardiovascular com-
plications with nifedipine use are more likely to occur in women with reduced cardiac 
reserve.6 In women with pre-existing cardiac disease, multiple pregnancy, (sub)clinical 
sepsis in preterm prelabour rupture of membranes, or use of multiple medications, 
further reduction of the TVR beyond a critical point or the incapacity to adequately 
compensate with the CO may induce haemodynamic compromise.
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Nifedipine readily crosses the placenta with a maternal/fetal plasma ratio of 0.93.3 
Despite significant changes in maternal haemodynamics we could not demonstrate any 
changes in the uterine, umbilical or middle cerebral pulsatility indices or time-averaged 
maximum velocities. This suggests that nifedipine has no effect on the uteroplacental or 
fetal circulation but the limitations of both measurements in reflecting total blood flow 
should be noted.
Our results are consistent with two studies on the short- term influence of a loading 
dose of nifedipine for tocolysis on placental, fetal cerebral and fetal atrioventricular 
Doppler results in normotensive women with preterm labour, where both maternal 
blood pressure and uteroplacental and fetal Doppler results were unaffected.2,9 Another 
study observed a significant decrease in uterine artery resistance but without changes 
in the arcuate or umbilical artery Doppler flows.3 The absence of changes in the uterine 
circulation is remarkable considering the substantial maternal afterload reduction. 
It indicates that in healthy normotensive pregnancy without signs of placental insuf-
ficiency, trophoblast invasion has lowered downstream resistance to such an extent that 
nifedipine is unable to further reduce uterine resistance, despite its potency to reduce 
the systemic resistance. Consequently, uterine hypoperfusion will only occur with hy-
potension, when the fall in TVR is not compensated by a rise in CO. This hypothesis is 
further supported by a study on prolonged nifedipine tocolysis, that only observed a 
decrease in uterine and middle cerebral pulsatility index when maternal blood pressure 
decreased significantly.10
Fetal acidaemia and hypoxaemia without changes in placental perfusion have been 
observed in animal studies.11 Despite widespread use of the drug in human pregnancy, 
there are no reports of fetal or neonatal acidosis related to nifedipine. Pirhonen et al.3 ob-
served cord blood pH and oxygen contents within normal ranges in postnatal samples. 
The reported fetal death could be attributed to maternal hypotension.12 An explanation 
for the discrepancy between animal and human findings is that while changes in pH and 
oxygen content are statistically significant in animal studies, it is questionable whether 
they are clinically relevant.
Precordial venous Dopplers may reflect changes in fetal acid–base status. This is the 
first report investigating the effect on paired ductus venosus measurements. We could 
not observe any changes after nifedipine administration. However, it is likely that minor 
changes in pH are too subtle to be reflected by this method.
The originality and strength of this study lie in the use of a non-invasive measure-
ment tool as well as in the selection of its population. The former allowed a thorough 
evaluation of maternal central haemodynamics, the latter permitted the examination 
of pregnant women in nearly physiological, controlled conditions without interference 
from labour-induced changes.
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Our study is limited by its observational design, the small number of women and large 
number of investigated parameters. Still we believe that its set-up, along with the mag-
nitude and remarkable consistency in the observed changes, allows us to draw conclu-
sions on the haemodynamic effects of nifedipine tocolysis despite the small population 
size. It is further supported by the observation that our results are in accordance with 
the effects one could expect based on the pharmacological profile of nifedipine.
ConClUsIon
Our results indicate that tocolysis with 20 mg oral nifedipine influences maternal hae-
modynamics 1 hour after intake in normotensive healthy pregnant women near term. 
Nifedipine induces an afterload reduction which triggers a rise in cardiac output. As a 
result, blood pressure often remains unchanged. Nifedipine has no negative effect on 
ventricular function. Neither the profound changes in maternal haemodynamics nor 
nifedipine itself seem to affect uteroplacental or fetal haemodynamics.
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absTRaCT
objective
Nicardipine permits rapid control of blood pressure in women with severe pre-eclampsia 
(PE) and hypertensive crisis. Our objective was to investigate its maternal and fetal he-
modynamic effects.
Methods
Ten severely pre-eclamptic pregnant women who required intravenous nicardipine 
for severe hypertension were included in this prospective observational trial. Ma-
ternal macrocirculation was assessed by transthoracic echocardiography. Maternal 
microcirculatory perfusion was examined sublingually with the sidestream dark field 
imaging technique. Fetal hemodynamics were assessed by Doppler examinations of the 
uteroplacental and fetal circulations. Maternal cardiac output, total vascular resistance, 
mitral E/A ratio and capillary heterogeneity index, uterine artery pulsatility index and 
fetal cerebroplacental ratio were considered primary outcomes. Paired measurements, 
obtained before administration of nicardipine infusion and after stabilization of blood 
pressure, were compared.
Results
Administration of nicardipine significantly reduced the mean arterial blood pressure 
(median difference, 26 mmHg; P = 0.002) and total vascular resistance (median differ-
ence, 791 dynes × s/cm5; P = 0.002) in all included women. This induced a reflex tachy-
cardia with consequent increase in cardiac output of 1.55 L/min (P = 0.004). There were 
no significant changes in the other determinants of maternal or fetal hemodynamic 
parameters.
Conclusions
Nicardipine effectively reduces blood pressure through selective afterload reduction 
that triggers an increase in cardiac output, without affecting maternal diastolic func-
tion, or microcirculatory, uteroplacental or fetal perfusion. This hemodynamic response 
is uniform and predictable. Fetomaternal cardiovascular profiling can be achieved by 
combining transthoracic echocardiography with obstetric Doppler.
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InTRoDUCTIon
A hypertensive crisis, defined as the occurrence of a systolic blood pressure (SBP) ≥ 
160 mmHg and/or diastolic blood pressure (DBP) ≥ 110 mmHg in women with pre-
eclampsia (PE), is a hypertensive emergency1,2. These women are at risk of developing 
complications such as cerebrovascular accidents and pulmonary edema3-6. Their blood 
pressure must be lowered rapidly without compromising the maternal or uteroplacental 
circulations. Nicardipine is a calcium channel blocker structurally related to nifedipine 
but with a distinctive pharmacological and hemodynamic profile that makes it attractive 
for the treatment of hypertensive emergencies in women with PE7-10. Its administration 
in intravenous form, rapid onset of action and short half-life allow easy titration against 
blood pressure while transplacental passage is limited (15%)11-13. Nicardipine induces 
general arterial relaxation that is more pronounced in cerebrovascular and coronary 
arteries8,14,15. The depressant action on myocardial muscle cells is less than with nifedip-
ine and its cerebrovascular selectivity renders it more effective in preventing ischemic 
stroke and hypertensive brain damage than other antihypertensive drugs16. Results from 
observational and comparative trials in women with severe PE are encouraging12,17-21. Ni-
cardipine seems equivalent or superior in reducing blood pressure to other intravenous 
drugs that are used commonly (labetalol, ketanserin, hydralazine), with excellent mater-
nal and fetal outcomes22,23. However, acute cardiac failure was described recently in two 
women with severe PE who were administered nicardipine combined with magnesium 
sulphate24. In addition, there are several reports of acute pulmonary edema associated 
with nicardipine when used for tocolysis, and animal studies have repeatedly shown 
uteroplacental hypoperfusion, acidosis and fetal death25–30. In fact, little is known on the 
effect of nicardipine on hemodynamic parameters other than blood pressure in cases of 
severe PE. The latter is important as PE is characterized by a profound hemodynamic in-
stability due to generalized endothelial dysfunction. We therefore aimed to investigate 
the hemodynamic effects of rapid blood pressure reduction with nicardipine in women 
with severe PE by analyzing the maternal macrocirculation, maternal microcirculatory 
perfusion, and uteroplacental and fetal circulations in a prospective observational study.
MeTHoDs
The study was conducted at the Department of Obstetrics and Prenatal Medicine, 
Erasmus Medical Centre, University of Rotterdam, Rotterdam, The Netherlands. Ten 
women with severe PE requiring intravenous nicardipine for a hypertensive crisis (SBP 
of ≥160mmHg and/or DBP of ≥110 mmHg) were included in the study. Severe PE was 
defined according to the NICE guideline on hypertension in pregnancy31. Informed 
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consent was obtained from all women and the study protocol was approved by the local 
medical ethics committee.
To minimize treatment delay, the presence and immediate availability of the main in-
vestigator at the time of inclusion was required. Inclusion was irrespective of previous or 
concomitant use of other oral antihypertensive medication. Women with known cardiac 
dysfunction, signs of imminent eclampsia or severe neurological symptoms, or those 
with signs of fetal distress or the need for respiratory support were excluded.
Patients were admitted to the obstetric high care unit and received a radial arterial 
line. All women were managed according to our standard protocol for severe PE. Fetal 
lung maturation was induced with steroids before 34 weeks and all women received 
magnesium sulphate for seizure prophylaxis. Restricted amounts of intravenous fluids 
were administered with medication. Nicardipine was initiated at 1 mg/h by continu-
ous infusion through a peripheral venous line. The dosage was subsequently titrated 
against blood pressure. Dose adaptations of 0.5mg/h occurred at 15-min intervals with 
a maximum infusion rate of 10mg/h. Treatment was targeted to a SBP ≤155mmHg and 
a DBP ≤100 mmHg.
Baseline hemodynamic measurements were obtained before treatment with nicar-
dipine. Measurements were repeated once blood pressure had been stabilized around 
the target values. Paired measurements, before and after nicardipine, were taken and 
compared in all women. Intra-arterial blood pressure recordings were obtained from 
the radial arterial line after appropriate cardiac levelling of the pressure transducer. 
Maternal central hemodynamics were assessed non-invasively by transthoracic echo-
cardiography, investigating the determinants of systolic function (cardiac dimensions, 
ejection fraction (EF), fractional shortening (FS), stroke volume (SV), cardiac output (CO) 
and total vascular resistance (TVR)) and diastolic function (mitral and pulmonary venous 
inflow patterns). Left ventricular end-diastolic and end-systolic diameters were obtained 
by M-mode ultrasound from which end-diastolic and end-systolic volumes were derived 
according to the Teichholz formula, and EF and FS were calculated. The left ventricular 
outflow tract diameter was measured at the base of the aortic leaflets. The ventricular 
outflow tract velocity time integral was obtained by pulsed-wave Doppler from an 
apical window and the corresponding heart rate was derived from the simultaneous 
electrocardiography recording. SV, CO and TVR were calculated accordingly. Diastolic 
function was assessed by pulsed-wave Doppler analysis of mitral and right superior 
pulmonary vein inflow signals. Mitral valve peak velocities were measured in early dias-
tole (E) and during atrial contraction (A) to give the E/A ratio, and the deceleration time 
and isovolumetric relaxation time were also measured. Pulmonary vein peak systolic, 
diastolic and atrial reversal flow velocities were recorded. The maximum and minimum 
left atrial areas were traced and the change in left atrial fractional area was calculated. 
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Peak regurgitation velocities over the pulmonary and tricuspid valves were determined 
by continuous-wave Doppler.
Uteroplacental and fetal hemodynamics were investigated by color-directed pulsed-
wave Doppler. Pulsatility index (PI) and time-averaged maximum velocity (TAMV) of 
the uterine arteries, umbilical artery, middle cerebral artery and ductus venosus were 
obtained, from which the cerebroplacental ratio (CPR; the middle cerebral artery PI/
umbilical artery PI) and gestational age-adjusted percentiles were calculated.
All ultrasound measurements were obtained at a 15° left lateral tilt by one investigator 
(J.C.) using a commercially available ultrasound device (iU22, Philips Ultrasound, Bothell, 
WA, USA), with cardiac and obstetric transducers and software packages as described 
in detail previously32. Two-dimensional, M-mode and Doppler waveform images were 
stored digitally. Tracing and analysis were performed off site. For each variable the mean 
of three measurements was used for analysis.
Changes in maternal cardiac function were also assessed by determination of the 
maternal serum brain natriuretic peptide (BNP). Contrary to the N-terminal prohormone 
BNP (NT-proBNP), BNP has a short half-life and can thus be used to monitor rapid 
changes in filling pressures33,34. From the arterial line, 4mL of blood was drawn and cen-
trifuged and the plasma was stored at −80°C. After collection of all samples, plasma was 
extracted on Sepac columns and the level of BNP was assessed using a commercially 
available radioimmunoassay (BNP-32, Peninsula Laboratories, San Carlos, CA, USA).
Changes in maternal microcirculatory perfusion were assessed sublingually by the 
sidestream dark field (SDF) imaging technique. We have reported previously on this in-
novative technique in women with severe PE, in which details on the method, measure-
ment and reliability of the technique are described in depth35. In brief, the technique 
consists of a handheld video microscope (MicroScan Video Microscope, MicroVision 
Medical, Amsterdam, The Netherlands) which emits stroboscopic green light that is 
absorbed by hemoglobin of individual red blood cells in superficial vessels of the sublin-
gual mucosa. High-contrast video images of circulating erythrocytes in the microcircula-
tion were recorded and later analyzed with specific software (AVA 3.0). Perfused vessel 
density (PVD), microvascular flow index (MFI) and a heterogeneity index (HI) for both 
capillaries (diameter <20 μm) and venules and arterioles (diameter 20–100 μm) were cal-
culated. PVD is a good reflection of functional microvascular density. MFI describes the 
predominant pattern and HI describes the heterogeneity of the microvascular flow. The 
microcirculatory characteristics before administration of nicardipine were also included 
in the previous study on microcirculation in women with severe PE35.
This study was undertaken as an exploratory pilot. Statistics were performed with IBM 
SPSS Statistics v. 20.0 (IBM, Armonk, NY, USA). Based on previous results and clinical rel-
evance, CO, TVR, mitral E/A ratio, uterine artery PI, CPR and capillary HI were considered 
primary outcome parameters32,35-37. Measurements obtained before and after nicardipine 
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were compared using non-parametric Wilcoxon signed-ranks test. In view of the number 
of parameters evaluated, we set P ≤ 0.01 (two-sided) as the limit of significance.
ResUlTs
Mean maternal age was 30 (range, 18–42) years and mean gestational age was 28 (range, 
25–34) weeks. An episode of HELLP-syndrome complicated the PE in six women; four 
occurred at the time of the measurements and two occurred in the following days. The 
mean 24-h protein excretion was 2.2 g (range, 0.3–6.7 g).
All women had a uterine artery PI≥95th centile, and 80% had early diastolic notches. 
Nine fetuses had Doppler signs of cerebral redistribution, with CPR≤5th centile, and eight 
were growth restricted (birth weight <10th percentile). Mean birth weight was 1086 
g (range, 540–2120 g). All women delivered by Cesarean section within 6 days of the 
measurements being obtained (mean, 2.5 days (range, 9 h to 6 days)). Indications for 
delivery were signs of fetal distress (n = 6), deteriorating maternal condition (n = 2) and 
failed induction of labor (n = 2), none of which could be related to the administration of 
nicardipine. All infants were alive at the time of writing.
All women were on concomitant oral antihypertensive medication before inclusion. 
Eight women were treated with α-methyldopa in various doses ranging from 1500 to 
3000 mg. Four women received concomitant nifedipine (dose range, 30–90 mg), two of 
which were administered in combination with α-methyldopa and one in combination 
with labetalol (600 mg).
Nicardipine was administered because of insufficient blood pressure control. The 
mean dose required to achieve the target blood pressures was 3.5mg/h. Seven women 
required a dose between 1.5 and 3mg/h and achieved the target blood pressures within 
1 h from administration. The remaining three women required 4, 6 and 7 mg/h, respec-
tively, and achieved the target blood pressure within 3 h from administration.
Two women experienced complications that could be attributed to nicardipine infu-
sion; one experienced two hypotensive episodes without signs of fetal compromise, 
which responded well to a fluid challenge and temporary cessation of nicardipine 
infusion, and another experienced a transient episode of chest pain. Thorough inves-
tigations with cardiac enzymes and electrocardiography ruled out ischemia. The pain 
disappeared and nicardipine was continued. No women developed pulmonary edema.
All paired measurements were performed within 6 h of one another. Paired measure-
ments of all major parameters of systolic and diastolic function, as well as uteroplacental 
and fetal Dopplers, were obtained in most women. BNP could not be measured reliably 
in one woman. The SDF-imaging microscope became available only after inclusion into 
the study of the third patient, and thus sublingual microcirculatory perfusion was ana-
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lyzed in seven women. The number and results of the paired measurements of maternal 
hemodynamics, uteroplacental and fetal Dopplers and microcirculatory perfusion are 
given in Tables 1–3, respectively.
Table 1 Maternal central hemodynamics obtained by radial arterial line and transthoracic echocardiogra-
phy in 10 pregnant women with pre-eclampsia and hypertensive crisis, before and after administration of 
nicardipine
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Table 1 Maternal central hemodynamics obtained by radial arterial line and transthoracic echocardiography in 10 pregnant women with
pre-eclampsia and hypertensive crisis, before and after administration of nicardipine
Parameter n Before nicardipine After nicardipine Median difference* P
Maternal systolic function
Systolic BP (mmHg) 10 188 153 35 (30 to 49) 0.002
Diastolic BP (mmHg) 10 105 83 19 (13 to 25) 0.002
MAP (mmHg) 10 130 105 26 (21 to 28) 0.002
LV end-diastolic diameter (cm) 10 4.85 4.60 0.05 (−0.08 to 0.25) 0.469
LV end-systolic diameter (cm) 10 3.00 2.75 0.25 (−0.15 to 0.68) 0.262
Ejection fraction (%) 10 67 74 −5 (−14 to 2) 0.186
Fractional shortening (%) 10 36 44 −7 (−13 to 2) 0.160
Aortic diameter (cm) 10 2.40 2.30 0.00 (−0.13 to 0.23) 0.642
LVOT diameter (cm) 10 2.00 2.00 0.00 1
LVOT velocity time integral 10 23.00 26.55 −0.85 (−2.80 to 0.73) 0.201
Heart rate (bpm) 10 76 91 −22 (−26 to −14) 0.006
Stroke volume (mL) 10 72 77 −2.5 (−7 to 2) 0.193
Cardiac output (L/min) 10 5.30 6.75 −1.55 (−2.10 to 0.95) 0.004
Total vascular resistance (dynes× s/cm5) 10 2010 1264 791 (662 to 921) 0.002
Maternal diastolic function
E (cm/s) 9 90 82 2 (−9 to 27) 0.340
A (cm/s) 9 83 90 −12 (−24 to 11) 0.426
E/A 9 1.1 0.9 0.3 (0.0 to 0.5) 0.125
Deceleration time (ms) 6 160 182 −15 (−46 to 26) 0.688
Isovolumetric relaxation time (ms) 10 88 86.5 0 (−14 to 25) 0.643
Pulmonary vein peak systolic velocity (cm/s) 6 62 71 −6 (−18 to 10) 0.625
Pulmonary vein peak diastolic velocity (cm/s) 6 57 53 7.5 (−9 to 17) 0.281
Pulmonary vein peak atrial reversal velocity (cm/s) 6 29 32 −3 (−6 to 8) 0.906
Diastolic grade 9 0 1 0 (0 to 1) 0.500
Left atrial fractional area change (%) 9 52 55 −1 (−11 to 3) 0.426
Tricuspid valve regurgitation (cm/s) 5 125 121 1 (−6 to 37) 0.813
Pulmonary valve regurgitation (cm/s) 4 163 155 5 (−12 to 20) 0.875
Brain natriuretic peptide (pmol/L) 9 15 12 0 (−8 to 4) 0.945
Data are given as median or median (interquartile range). *Difference calculated as value before nicardipine minus value after nicardipine.
A, mitral valve peak velocity during atrial contraction; BP, blood pressure; E, mitral valve peak velocity during early diastole; LV, left
ventricle; LVOT, left ventricular outflow tract; MAP, mean arterial pressure.
Table 2 Uteroplacental and fetal Doppler measurements in 10 pregnant women with pre-eclampsia and hypertensive crisis, before and after
administration of nicardipine
Parameter n Before nicardipine After nicardipine Median difference* P
UtA-PI 10 1.58 1.64 0.03 (−0.13 to 0.13) 0.734
UtA-TAMV (cm/s) 10 39 37 −1 (−13 to 6) 0.625
UA-PI 10 1.36 1.43 0.00 (−0.10 to 0.13) 0.941
UA-TAMV (cm/s) 10 18 19 −1 (−4 to 3) 0.902
MCA-PI 10 1.48 1.48 −0.01 (−0.15 to 0.18) 0.980
MCA-TAMV (cm/s) 10 23 25 1 (−4 to 4) 0.922
CPR 10 1.07 1.00 −0.04 (−0.19 to 0.13) 0.770
DV-PI 8 0.70 0.69 −0.02 (−0.20 to 0.34) 0.844
DV-TAMV (cm/s) 8 52 47 −6 (−8 to −1) 0.195
Data are given as median or median (interquartile range). *Difference calculated as value before nicardipine minus value after nicardipine.
CPR, cerebroplacental ratio; DV, ductus venosus; MCA, middle cerebral artery; PI, pulsatility index; TAMV, time-averaged maximum
velocity; UA, umbilical artery; UtA, mean uterine artery.
The powerful reduction in peripheral resistance with
enhancement of systolic function and preservation
of diastolic function is in accordance with obser-
vations in animals and non-pregnant subjects. They
are specific to nicardipine, as compared with other
dihydropiridines8–10,39. The increase in CO most likely
results from an increase in both heart rate and SV but the
latter failed to reach statistical significance. It occurred
despite the use of concomitant sympatholytic medication
(central α-blockade or β-blockade) in 90% of women.
This is comparable to previous studies showing that the
combination of nicardipine with sympatholytic drugs
(mostly β-blockers) resulted in increased antihypertensive
and anti-ischemic potency, while each drug alleviated the
negative hemodynamic properties of the other9,39–43.
Nicardipine has been associated with pulmonary edema
and acute cardiac failure in pregnant women24,29,30. None
of the women in this study developed these complications.
Women with PE are prone to developing pulmonary
edema when capillary leak is combined with cardiac
Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2016; 47: 89–95.
Data are given as median or median (interquartile range). *Difference calculated as value before nicardip-
ine minus value after nicardipine. A, mitral valve peak velocity during atrial contraction; BP, blood pressure; 
E, mitral valve pe k velocity du ing early diastole; LV, left v tricle; LVOT, left ventricular outflow tr ct; MAP, 
mean arterial pressure.
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Table 1 Maternal central hemodynamics obtained by radial arterial line and transthoracic echocardiography in 10 pregnant women with
pre-eclampsia and hypertensive crisis, before and after administration of nicardipine
Parameter n Before nicardipine After nicardipine Median difference* P
Maternal systolic function
Systolic BP (mmHg) 188 153 35 (30 to 49) 00
Diastolic BP (mmHg) 1 5 83 19 (13 to 25) 0.002
MAP (mmHg) 13 10 26 (21 to 28) 0 2
LV end-diastolic diameter (cm) 4.85 4.60 0.05 (−0.08 to 0.25) 469
LV end-systolic diameter (cm) 3.00 2. 5 0.25 (−0.15 t 0.68) 262
Eject on fraction (%) 67 74 −5 (−14 to 2) 186
Fractional short ning (%) 36 44 −7 (−13 to ) 160
Ao tic diameter (cm) 10 2.40 2.30 0.00 (−0.13 to 0.23) 0.642
LVOT diameter (cm) 10 2. 0 2.00 0.00 1
LVOT velocity time integral 10 23.00 26.55 −0.85 (−2.80 to 0.73) 201
Heart rate (bpm) 10 76 91 −22 (−26 to −14) 006
Strok volume (mL) 10 72 77 −2.5 (−7 t ) 193
Cardiac output (L/min) 5.30 6.7 −1.55 ( 2.10 to 0.95) 004
Total vascular resistance (dynes× s/cm5) 10 2010 1264 791 662 to 921) 002
Maternal diastolic function
E (c /s) 9 90 8 2 (−9 to 27) 340
A (cm/s) 83 90 −12 (−24 to 11) 426
E/A 1.1 0.9 0.3 (0.0 to 0.5) 1 5
De eleration tim (ms) 6 60 82 − 5 (−46 to 26) 688
Isovolumetric relaxation time (ms) 10 88 86. 0 4 5 643
Pulmo ary v in peak systolic velocity (cm/s) 6 62 71 −6 ( 18 to 10) 62
Pulmonary vein peak diastolic velocity (cm/s) 6 57 53 7.5 (−9 to 17) 0.281
Pulmonary vein peak atrial reversal velocity (cm/s) 6 29 32 −3 (−6 to 8) 0.906
Diastolic grade 9 0 1 0 (0 to 1) 0.500
Left atrial fr ction l area change (%) 9 52 55 −1 (−11 to 3) 0.426
Tricuspid valve regurgitation (cm/s) 5 125 121 1 (−6 to 37) 0.813
Pulmonary valve regurgitation (cm/s) 4 163 155 5 (−12 to 20) 0.875
Brain natriuretic peptide (pmol/L) 9 15 12 0 (−8 to 4) 0.945
Dat are given as median or median (interquartile range). *Difference calculated s valu before nicardipine minus value after nicardipine.
A, mitral valve peak velocity during atrial contraction; BP, blood pressure; E, mitral valve peak velocity during early diastole; LV, left
ventricle; LVOT, left ventricular outflow tract; MAP, mean arterial pressure.
Table 2 Uteroplacental and fetal Doppler measurements in 10 pregnant women with pre-eclampsia and hypertensive crisis, before and after
administration of nicardipine
Parameter n Before nicardipine After nicardipine Median difference* P
UtA-PI 10 1 58 1 4 0.03 (−0.13 to 0.1 ) 73
UtA-TA V (c /s) 10 39 3 1 13 to 6) 62
UA-PI 10 1.36 1.43 0.00 (−0.10 to 0.13) 0.941
UA-TAMV (cm/s) 10 18 19 −1 (−4 to 3) 0.902
MCA-PI 10 1.48 1.48 −0.01 (−0.15 to 0.18) 0.980
MCA-TAMV (cm/s) 10 23 25 1 (−4 to 4) 0.922
CPR 10 1.07 1.00 −0.04 (−0.19 to 0.13) 0.770
DV-PI 8 0.70 0.69 −0.02 (−0.20 to 0.34) 0.844
DV-TAMV (cm/s) 8 52 47 −6 (−8 to −1) 0.195
Data are given as median or med an (interquartile range). *Difference calculated as va ue b fore nicardipine minus value fter nicardipine.
CPR, cerebroplacental ratio; DV, ductus venosus; MCA, middle cerebral artery; PI, pulsatility index; TAMV, time-averaged maximum
velocity; UA, umbilical artery; UtA, mean uterine artery.
The p werful reduction in peripheral resistance with
enhancement of systolic funct o and preservation
of dias olic function is i accordance with obser-
vations in animals and n n-pr gnant subjects. They
are specific to nicardipine, as compared with other
dihydropiridines8–10,39. The increase in CO most likely
results from an increase in both heart rate and SV bu the
latter failed to reach statistical significance. It occurred
despite the use of concomitant sympatholytic medication
(central α-blockade or β-blockade) in 90% of women.
This is compar ble to previous studies showing that th
combination of nicardipin with sympatholyti drugs
(m stly β-blockers) resulted in increas d antihypertensive
and anti-ischemic potency, while each drug alleviated the
negative hemodynamic properties of the other9,39–43.
Nicardipine has been associated with pulmonary edema
and acute cardiac failure i pregnant women24,29,30. None
of the women in this study developed these complications.
Women with PE are prone to developing pulmonary
edema when capillary leak is combined with cardiac
Data are given as median or median (interquartile range). *Difference calculated as value before nicardip-
ine minus value after nicardipine. CPR, cerebr placental ratio; DV, uctus venosus; MCA, middle cerebral 
artery; PI, pulsatility index; TAMV, time-averaged maximum velocity; UA, umbilical artery; UtA, mean uter-
ine artery.
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Nicardipine induced a significant afterload reduction (39%) and fall in blood pressure 
(19%) below targeted values in all women. It triggered a rise in heart rate (25%), which 
resulted in a significant increase in maternal CO (34%) in all but one woman, who experi-
enced hypotension (Figure 1). She had tachycardia before administration of nicardipine 
(109 bpm). After the fluid challenge and continuation of nicardipine, the heart rate 
lowered but CO remained unchanged.
Table 3 Parameters of microcirculatory perfusion obtained by sidestream darkfield imaging for small (di-
ameter< 20 μm) and non-small (diameter ≥ 20 μm) vessels in pregnant women with pre-eclampsia and 
hypertensive crisis, before and after administration of nicardipine
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Table 3 Parameters of microcirculatory perfusion obtained by sidestream darkfield imaging for small (diameter< 20μm) and non-small
(diame er≥ 20μm) vessels in pregna t wom n with pre-eclampsia and hypertensive crisis, before and after administration of nicardipine
Maternal microcirculation n Before nicardipine After nicardipine Median difference* P
Perfused vessel density
Small vessels (/mm) 7 9.9 9.1 −1.4 (−2.7 to 0.9) 0.578
Non-small vessels (/mm) 7 2.4 2.0 0.1 (0.0 to 0.8) 0.469
Microvascular flow index
Small vessels 7 3.42 3.75 −0.02 (−0.25 to 0.17) 0.813
Non-small vessels 7 3.73 3.75 0.03 (−0.15 to 0.09) 1
Heterogeneity index
Small vessels 7 0.59 0.27 0.00 (−0.02 to 0.72) 0.438
Non-small vessels 7 0.27 0.25 0.00 (−0.03 to 0.07) 0.688
Data are given as median or median (interquartile range). *Difference calculated as value before nicardipine minus value after nicardipine.
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Figure 1 Evolution of: (a) systolic (SBP) and (b) diastolic (DBP) blood pressure, (c) total vascular resistance (TVR) and (d) cardiac output
(CO), in 10 pregnant women with pre-eclampsia and hypertensive crisis, before and after stabilization of blood pressure with nicardipine.
dysfunction resulting from severe hypertension44. The
cardioprotective effect we observed in our PE women is
therefore reassuring and seems specific to nicardipine as
opposed to several other antihypertensive drugs8.
The absence of uterine artery relaxation remains
remarkable. Uterine artery resistance was increased
in all women and one would then expect to see an
increased sensitivity to a potent vasodilator. Vascular
selectivity seems the most plausible explanation for this
phenomenon. The reactivity of nicardipine is known
to be less in femoral, renal and mesenteric arteries as
compared to cerebral and coronary arteries, and could
be equally so in uterine arteries14. The absence of fetal
Doppler changes is also reassuring. It suggests that
placental perfusion remains sufficient and transplacental
passage is too small to induce fetal responses, even in
more susceptible growth-restricted fetuses. These findings
are relevant as human data on uteroplacental and fetal
perfusion after treatment of hypertensive crisis with
nicardipine are lacking. However, the study design and
sample size do not permit the dismissal of all possible fetal
side-effects.
Despite the major macrocirculatory changes, we
observed neither improvement nor worsening in micro-
circulatory perfusion. This discrepancy between central
hemodynamics and microcirculation is well known from
other disease states with hemodynamic imbalance45,46.
On one hand it is reassuring to observe that microcircu-
lation and end-organ perfusion seem to be maintained,
despite a substantial afterload reduction. On the other, the
Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2016; 47: 89–95.
Data are given as median or median (interquartile range). *Difference calculated as value before nicardip-
ine minus value after nicardipine.Nicardipine in severe PE with hypertensive crisis 93
Table 3 Parameters of microcirculatory perfusion obtained by sidestream darkfield imaging for small (diameter< 20μm) and non-small
(diameter≥ 20μm) vessels in pregnant women with pre-eclampsia and hypertensive crisis, before and after administration of nicardipine
Maternal microcirculation n Before nicardipine After nicardipine Median difference* P
Perfused vessel density
Small vessels (/mm) 7 9.9 9.1 −1.4 (−2.7 to 0.9) 0.578
Non-small vessels (/mm) 7 2.4 2.0 0.1 (0.0 to 0.8) 0.469
Microvascular flow index
Small vessels 7 3.42 3.75 −0.02 (−0.25 to 0.17) 0.813
Non-small vessels 7 3.73 3.75 0.03 (−0.15 to 0.09) 1
Heterogeneity index
Small vessels 7 0.59 0.27 0.00 (−0.02 to 0.72) 0.438
Non-small vessels 7 0.27 0.25 0.00 (−0.03 to 0.07) 0.688
Data are given as median or median (interquartile range). *Difference calculated as value before nicardipine minus value after nicardipine.
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Figure 1 Evolution of: (a) systolic (SBP) and (b) diastolic (DBP) blood pressure, (c) total vascular resistance (TVR) and (d) cardiac output
(CO), in 10 pregnant women with pre-eclampsia and hypertensive crisis, before and after stabilization f bloo pressure with nicardipine.
dysfunction resulting from severe hypertension44. The
cardioprotective effect we observed in our PE women is
therefore reassuring and seems specific to nicardipine as
opposed to several other antihypertensive drugs8.
The absence of uterine artery relaxation remains
remarkable. Uterine artery resistance was increased
in all women and one would then expect to see an
increased sensitivity to a potent vasodilator. Vascular
selectivity seems the most plausible explanation for this
phenomenon. The reactivity of nicardipine is known
to be less in femoral, renal and mesenteric arteries as
passage is too small to induce fetal responses, even in
more susceptible growth-restricted fetuses. These findings
are relevant as human data on uteroplacental and fetal
perfusion after treatment of hypertensive crisis with
nicardipine are lacking. However, the study design and
sample size do not permit the dismissal of all possible fetal
side-effects.
Despite the major macrocirculatory changes, we
observed neither improvement nor worsening in micro-
circulatory perfusion. This discrepancy between central
hemodynamics and microcirculation is well known from
fi re 1 Evolution of: (a) systolic (SBP) and (b) diastolic (DBP) blood pressure, (c) total vascular resistance 
(TVR) and (d) cardiac output (CO), in 10 pregnant women with pre-eclampsia and hypertensive crisis, be-
fore and after stabilization of blood pressure with nicardipine.
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There were no significant changes in other parameters of cardiac function, BNP, mi-
crocirculatory perfusion and uteroplacental or fetal Dopplers. The mean infusion rate 
and hemodynamic effects of nicardipine were similar in women with and without the 
concomitant use of oral nifedipine.
DIsCUssIon
Our results indicate that intravenous nicardipine effectively lowers blood pressure 
through afterload reduction without compromising the maternal or fetal circulations 
in women with PE and a hypertensive crisis. The baroreceptor-mediated increase in 
heart rate induces a substantial rise in CO, which assures sufficient tissue perfusion. 
The uniformity and consistency of this hemodynamic effect in all included women is 
illustrated in Figure 1 and is remarkable, as previous studies have shown unpredictable 
hemodynamic responses once any form of treatment is initiated in women with PE38.
The powerful reduction in peripheral resistance with enhancement of systolic func-
tion and preservation of diastolic function is in accordance with observations in animals 
and non-pregnant subjects. They are specific to nicardipine, as compared with other 
dihydropiridines8-10,39. The increase in CO most likely results from an increase in both 
heart rate and SV but the latter failed to reach statistical significance. It occurred despite 
the use of concomitant sympatholytic medication (central α-blockade or β-blockade) 
in 90% of women. This is comparable to previous studies showing that the combina-
tion of nicardipine with sympatholytic drugs (mostly β-blockers) resulted in increased 
antihypertensive and anti-ischemic potency, while each drug alleviated the negative 
hemodynamic properties of the other9,39-43.
Nicardipine has been associated with pulmonary edema and acute cardiac failure in 
pregnant women24,29,30. None of the women in this study developed these complica-
tions. Women with PE are prone to developing pulmonary edema when capillary leak is 
combined with cardiac dysfunction resulting from severe hypertension44. The cardiopro-
tective effect we observed in our PE women is therefore reassuring and seems specific to 
nicardipine as opposed to several other antihypertensive drugs8.
The absence of uterine artery relaxation remains remarkable. Uterine artery resistance 
was increased in all women and one would then expect to see an increased sensitivity 
to a potent vasodilator. Vascular selectivity seems the most plausible explanation for 
this phenomenon. The reactivity of nicardipine is known to be less in femoral, renal 
and mesenteric arteries as compared to cerebral and coronary arteries, and could be 
equally so in uterine arteries14. The absence of fetal Doppler changes is also reassuring. 
It suggests that placental perfusion remains sufficient and transplacental passage is 
too small to induce fetal responses, even in more susceptible growth-restricted fetuses. 
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These findings are relevant as human data on uteroplacental and fetal perfusion after 
treatment of hypertensive crisis with nicardipine are lacking. However, the study design 
and sample size do not permit the dismissal of all possible fetal side-effects.
Despite the major macrocirculatory changes, we observed neither improvement nor 
worsening in microcirculatory perfusion. This discrepancy between central hemody-
namics and microcirculation is well known from other disease states with hemodynamic 
imbalance45,46. On one hand it is reassuring to observe that microcirculation and end-
organ perfusion seem to be maintained, despite a substantial afterload reduction. On 
the other, the increased output does not automatically imply increased capillary recruit-
ment. The lack of changes might be attributed to the fact that baseline microcirculatory 
perfusion before nicardipine was relatively normal in our population. We demonstrated 
previously that sublingual microcirculatory perfusion is disturbed mainly in severe PE 
with concurrent HELLP syndrome35. Only four women in this study had an episode of 
HELLP syndrome at the time of the microcirculatory measurements. Therefore, vessel 
densities were within normal ranges with nearly maximal perfusion and normal-to-hy-
perdynamic flow. Only capillary flow heterogeneity was relatively high in some women, 
resulting in a high mean score. While the latter improved substantially (lowered), it failed 
to reach statistical significance. It is highly plausible that our sample size was too small 
to demonstrate significant changes.
This study highlights the importance and potential of ultrasound for cardiovascular 
profiling in the study of complex hemodynamic conditions like severe PE. By investigat-
ing different components of the cardiovascular system, thereby looking from different 
angles, one receives a far more accurate, balanced, detailed and complete overview of 
hemodynamic function of both mother and fetus. This global cardiovascular perspective 
can be achieved by adding a sector probe and software for transthoracic echocardiogra-
phy to the readily available obstetric ultrasound devices. Despite our results, we believe 
that inclusion of microcirculatory assessment is also essential in this concept of cardio-
vascular profiling. It is the site at which oxygen and nutrient exchange, the ultimate 
goals of circulation, takes place and research has demonstrated the importance and 
potential of these parameters47.
Besides effectively reducing perfusion pressure, nicardipine is known for its selec-
tivity for cerebral and coronary vessels and potency to reduce cardiac and cerebral 
ischemia48-50. In future studies, the inclusion of cerebrovascular Doppler parameters and 
techniques that enable continuous monitoring should be considered.
Our study is limited by the relatively small number of patients and the concomitant 
use of other vasoactive medication. The hypertensive emergency warranted minimal 
treatment delay and immediate availability of the main investigator, which limited the 
inclusion population. The consistency, magnitude and level of significance of most 
primary outcomes make it unlikely that our conclusions would be challenged in a larger 
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study population. Furthermore, our results are in accordance with the pharmacologi-
cal profile of nicardipine in non-pregnant subjects. The study set-up was conceived to 
observe selectively the short-term effects of nicardipine. The heterogeneity in combina-
tion, dose and time since administration prevented detailed analysis of their individual 
influence of the concomitant medication. Four women were on nifedipine-regulated 
release tablets in doses of up to 90 mg a day before study inclusion. The efficacy and 
safety of intravenous nicardipine are remarkable in women who are already on oral nife-
dipine. This observation confirms our clinical experience and supports the distinctive 
pharmacological profile and potency of intravenous nicardipine.
Our findings indicate that nicardipine induces a predictive hemodynamic response in 
women with PE, characterized by an effective control of blood pressure through afterload 
reduction and increased ventricular performance, without compromising maternal or 
fetal circulation. Our observations offer theoretical support for the positive experiences 
seen in previous studies18,20,23. Finally, ultrasound can be used for fetomaternal cardio-
vascular profiling. This concept will become increasingly important for understanding 
the complex hemodynamic interactions in complicated pregnancies.
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absTRaCT
objective To compare microcirculatory perfusion in women with severe pre-eclampsia 
against that in healthy pregnant women, and secondly in women with severe pre-
eclampsia with or without HELLP syndrome (haemolysis, elevated liver enzymes, and 
low platelets).
Design Case–control study.
setting University Hospital Rotterdam, the Netherlands.
Population Twenty-three women with severe pre-eclampsia and 23 healthy pregnant 
controls, matched for maternal and gestational age. Out of the 23 women with severe 
pre-eclampsia, ten presented with HELLP syndrome.
Methods Microcirculation was analysed sublingually by a non-invasive sidestream dark-
field imaging device (SDF).
Main outcome measures Perfused vessel density (PVD), micro-circulatory flow index 
(MFI), and heterogeneity index (HI) were calculated for both small vessels (∅ < 20 µm; 
capillaries) and non-small vessels (∅ > 20 µm; venules and arterioles).
Results There were no significant differences between women with severe pre-eclamp-
sia and healthy controls. Women with pre-eclampsia and HELLP syndrome showed a 
reduced PVD (P = 0.045), MFI (P = 0.008), and increased HI (P = 0.002) for small vessels, as 
compared with women with pre-eclampsia but without HELLP syndrome.
Conclusions Sidestream dark-field is a novel, promising technique in obstetrics that 
permits the non-invasive evaluation of microcirculation. We did not observe major 
differences in sublingual microcirculatory perfusion between women with severe pre-
eclampsia and healthy pregnant controls. In women with severe pre-eclampsia, the 
presence of HELLP syndrome is characterised by impaired capillary perfusion.
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InTRoDUCTIon
The microcirculation is a vast network of small vessels with a diameter below 100 µm. 
It consists of arterioles that regulate flow to the capillaries, which subsequently drain 
in venules.1 Exchange of oxygen and nutrients occurs at the level of the capillaries, 
which mainly consist of a thin layer of endothelium. With the availability of new imaging 
modalities, the importance of microcirculatory perfusion in the pathophysiology, prog-
nosis, and treatment of conditions with profound haemodynamic imbalance, like sepsis, 
shock, and cardiac disease, is emerging. Parameters of microcirculatory perfusion seem 
independent of global haemodynamic status and appear to be strong predictors of out-
come.1-6 Sidestream dark-field (SDF) imaging is a novel technique enabling direct, non-
invasive visualisation of microcirculatory perfusion at the bedside in adults, children, 
and newborns.1-3 Severe pre-eclampsia is characterised by a maternal haemodynamic 
instability caused by generalised endothelial dysfunction.7 Many of its symptoms and 
complications strongly suggest microcirculatory dysfunction. A recent study indicates 
that capillary rarefaction precedes the clinical onset of pre-eclampsia.8 HELLP syndrome 
(haemolysis, elevated liver enzymes, and low platelets) is considered an expression of 
disease severity.9,10 Although its exact pathophysiology is not completely understood, 
the haemolysis, platelet consumption, and liver cell necrosis might reflect a more pro-
found disturbance in microcirculatory function. Our aim was to explore the potential 
and reliability of SDF in pregnant women, and to analyse microcirculatory perfusion in 
women with severe pre-eclampsia as compared with that in healthy pregnant women. 
Secondly, we investigated the influence of HELLP syndrome on microcirculation in 
women with severe pre-eclampsia.
MeTHoDs
study setting
The study was conducted from November 2009 to September 2012 at the department 
of Obstetrics and Prenatal Medicine of the Erasmus Medical Centre of the University 
of Rotterdam. Twenty-three women with severe pre-eclampsia were included. In ten of 
these women, pre-eclampsia was complicated by HELLP syndrome. Four women with 
severe pre-eclampsia had a history of systemic lupus erythematosus or chronic hyper-
tension. Twenty-three healthy pregnant women, matched for maternal and gestational 
age, were included as controls. Informed consent was obtained from all women and the 
study protocol was approved by the local medical ethical committee.
Severe pre-eclampsia was defined as pre-eclampsia (hypertension and significant 
proteinuria) with severe hypertension, and/or with symptoms, and/or with biochemical 
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and/or haematological impairment.11 HELLP syndrome was defined as the presence of 
at least two components of either haemolysis (lactate dehydrogenase, LDH ≥ 600 U/l), 
elevated liver enzymes (aspartate aminotransferase, AST ≥ 70 U/l), or thrombocytopenia 
(thrombocytes < 100 x 109/l).10 All women with severe pre-eclampsia were categorised 
into severe pre-eclampsia either with or without HELLP syndrome according to previous 
definitions after expert agreement by three of the authors (J.C., E.H., and J.D.). Women 
with severe pre-eclampsia were managed according to our local protocol, as described 
in Appendix S1.
In women with severe pre-eclampsia we aimed to perform microcirculatory analy-
sis at time points when disease activity was estimated to be maximal and when the 
interference from treatment was estimated to be as minimal as possible. Therefore, 
measurements were performed either before intravenous nicardipine, magnesium 
sulphate bolus, or when laboratory abnormalities consistent with HELLP syndrome 
occurred, irrespective of other concomitant medication. Age, parity, body mass index 
(BMI), gestational age, and medical history were obtained for all women.
All measurements were performed in a 15° left lateral tilt. Women were asked to 
refrain from eating or drinking for 30 minutes before measurements. Blood pressure 
was determined by manual sphygmomanometry. LDH, AST analysis, and thrombocyte 
count, as well as haematocrit and haemoglobin counts, were performed as part of the 
routine clinical procedure in women with severe pre-eclampsia on the day of the mea-
surements.
sidestream dark-field imaging
The sublingual microcirculation was visualized using SDF (Figure 1A).12 This hand-held 
video microscope (MicroScan; MicroVision Medical, Amsterdam, the Netherlands) emits 
stroboscopic green light (530 nm) from an outer ring of light-emitting diodes (LEDs), 
which penetrates the tissue to a depth of approximately 3 mm. The light is absorbed by 
the haemoglobin of individual red blood cells in superficial vessels. A negative image 
is transmitted back, after 5x optical magnification, to an isolated synchronised charge-
coupled device camera in the core of the probe. This allows high-contrast video images 
of circulating erythrocytes to be recorded with a 286x magnification from the microcir-
culation of organs covered with a thin epithelial layer. (Figure 1B, Video S1).5 SDF imaging 
has been validated against and found to be superior to intravital videomicroscopy.1,12
The consensus recommendations on how to best obtain and evaluate SDF measure-
ments were followed.4,13 After obtaining good image focus and contrast, with specific 
attention paid to avoiding pressure artefacts by assuring continuous venous perfusion, 
one investigator (E.H.) recorded three high-quality video clips per measurement, with a 
duration of at least 20 seconds, each at a different sublingual site (using a high-definition 
videocassette recorder: GV-HD700; Sony Instruments, Tokyo, Japan).These were digital-
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ised, blinded, and stored on an external hard drive. After completion of the data set, 
E.H. performed analysis of the blinded recordings using AVA 3.0 (Automated Vascular 
Analysis, MicroVision Medical, Amsterdam, the Netherlands).
Inter-observer variability was assessed though separate analysis of the 45 recordings 
of 15 randomly selected cases by a different investigator (E.B.).
As described in the consensus recommendations, the perfused vessel density (PVD), mi-
crocirculatory flow index (MFI), and the heterogeneity index (HI) for MFI were calculated, 
each reflecting distinctive characteristics of microcirculatory perfusion.4,13 Each parameter 
was determined separately for both small vessels (∅ < 20 µm, capillaries) and non-small 
vessels (20 µm ≤ ∅ ≤ 100 µm, mostly venules and arterioles).13-15 A detailed description 
of these parameters and respective methods of calculation is available in Appendix S2.
figure 1 (a) Set-up for a sublingual microcirculatory perfusion measurement with SDF. A disposable sterile 
plastic cap covers the mouthpiece of the probe. (b) A frozen video-clip image of sublingual microcirculation 
as viewed with SDF.
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statistical analysis
Statistical analysis was performed with SPSS 20.0 (SPSS Inc., Chicago, IL, USA). Variables 
were tested for normality and compared with the Students’ t-test or non-parametric 
Mann–Whitney U-test, as appropriate. The effect of parameters with a known potential 
to influence haemodynamics (gestational age, use of oral antihypertensive medication), 
vascular structure (maternal age, BMI, race), or SDF measurements (haematocrit, haemo-
globin) was assessed by analysis of covariance (ANCOVA) or by its non-parametric vari-
ant (the Quade test), as appropriate.16-20 The adjusted P values, with P ≤ 0.05 (two-sided) 
as the limit of significance, were used without correction for multiple comparisons.
Inter-observer reliability was assessed by calculation of the intraclass correlation 
coefficients from each parameter (PVD, MFI, and HI), separated for small- and non-small 
vessels in 15 cases. Inter-observer agreement for PVD was shown in Bland–Altman plots.
In the absence of SDF data on microcirculatory perfusion in pregnancy and severe 
pre-eclampsia, no power calculation was performed and this study was undertaken as 
an exploratory pilot.
ResUlTs
Adequate recordings and measurements were obtained for all participants. Intraclass 
correlation coefficients were good for capillary measurements and were moderate for 
larger vessels (Table 1). Figure 2 shows the inter-observer agreement for PVD in small 
and non-small vessels. Twelve women with severe pre-eclampsia received concomi-
tant oral antihypertensive medication. This included women with and without HELLP 
syndrome. All received methyldopa, nifedipine, or a combination of both. One woman 
received additional oral labetalol.
Table 1. Intraclass correlation coefficients (ICCs) and 95% CIs for inter-observer reliability
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woman received additional oral labetalol.
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Table 1. Intraclass correlation coefficients (ICCs) and 95% CIs for
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ICC
(95% CI)
PVD MFI HI
Small
vessels
0.87 (0.61–0.96) 0.94 (0.77–0.98) 0.96 (0.84–0.99)
Non-small
vessels
0.66 (0.05–0.89) 0.88 (0.63–0.96) 0.73 (0.15–0.91)
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The baseline characteristics of women with severe pre-eclampsia and healthy controls 
were similar (Table 2). As expected, blood pressure was significantly higher in women with 
severe pre-eclampsia. Pre-eclampsia was considered to be severe in all women either 
because of the severity of their hypertension (systolic blood pressure, SBP, ≥ 160 mmHg 
and/or diastolic blood pressure, DBP, ≥ 110 mmHg) or because of the presence of HELLP.
We could not observe any significant differences in sublingual microcirculatory perfu-
sion in women with severe pre-eclampsia, as compared with healthy controls (Figure 3A, B).
figure 2 Bland–Altman plots showing interobserver agreement for PVD in small and non-small vessels.
Table 2. Population characteristics
images were obtained at the bedside and with minimal
discomfort in all women. Inter-observer variability showed
good reliability for capillary vessels, but is less evident in
non-small vessels given the wide confidence intervals for
PVD and HI, despite acceptable intraclass correlation coef-
ficients. These findings are in line with previous results in
non-pregnant populations.4,15,21,22 Fortunately previous
research and our results suggest that the capillary com-
partment is the main area of interest in microcirculatory
perfusion. Therefore, SDF seems a preferred method for
microcirculatory analysis in obstetrics.1 Nevertheless,
although image recording is relatively straightforwards, off-
line analysis still requires substantial human input and
remains time consuming. Developments in the most
recent version of the SDF camera now permit automatic
image analysis, which will further improve reliability, and
holds promise for bedside recording and analysis in the
future.
Despite the increased blood pressure we did not observe
any difference in microcirculatory parameters in women
with severe pre-eclampsia, as compared with healthy preg-
nant controls.
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Figure 2. Bland–Altman plots showing interobserver agreement for PVD in small and non-small vessels.
Table . Population characteristics
Characteristics Women with severe pre-eclampsia
(n = 23)
Controls
(n = 23)
P
Severe pre-eclampsia versus control pregnancies
Nulliparous 54.5% 45.5% ns
Gestational age (weeks)* 33 (21–37) 33 (20–38) nt
Age (years) 31 (5) 31 (5) nt
BMI* 28 (20–56) 26 (18–41) ns
Systolic blood pressure (mmHg)* 170 (130–2015) 110 (99–135) <0.001
Diastolic blood pressure (mmHg)* 102 (76–115) 68 (50–90) <0.001
Characteristics With HELLP
(n = 10)
Without HELLP
(n = 13)
P
Severe pre-eclampsia with or without HELLP syndrome
Nulliparous 50% 54% ns
Gestational age (weeks)* 30 (21–37) 33 (25–37) ns
Age (years) 31.1 (3.9) 31.7 (6.5) ns
BMI* 26 (20–32) 30 (20–56) ns
Systolic blood pressure (mmHg) 157 (31) 174 (20) ns
Diastolic blood pressure (mmHg) 96 (12) 102 (7) ns
Oral antihypertensive medication 40% 69% ns
LDH (U/l)* 850 (602–2964) 426 (265–575) <0.001
AST (U/l)* 221 (42–1593) 23 (14–52) <0.001
Thrombocytes (109/l)* 99 (41–289) 250 (134–375) <0.001
ns, not significant; nt, not tested (matching criterion).
Values are expressed as means  standard deviations or medians with ranges according to normality.
*Non-parametric test used.
Cornette et al.
ns, not significant; nt, not tested (matching criterion).
Values are expressed as means ± standard deviations or medians with ranges according to normality.
*non-parametric test used.
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figure 3 (A) Scatter plots depicting differences in perfused vessel density (PVD), microcirculatory flow 
index (MFI), and heterogeneity index (HI) for small and non-small vessels between women with severe 
pre-eclampsia and controls, as well as between women with severe pre-eclampsia with and without HELLP 
syndrome. *Non-parametric test used. Adjusted P values are depicted for comparisons with statistical sig-
nificant difference; HELLP, severe pre-eclampsia with HELLP syndrome; PE, severe pre-eclampsia without 
HELLP syndrome. (B) Box plots depicting differences in PVD, MFI, and HI for small and non-small vessels 
between women with severe pre-eclampsia and controls, as well as between women with severe pre-ec-
lampsia with and without HELLP syndrome. Boxes denote interquartile ranges, bars in boxes represent 
median values, and error bars represent ranges.
*non-parametric test used. Adjusted P values are depicted for comparisons with statistical significant 
difference; HELLP, severe pre-eclampsia with HELLP syndrome; PE, severe pre-eclampsia without HELLP 
syndrome.
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Baseline characteristics between women with severe pre-eclampsia, with or without 
HELLP, were also comparable, except for the components of HELLP syndrome (Table 2).
Women with HELLP syndrome had significantly lower values of PVD and MFI and 
significantly higher values of HI for small vessels, as compared with women with severe 
pre-eclampsia without HELLP (Figure 3A, B). These differences remained significant 
after adjusting for haemoglobin count, haematocrit, BMI, medication use, pre-existent 
disease, maternal age, and gestational age.
DIsCUssIon
Main findings
In this study we explored microcirculatory perfusion in women with severe pre-eclamp-
sia with SDF, a novel technique in obstetrics.
Microcirculatory research has mainly been hampered by technological limitations. 
SDF allows the direct recording of high-contrast images and assessment of different 
aspects of microcirculatory perfusion. In our study, satisfactory images were obtained 
at the bedside and with minimal discomfort in all women. Inter-observer variability 
showed good reliability for capillary vessels, but is less evident in non-small vessels 
given the wide confidence intervals for PVD and HI, despite acceptable intraclass cor-
relation coefficients. These findings are in line with previous results in non-pregnant 
populations.4,15,21,22 Fortunately previous research and our results suggest that the capil-
lary compartment is the main area of interest in microcirculatory perfusion. Therefore, 
SDF seems a preferred method for microcirculatory analysis in obstetrics.1 Nevertheless, 
although image recording is relatively straightforwards, off- line analysis still requires 
substantial human input and remains time consuming. Developments in the most re-
cent version of the SDF camera now permit automatic image analysis, which will further 
improve reliability, and holds promise for bedside recording and analysis in the future.
Despite the increased blood pressure we did not observe any difference in microcir-
culatory parameters in women with severe pre-eclampsia, as compared with healthy 
pregnant controls. Apparently, the major macrocirculatory disturbances of severe 
pre-eclampsia are not reflected in significant differences in sublingual microcirculatory 
perfusion. Interestingly, when comparing women with severe pre-eclampsia with or 
without HELLP syndrome, we observed significant differences in all aspects of capillary 
perfusion, with a decrease in PVD and MFI and an increased HI in women with HELLP 
syndrome.
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Interpretation and relation to other studies
Previous microcirculation studies described a decreased venular diameter and increased 
postcapillary (venular) resistance in women with pre-eclampsia using intravital mi-
croscopy and plethysmography.23,24 Although we did not specifically asses changes in 
vessel diameters and used different techniques in different organ systems, we did not 
observe major changes in large vessels, which mostly consist of venules and arterioles 
to a lesser extent. Hasan, using intravital capillaroscopy, reported a reduced capillary 
density in 11 women with pre-eclampsia, as compared with normal healthy pregnant 
and non-pregnant women.25 Houben, using a similar set-up, could not confirm these 
findings, and Vollebregt, using orthogonal polarisation spectral imaging (OPS), did not 
find any changes in nail-fold capillary red blood cell velocity.24,26 Neither did we observe 
any changes at a capillary level between women with severe pre-eclampsia and healthy 
pregnant women. This discrepancy may be explained by the use of medication in women 
with pre-eclampsia, as Hasan performed the measurements before any intervention. 
Most women in our, Vollebregt’s, and Houben’s studies had already received some form 
of antihypertensive therapy, magnesium sulphate, or steroids for fetal lung maturation. 
These drugs have the potential to infuence capillary perfusion.27 In further studies, at-
tempts should be made to perform measurements before any treatment; however, this 
remains difficult, as the maternal condition often does not permit treatment delay in 
severe pre-eclampsia.
The suggestion of impaired capillary perfusion in women with both pre-eclampsia 
and HELLP syndrome might explain some aspects of the pathophysiology of HELLP syn-
drome.10 The reduced PVD and MFI might be a reflection of microvascular erythrocyte 
fragmentation and platelet adherence to the damaged endothelial surface in narrowed 
capillaries.28 The increased heterogeneity could explain the diffuse pattern of liver cell 
necrosis in HELLP, where fibrin microthrombi and fibrinogen deposits are often observed 
both in intact hepatic sinusoids and in areas with hepatocellular necrosis upon histol-
ogy.9 Heterogeneity of flow is an important characteristic of impaired microcirculation.1,4 
With heterogeneous flow, a reduced number of capillaries are perfused. Cells close to 
the capillaries extract the normal quantity of oxygen, but cells too far away become 
hypoxic. Although the total oxygen delivery is the same, heterogeneous perfusion prob-
ably affects tissue oxygenation more than a reduced but homogenous flow.
future research
Sublingual microcirculation is easily accessible for SDF. It is representative in sepsis, 
probably because of the embryological and metabolic similarities with the splanchnic 
mucosa.1,4 Even so, pre-eclampsia is a complex syndrome that groups a broad clini-
cal spectrum with variable degrees of organ dysfunction. It is therefore questionable 
whether the endothelial dysfunction is always manifested equally in all vascular beds. 
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Our results, both in women with and without HELLP, could be explained by the fact 
that the sublingual microcirculation may not be the most representative site in all 
pre-eclamptic women. SDF enables microvascular analysis in different areas (e.g. skin, 
conjunctiva, nail-fold, vagina, cervix, etc.). Further research in obstetrics should explore 
microcirculatory perfusion at various sites during the haemodynamic adaptation of nor-
mal pregnancy, and explore eventual representative areas in pathological conditions.
Besides facilitating (patho) physiological research in larger populations, future im-
proved versions with rapid bedside analysis also offer perspectives for clinical implica-
tions. As in sepsis and cardiogenic shock, microcirculatory perfusion analysis has the 
potential to improve outcome prediction, and assist in the selection of candidates for 
expectant management or monitoring of medical treatment.6,29
strengths and limitations
This is the largest population of women with pre-eclampsia investigated for microcircula-
tory changes in a prospective, case-controlled design. Our control group of 23 pregnant 
women is also one of the largest investigated populations of healthy subjects using SDF. 
The significant capillary differences in women with HELLP syndrome seem supported 
by a large effect size. Although it remains controversial whether this exploratory set-up 
allows for adjustment, significant differences remained, irrespective of adjustment for 
confounding factors. The absence of clinically relevant spread in the 95% confidence 
intervals of most parameters suggest that the size of our population was probably suf-
ficient to exclude differences in sublingual microcirculation between healthy women 
and women with pre-eclampsia. Still, the populations remain small and this study 
should merely be viewed as an exploratory analysis. Our results certainly need further 
confirmation in a larger trial, separating women with and without HELLP syndrome, and 
preferably before any intervention.
ConClUsIon
Sidestream dark-field (SDF) imaging is a promising technique for the study of microcir-
culatory perfusion in obstetrics. Our study indicates that there are no major differences 
in sublingual microcirculatory perfusion between women with severe pre-eclampsia 
and healthy pregnant controls; however, HELLP syndrome is associated with an impair-
ment of all aspects of capillary perfusion.
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ResPonse To 2016-lT-17311
Dear Sir,
In their letter the authors describe a case of placental abruption with fetal demise in 
a women with severe pre-eclampsia and HELLP syndrome. Despite delivery and sup-
portive treatment, she deteriorated over the following days with occurrence of kidney 
failure, eclamptic seizures and cardiac arrest, for which CPR was started. Spontaneous 
circulation was recovered but remained unstable, for which ECMO and hypothermia 
were initiated with short delays. While experience with extracorporeal cardiopulmonary 
resuscitation (E-CPR) in pregnancy is limited, evidence in the general population sug-
gests its superiority over conventional CPR.1 It is probably the prompt action of the team 
with rapid initiation of ECMO that contributed to the good maternal recovery. As timing 
is crucial in these circumstances and obstetricians are often first involved, knowledge 
about these evolutions in E-CPR will probably help in reducing ECMO initiation time, 
thereby improving outcome.
We also agree with the authors that this case strongly suggests microvascular dys-
function. It can occur independently from the apparent macrocirculatory hemodynamic 
instability. Yet, it is on this capillary level that the main goal of circulation, the exchange 
of O2, nutrients and fluids, for CO2, and waste products between blood and tissue cells 
takes place.
We and others have previously demonstrated microcirculatory perfusion problems 
in women with HELLP.2,3 While more research is needed on the subject, microvascular 
assessment has the potential to assist in predicting prognosis and in guiding treatment.
In this case, the clinical condition deteriorated despite delivery and adequate sup-
portive treatment. It highlights that in severe pre-eclampsia, our current management 
is in essence limited to damage control until the maternal condition spontaneously 
recovers after delivery. Hypertension control within the safe zone merely prevents cere-
brovascular incidents and magnesium sulphate is mainly for seizure prophylaxis. None 
of these actions substantially improves the pre-eclamptic condition. While intravascular 
volume depletion is prominent, fluid management remains a controversial issue, given 
the capillary leak and risk of iatrogenic pulmonary oedema. In the future, assessment of 
functional microcirculatory haemodynamics with small handheld cameras, might assist 
in optimising fluid therapy.4 The main two mechanisms behind oxygen delivery from red 
blood cells (RBC) to tissues are convection and diffusion. The former depends on RBC 
velocity, O2 saturation and O2 carrying capacity. The latter is mainly dependent on the 
O2 gradient and is inversely proportional to the distance between tissues and RBC. Al-
though crystalloids have little inherent capacities to improve O2 delivery, administration 
can increase RBC velocity, thereby improving convection and, by opening previously 
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closed capillaries, reducing distance and improving passive interstitial oedema again 
increases the distance.
Microvascular imaging could assist in achieving optimal convection and diffusion by 
measuring parameters of RBC velocity and perfused capillary density. While this concept 
seems promising, it remains experimental at this moment. Extensive research is still 
needed before its clinical value and benefice can be truly be evaluated in women with 
severe pre-eclampsia.
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absTRaCT
Although its prevalence is relatively low in pregnant women, heart disease is the most 
important cause of maternal mortality. Problems may arise due to hemodynamic bur-
den and the hypercoagulable state of pregnancy. Heart disease may be congenital or 
acquired. In developed countries, the former composes the biggest part of women with 
heart disease. Patients with unrepaired lesions, cyanotic lesions, diminished systemic 
ventricular function, complex congenital heart disease, left ventricular outflow tract 
obstruction, pulmonary hypertension, or mechanical valves are at highest risk of devel-
oping complications during pregnancy.
All patients with known cardiac disease should preferably be counseled before 
conception. Pre-pregnancy evaluation should include risk assessment for the mother 
and fetus, including medication use and information on heredity of the cardiac lesion. 
Management of pregnancy and delivery should be planned accordingly on individual 
bases. The types of complications are related to the cardiac diagnosis, with arrhythmias 
and heart failure being most common. Treatment options should be discussed with the 
future parents, as they may affect both mother and child. In general, the preferred route 
of delivery is vaginal. The optimal care for pregnant women with heart disease requires 
multidisciplinary involvement and is best concentrated in tertiary centers.
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InTRoDUCTIon
epidemiology
In the developed world many women with congenital heart disease are reaching child-
bearing age and wish to become pregnant.
While congenital heart disease is more often encountered than acquired disease in 
pregnant women, it seems associated with a lower risk. Acquired conditions such as 
aortic dissection, peripartum cardiomyopathy, and acute coronary syndrome (ACS) 
cause the highest maternal mortality rates 1,2. Pregnancy increases the risk of having an 
ACS three- to four-fold 3. The overall incidence of pregnancy related ACS is reported to 
be between 2.7 and 6.2 per 100,000 deliveries and this figure is increasing, probably due 
to changes in lifestyle, higher prevalence of obesity, and older age at pregnancy 3,4. In 
the developing world, rheumatic heart disease remains the most common pathology 5.
PHysIologICal CHanges In noRMal PRegnanCy
Major hemodynamic changes take place during pregnancy. Total peripheral vascular 
resistance (TPVR) is reduced and blood volume and cardiac output are increased around 
50% 6. During labor and delivery, cardiac output is further increased as a result of uterine 
contractions and maternal effort 6. After delivery, most changes are rapidly reversed in 
the first 2 weeks with further normalization toward preconception values after 3–12 
months. Fig. 1 shows the hemodynamic changes. However, some structural changes 
might never completely be reversed.
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Fig. 1. Hemodynamic changes in pregnancy. CO, cardiac output; SV, stroke volume;
HR, heart rate; Hb, hemoglobin; TPVR, total peripheral vascular resistance.
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In order to reduce blood loss around delivery, the production of tissue plasminogen 
activator (tPA), protein C and S is decreased and tPA inhibitor and factors V, VII, VIII, IX, X, 
XII and von Willebrand factor are increased, leading to a hypercoagulable state 7-9.
ManageMenT of PRegnanCy In woMen wITH HeaRT DIsease
Pre-pregnancy counseling
Counseling after thorough evaluation should be offered to all women of reproductive age 
with known cardiac disease. This should preferably be done before conception or alterna-
tively in early pregnancy 5. Risk for persistent deterioration of heart function may influence 
the choice whether to become pregnant. Pre-pregnancy evaluation should focus on iden-
tifying and quantifying risks for both mother and offspring. An exercise test (with VO2 max 
measurements) and echocardiogram provide essential information on pre-pregnancy 
cardiac status and reserve. Life expectancy and ethical aspects of parenthood should also 
be discussed during the pre-pregnancy consultation. Genetics and inheritance will be of 
special interest in some patient groups (congenital heart disease, Marfan syndrome, and 
hypertrophic cardiomyopathy) 5. The advantages and disadvantages of medication should 
be discussed including teratogenicity. If necessary, drug schedules should be adapted. 
More information on medication in pregnancy can be found in Table 1.
Table 1 Medication during pregnancy. Food and drug administration (FDA) classification: Category A: Ad-
equate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of 
pregnancy (and there is no evidence of risk in later trimesters). Category B: Animal reproduction studies 
have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in 
pregnant women. Category C: Animal reproduction studies have shown an adverse effect on the fetus and 
there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of 
the drug in pregnant women despite potential risks. Category D: There is positive evidence of human fetal 
risk based on adverse reaction data from investigational or marketing experience or studies in humans, 
but potential benefits may warrant use of the drug in pregnant women despite potential risks. Category X: 
Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of 
human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks 
involved in use of the drug in pregnant women clearly outweigh potential benefits.
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Table 1
Medication during pregnancy. Food and drug administration (FDA) classiﬁcation: Category A: Adequate and well-controlled studies have failed to demonstrate a risk to the
fetus in the ﬁrst trimester of pregnancy (and there is no evidence of risk in later trimesters). Category B: Animal reproduction studies have failed to demonstrate a risk to
the fetus and there are no adequate and well-controlled studies in pregnant women. Category C: Animal reproduction studies have shown an adverse effect on the fetus and
there are no adequate and well-controlled studies in humans, but potential beneﬁts may warrant use of the drug in pregnant women despite potential risks. Category D:
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential beneﬁts may
warrant use of the drug in pregnant women despite pot ntial r sks. Category X: Studies in animals or hum ns have demons rated f tal abnormalities nd/or t ere is positive
evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women
clearly outweigh potential beneﬁts.
Medication FDA Information
Atenolol D Intrauterine growth restriction and premature birth
Other beta-blockers C Low birth weight, hypoglycemia, and bradycardia in the fetus
Angiotensin-converting enzyme inhibitors D High incidence fetal death and fetotoxic effect: renal failure, renal dysplasia
Amiodarone D Thyroid insufﬁciency
Angiotensin receptor blockers D High incidence fetal death and fetal renal failure
Aspirin B Low-dose aspirin is safe (large database)
Calcium channel antagonists C Diltiazem: an increase in major birth defects has been reported
Clopidogrel B The beneﬁts of using clopidogrel in some high-risk pregnancies may outweigh the potential
fetal risks
Digoxin C No reports of congenital defects, monitor serum levels
Loop diuretics C Hypovolemia can lead to reduced uterine perfusion
Low molecular weight heparin and
unfractionated heparin
C Factor Xa should by measured weekly, levels may ﬂuctuate during pregnancy
Nitrates B Careful titration is advised to avoid maternal hypotension
Spironolactone D Potential anti-androgenic effects on the developing male fetus
Statins X Animal studies demonstrated increased skeletal abnormalities, fetal and neonatal mortality.
Thiazide diuretics B Hypovolemia can lead to reduced uterine perfusion
Diagnosis in pregnancy
Identifying deterioration of an existing cardiac condition can be
a diagnostic challenge as cardiopulmonary signs and symptoms
reported during normal pregnancy closely mimic heart disease.
In addition, acquired heart diseases often present acutely and
catastrophically in women with no known pre-existing disease.
during the second day after labor [21]. Troponin I is not elevated
in normal pregnancy, as a result troponin I is the recommended
laboratory test in pregnancy [22]. However, troponin I serum levels
can be elevated in patients with pre-eclampsia or a hypertensive
crisis. It is not clear whether this is a sign of cardiac ischemia in
thesepatients. IncreasedB-typenatriureticpeptide levels are found
during pregnancy in many pregnant women with heart disease. In
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Several risk stratification models have been described over the years. Siu et al. pub-
lished the CARPREG risk score in 2001 mainly based on women with congenital and 
valvular heart disease. Significant predictors for adverse maternal and neonatal out-
come were prior cardiac events (heart failure, transient ischemic attack, stroke before 
pregnancy or arrhythmia), baseline New York Heart Association (NYHA) functional class 
>II or cyanosis, left heart obstruction (mitral valve area <2 cm2, aortic valve area <1.5 
cm2, peak left ventricular outflow tract gradient >30 mmHg by echocardiography) and 
reduced systemic ventricular systolic function (ejection fraction <40%) 10. Khairy et al. 
found additional predictors for adverse outcome namely a history of smoking and severe 
pulmonary regurgitation 11. The ZAHARA investigators showed in a large retrospective 
cohort of women with congenital heart disease that a history of arrhythmic events or 
mechanical valve implantation are independent predictors for maternal and neonatal 
complications 12. The World Health Organization (WHO) developed a risk score based 
on cardiac pathology and co-morbidity. WHO class 1 indicates low risk, WHO class 2 
indicates an intermediate risk, WHO class 3 indicates high risk, and WHO class 4 indicates 
a contraindication for pregnancy (Table 2) 13.
Complications during pregnancy
The type of complication depends on the specific cardiac pathology (Table 2). Arrhyth-
mias and heart failure are the most common complications encountered 14.
Heart failure: All patients with heart failure during pregnancy should be admitted for 
bed rest. Medical treatment includes salt and fluid restriction, diuretics to limit the vol-
ume load, and antihypertensive therapy for afterload reduction. Angiotensin-converting 
enzyme (ACE) inhibitors can induce fetal anuria, pulmonary hypoplasia, and skull de-
formities especially when used in the second and third trimester. They are, therefore, 
contraindicated during pregnancy. However, in some specific situations the maternal 
benefits can outweigh the fetal risks and ACE inhibitors may be used for a short time 5,15.
Arrhythmias: The incidence of arrhythmias may be increased during pregnancy in 
women with heart disease. When drug therapy is deemed necessary, beta-blockers or 
digoxin are the preferred choice. The latter can be used in women with atrial fibrillation. 
Due to the increase in blood volume during pregnancy, higher doses are necessary to 
reach adequate blood levels. Electrical cardioversion is the treatment of choice for all 
drug-refractory maternal arrhythmias. It can be performed safely during pregnancy16.
Bradyarrhythmias are uncommon and usually well tolerated. Pacemaker implantation 
may be necessary in selected patients whereby radiation should be kept to a minimum 
17. Ectopic beats are often benign and also present in one-third of healthy pregnant 
women. Management mainly consists of reassurance. Supraventricular tachyarrhythmias 
are rare 17. Nakagawa et al. studied 11 patients with new-onset ventricular arrhythmia 
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during pregnancy, 73% of these originated from the right ventricular outflow tract, post-
pregnancy the arrhythmia disappeared completely in all patients 18.
Diagnosis in pregnancy
Identifying deterioration of an existing cardiac condition can be a diagnostic challenge 
as cardiopulmonary signs and symptoms reported during normal pregnancy closely 
mimic heart disease. In addition, acquired heart diseases often present acutely and 
catastrophically in women with no known pre-existing disease. Recognition of the acute 
Table 2 Different diagnoses with corresponding risks categories and most encountered problems.
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Table 2
Different diagnoses with correspondi g ri ks categories and mo t encountered problems.
Type of heart disease WHO
categories
Most often encountered complications Other important information
Congenital heart disease (corrected)
Atrial septal defect 1 Arrhythmias (1%) In uncorrected atrial septal defect higher risk
of pre-eclampsia
Ventricular septal defect 1 Premature delivery (12%) In uncorrected ventricular septal defect higher
risk of pre-eclampsia
Atrio-ventricular septum defect 2 or 3 Arrhythmias (10%)/deterioration of
atrio-ventricular valve regurgitation (17%)
Recurrence of congenital heart disease in up to
10%
Tetralogy of Fallot 2 Arrhythmias (6%) Patients with severe pulmonary regurgitation
are at risk for progressive right ventricular
dilation
Coarctation of the aorta 2 or 3 Hypertensive disorders (11%) Increased risk of aortic dissection
Transposition of the great arteries
(Mustard/Senning)
3 Arrhythmias (22%)/heart failure (11%) Irreversible ventricular dysfunction in 10%
Fontan operation 3 Arrhythmias (16%)/heart failure (4%) In case of cyanosis risk for miscarriage
Eisenmengers syndrome 4 Heart failure (21%)/maternal mortality up to
50%
Mainly in post-partum period (ﬁrst 3 days)
Valvular heart disease
Mitral stenosis 2 or 3 Heart failure (31%)/arrhythmias (11%) Mainly in patients with mitral valve <1.5 cm2
Aortic stenosis 2 or 3 Heart failure (3–44%)/arrhythmias (6–25%) Mainly in patients with an aortic
valve <1.5 cm2
Pulmonary stenosis 1 Right sided heart failure (9%) Mainly in patients with moderate to severe
pulmonary stenosis
Regurgitation lesions 1 or 2 Heart failure (7%)/supra ventricular
tachycardia (9%)
Mainly in patients with decreased cardiac
function at baseline
Mechanical valves 3 Valvular thrombosis up to 10% maternal
mortality up to 4%
Outcome depends on anticoagulation regimen
used
Cardiomyopathy
Peri-partum cardiomyopathy in
current pregnancy
2 or 3 Severe heart failure at the end of pregnancy
100%, maternal mortality in 15%
Half of the patients have complete recovery of
ventricular function
Peri-partum cardiomyopathy in
previous pregnancy without
abnormal ventricular function
2 or 3 Recurrence of heart failure (21%) Ventricular function further decreases in some
patients
Peri-partum cardiomyopathy in
previous pregnancy with abnormal
ventricular function
4 Recurrence of heart failure (44%) maternal
mortality (20%)
Ventricular function further decreases in most
patients
Dilated cardiomyopathy 2 or 3 Heart failure (25%) arrhythmia’s (19%) Mainly in patients with abnormal ventricular
function (left ventricular ejection fraction
<45%) at baseline
Hypertrophic obstructive
cardiomyopathy
2 or 3 Heart failure (28%) Mainly in symptomatic patients at baseline,
beta-blockers should be considered
Hypertrophic non obstructive
cardiomyopathy
2 or 3 Low risk of heart failure Mainly in symptomatic patients at baseline
Ischemic heart disease
Before pregnancy 2 or 3 Recurrence risk unknown, heart failure in
patient with reduce ventricular function
Increasing prevalence in recent decades
During pregnancy Not
applicable
Maternal mortality (9%) Electrocardiographic changes and troponin are
essential diagnostic tools
Peri-partum Not
applicable
High risk of coronary dissection (34%)
Maternal mortality (18%)
Coronary dissection partly due to hormonal
changes during the last trimester and
hemodynamic burden
Aortic disease
Marfan 2 or 3 Aortic dissection (1–10%) High risk in patients with aortic
diameter >45mm
Bicuspid aortic valve disease 2 or 3 Aortic dissection (<1%) High risk in patients with aortic
diameter >50mm
Turner’s syndrome 3 Hypertensive disorders (67%)/aortic dissection
(5%)
Women with Turner’s syndrome are often not
fertile
Ehlers-Danlos 3 or 4 Maternal mortality (11.5%) An increased risk of spontaneous uterine
rupture
Pulmonary arterial hypertension 4 Maternal mortality (17–33%) Mainly in post-partum period (ﬁrst 3 days)
perfusion and should be used to guide bypass pump ﬂow. How-
ever, one should take into account that fetal heart rate variability
andmovementswill probably bedepressed as a result of the central
anesthetics and hypothermia. External tocolysis and clinical exam-
ination might reveal uterine contractions. Due to an increased risk
of malformations, surgery is best avoided in the ﬁrst trimester. In
the third trimester, the risks of prematurity should be balanced
against the risks of surgery. Therefore European guidelines advise
consideringdeliverybefore surgeryafter28weeksofgestation [26].
Management of delivery
Delivery team
Timing and mode of delivery should be discussed in advance
in a multidisciplinary team consisting of at least an obstetrician,
an anesthesiologist, and a cardiologist. The patient’s preference
should to be taken into account and she should be thoroughly coun-
seledabout thedeliveryplanandpotential complications.Awritten
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presentation, immediate diagnostic examination, and appropriate management will 
improve their chances of survival 15.
Physical examination: In a healthy pregnant woman, normal findings include a mild 
increase in resting heart rate, a widened pulse pressure, peripheral edema, and a slight 
elevation of venous pressure. During the later stages of pregnancy there is a physi-
ological fixed splitting of the second heart sound (S2). Systolic murmurs are common, 
secondary to the increased cardiac output. However, diastolic murmurs are unusual and 
therefore call for further evaluation 16.
Electrocardiogram: The electrocardiogram changes as a result of the upward shift of 
the diaphragm caused by the growing uterus. There is left axis deviation and in the third 
trimester Q waves in lead III and aVF and inverted T waves in leads III, V1, and V2 are seen 
17.
Echocardiography: Trans-thoracic (and trans-esophageal) echocardiography is a safe, 
rapid, and useful diagnostic tool. In a normal pregnancy a significant increase in cardiac 
output, cardiac index, left ventricular end-diastolic volume, and left ventricular wall 
thickness is observed 17. Cardiac ultrasound is indicated in women with symptoms of 
cardiac disease as well as in women with established heart disease in order to monitor 
cardiac condition and valvular function 5. In patients with aortic dilatation, echocardiog-
raphy should be done at 6–8 weeks intervals throughout the pregnancy until 6 months 
postpartum 15.
Imaging: Chest X-ray should be performed on indication 19. Magnetic resonance imag-
ing (MRI) may be useful in complex heart disease and aortic pathology. MRI is considered 
to be safe from 12 weeks’ gestation. Gadolinium contrast is best avoided 20.
Laboratory: For the diagnosis of ACS both creatinine kinase (CK) MB and troponin are 
used. During labor elevated CK and CK MB can be found due to uterine contractions. 
These levels normalize during the second day after labor 21. Troponin I is not elevated in 
normal pregnancy, as a result troponin I is the recommended laboratory test in pregnan-
cy 22. However, troponin I serum levels can be elevated in patients with pre-eclampsia or 
a hypertensive crisis. It is not clear whether this is a sign of cardiac ischemia in these pa-
tients. Increased B-type natriuretic peptide levels are found during pregnancy in many 
pregnant women with heart disease. In the study by Tanous et al. B-type natriuretic 
peptide levels lower than 100 picograms per milliliter had a negative predictive value of 
100% for identifying events during pregnancy. Therefore during pregnancy serial B-type 
natriuretic peptide levels could be helpful, specifically in excluding suspected adverse 
cardiac events 23.
Treatment during pregnancy
Medication: Table 1 shows the safety profile of commonly used cardiovascular drugs 
during pregnancy.
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Interventional treatment: An intervention may arise when cardiac function deteriorate 
during pregnancy or when a cardiac condition is either unknown or underestimated 
before pregnancy 24. In emergency situations, interventional procedures are justified. 
Ultrasound-guidance and abdominal shielding can help to limit fetal radiation exposure 
to acceptable doses. The uterus receives radiation scattered from the irradiated area, 
which is more important than the direct exposure (only 2%). The actual risk depends on 
the dose and stage of development of the fetus. Radiation doses to the fetus higher than 
50–100 mGy place the child at risk for growth retardation, malformation, or miscarriage. 
For low doses to the fetus, the principal risk is radiation-induced cancer (stochastic ef-
fects) 19.
Cardiac surgery: Cardiac surgery during pregnancy should only be done if all other 
treatment modalities (medication and percutaneous intervention) have failed. Intraop-
erative hypotension and hypothermia, embolic complications, and placental hypoper-
fusion and preterm labor cause fetal mortality in 14-33% or severe morbidity in another 
20% where maternal mortality is not much encountered. Severe maternal illness, total 
operative time, emergency surgery, necessity of revision, advanced maternal age, and 
gestational age are all associated with poorer outcome 25.
Fetal heart rate monitoring eventually combined with intermittent uterine and um-
bilical artery Dopplers reflect placental perfusion and should be used to guide bypass 
pump flow. However, one should take into account that fetal heart rate variability and 
movements will probably be depressed as a result of the central anesthetics and hypo-
thermia. External tocolysis and clinical examination might reveal uterine contractions. 
Due to an increased risk of malformations, surgery is best avoided in the first trimester. 
In the third trimester, the risks of prematurity should be balanced against the risks of 
surgery. Therefore European guidelines advise considering delivery before surgery after 
28 weeks of gestation 26.
ManageMenT of DelIVeRy
Delivery team
Timing and mode of delivery should be discussed in advance in a multidisciplinary 
team consisting of at least an obstetrician, an anesthesiologist, and a cardiologist. The 
patient’s preference should to be taken into account and she should be thoroughly 
counseled about the delivery plan and potential complications. A written record should 
be available at all times for all involved caregivers and should include plans to manage 
foreseeable complications.
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Timing
In asymptomatic women in good condition, spontaneous delivery can be awaited. In 
women with complex lesions, severe cardiac dysfunction, heart failure, aortic dilatation, 
Eisenmenger syndrome, or mechanical valve switched to heparin, a planned delivery 
might be more appropriate. Maternal or fetal condition might warrant a planned deliv-
ery before 37 weeks.
Mode of delivery
The mode of delivery mainly depends on obstetric indication and the maternal hemody-
namic condition. Vaginal delivery is preferred in women with adequate cardiac output. 
According to the European guidelines, primary Cesarean section should be considered 
for the patient on oral anticoagulants (OAC) in pre-term labor, in women with severe 
heart failure, aortic root diameter >45 mm, and patients with acute or chronic aortic 
dissection 5,27.
Vaginal delivery
Vaginal delivery is uncomplicated in most women with heart disease. Decreased blood 
loss, more rapid recovery, absence of abdominal surgery, and decreased thrombogenic 
risks are the most important benefit over Cesarean section. Adequate pain relief with 
epidural analgesia can help to attenuate the hemodynamic changes that accompany 
labor and delivery. It also allows controlled fetal descent to the pelvic floor by suppress-
ing bearing down reflex. As such the need for bearing down effort with accompanying 
Valsava manoeuver is often reduced. Epidural catheters are contraindicated in women 
using anticoagulants. Alternatives like intravenous analgesia can be considered. Ad-
equate measures to prevent a sudden fall in peripheral vascular resistance associated 
with epidural anesthesia should be taken in women with left ventricular outflow tract 
obstruction 28. Assisted vaginal delivery (by vacuum or forceps extraction) is recom-
mended when excessive maternal efforts and prolonged labor are contraindicated. 
Cervical ripening using either prostaglandins or mechanical methods and induction of 
labor with oxytocine are relatively safe in most women with cardiac disease 29.
Cesarean section
Cesarean delivery annihilates the hemodynamic changes associated with labor. It also 
often permits more appropriate invasive and non-invasive hemodynamic monitoring 
and management. However it increases the risk of venous thrombo-embolism, infection, 
and post-partum hemorrhage. Controlled loco-regional anesthesia is often possible and 
preferred. However some cases may warrant general anesthesia 30,31.
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PosT-PaRTUM PeRIoD
Care should be given with intravenous bolus of oxytocine in the third stage of labor, as 
it might cause a sudden fall in cardiac output. Controlled intravenous infusion might 
be more appropriate. Also certain intravenous prostaglandins, used to prevent or treat 
post-partum hemorrhage can cause coronary vasospasms (such as sulprostone).
The volume shifts caused by auto-transfusion the first days after delivery have delete-
rious effects on patients with diminished left ventricular function. Several days of close 
monitoring for signs of heart failure is recommended in high-risk women 5. Prophylactic 
diuretics and ACE inhibitors may be indicated in high-risk patients with severe systemic 
ventricular dysfunction. A routine echocardiographic examination post-delivery in 
high-risk women is advisable, paying careful attention to the aortic root in women with 
Marfan syndrome or aortic valve disease. The risk of thrombo-embolic complications is 
further increased post-partum and anticoagulation should be adjusted accordingly 9.
In patients with low risk for heart failure and with normal ventricular function, a short 
observation period of several hours up to 48 h post-partum might be sufficient. While 
lactation is possible in most women with heart disease, it might be contraindicated due 
to medication use, severely decreased effort tolerance, or risk of mastitis and bacteremia 
in some women. The use of diuretics can complicate the initiation of milk production.
feTal oUTCoMe
Predictors
Neonatal outcome is strongly correlated with maternal outcome. Similar to maternal risk 
factors, several predictors for neonatal outcome have been described such as baseline 
NYHA class >II or cyanosis, left heart obstruction, smoking during pregnancy, the use of 
oral anticoagulants during pregnancy, mechanical valve prosthesis, and multiple gesta-
tion. Cardiac surgery causes high fetal mortality during pregnancy (up to 30%) 23.
Monitoring
Genetic counseling and invasive prenatal diagnosis should be offered women carriers of 
known genetic anomalies (e.g. Marfan syndrome, 22q11 deletions, familial cardiomyopa-
thies, and arrhythmias). A second trimester ultrasound screening for fetal abnormalities 
with special focus on potential congenital heart defects is indicated in all women with 
congenital heart disease as the risk for congenital heart disease in the offspring is around 
3–5% 5,32. From 24 weeks’ gestation, assessment of fetal growth and well-being should 
be performed at regular intervals using clinical examination, ultrasound biometry and 
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biophysical profile, uteroplacental and fetal Dopplers, and fetal heart rate monitoring as 
appropriate 33.
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absTRaCT
Young women who require aortic valve replacement (AVR) need information on the 
potential cardiac and obstetric complications of pregnancy for the different available 
valve substitutes. We therefore assessed pregnancy outcome in women who received 
an autograft, homograft, or mechanical valve in the aortic position. Women who were 
pregnant after surviving AVR in our institution between 1987 and 2011 were included. 
Information on cardiac status and pregnancy outcome was obtained through hospital 
medical records and by means of an extensive patient questionnaire. Forty women 
experienced 67 pregnancies of which 55 (82%) completed pregnancies, 6 (9%) miscar-
riages, and 6 (9%) terminations of pregnancy. Eighteen (45%) women had a pulmonary 
autograft, 13 (32%) a homograft, and 9 (23%) a mechanical valve. Mean age at first preg-
nancy was 30.0 ± 5.7 years. There was no maternal mortality, but 1 fetal death (1.8%) 
and 1 neonatal death (1.8%) occurred. Maternal cardiac complications occurred in 13% 
and obstetric complications in 38% of the completed pregnancies. Heart failure (9%), 
arrhythmias (7%), hypertension-related disorders (7%), preterm delivery (24%), and 
small for gestational age infants (15%) were most often encountered. Mechanical valve 
recipients had the highest incidence of both cardiac and obstetric complications. In con-
clusion, pregnancy-associated complications after AVR were common and human tissue 
valves should be considered in the discussion for the optimal aortic valve substitute in a 
young female. However, careful obstetric monitoring is mandatory.
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When a young woman requires aortic valve replacement (AVR), it is important to in-
corporate reliable information on potential pregnancy complications and pregnancy 
outcome when considering the available surgical options. In mechanical valve recipi-
ents, complications due to anticoagulation therapy represent a threat for both mother 
and her unborn child.1-3 Accelerated valve dysfunction due to degeneration may be a 
point of concern in biological valve substitutes although more recent studies report 
that pregnancy does not increase structural deterioration or reduce survival.4-6 There is 
limited evidence available on the rate of cardiac and obstetric complications in young 
women who become pregnant after AVR. Most available information concerns mechani-
cal –mainly mitral- valve recipients and shows increased risks of anticoagulation-related 
complications and increased maternal and fetal mortality and morbidity.1, 2, 5, 7-10 Also for 
human tissue valve recipients, reports on pregnancy related outcomes are scarce.5, 10-12 
In this perspective, the aim of the present study was to determine the occurrence of 
cardiac and obstetric complications in women who experienced a pregnancy after 
implantation of an autograft, homograft, or mechanical valve in the aortic position in 
our institution.
MeTHoDs
Women who were pregnant after surviving an AVR with a pulmonary autograft, a homo-
graft, or a mechanical valve prosthesis in the Erasmus University Medical Center, were 
aged 50 years or younger at time of surgery, were operated between April 1987 and 
January 2011, and were at least 16 years at the last clinical follow-up, were invited to 
participate. The study protocol was approved by the Institutional Review Board (MEC 
2010-272) and informed consent was obtained. All patients who receive a human tissue 
valve substitute in our institution are followed prospectively (MEC 2000-813). Eligible 
patients were identified through our prospective cohort study of human tissue valve 
recipients and through our departmental patient information system.13, 14
Information on pregnancy and cardiac status of the patients until January 1st, 2011 
was obtained through hospital medical records and structured patient questionnaire 
that was conducted between December 1st 2010 and September 1st, 2011. We collected 
data on underlying valve etiology at last surgery, hemodynamic diagnosis, previous 
surgical/interventional procedures, age at surgery, type (and size) of aortic valve substi-
tute, concomitant procedures, time from surgery to first pregnancy, age at conception, 
and preconceptional systolic left ventricular function (LVF), maximum aortic jet velocity 
(Vmax), and peak pulmonary artery pressure (PAP).
Pregnancy was defined as positive HCG test or obstetric ultrasound. Miscarriage was 
defined as spontaneous loss of pregnancy <20 weeks of gestation. Information about 
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each completed pregnancy (duration >20 weeks of gestation) included: New York Heart 
Association (NYHA) functional class, medication, physical examination, pregnancy 
duration, mode of delivery. For each baby, gender, birth weight, and APGAR score was 
registered.
Registered cardiac complications were: arrhythmia (symptomatic sustained docu-
mented arrhythmia), heart failure (requiring treatment), persistent NYHA functional 
class deterioration (≥1 year postpartum), syncope, thrombo-embolic complications, 
aortic dissection, and/or endocarditis. Obstetric complications included: pregnancy-
induced hypertension (PIH; de novo onset of hypertension after ≥20 weeks of gestation), 
preeclampsia (hypertension and proteinuria), eclampsia (preeclampsia with grand mal 
seizures), Hemolysis Elevated Liver Enzymes Low Platelets (HELLP) syndrome, preterm 
premature rupture of membranes (membrane rupture <37 weeks gestation), premature 
labor (spontaneous onset of labor <37 weeks gestation), postpartum hemorrhage 
(>1000 ml), placental abruption, premature delivery (<37 weeks of gestation), small-
for-gestational-age (birth weight <10th percentile), fetal death (≥20 weeks of gestation), 
and neonatal death (<30 days postpartum).15 The incidence of complications and mode 
of delivery in this study was compared to data derived from the 2008 Dutch Perinatal 
Registry. In this registry, maternal and fetal data of all deliveries occurring in the Neth-
erlands are recorded (about 180,000; 96% complete). It included both home as well as 
hospital deliveries and contained information on the presence of cardiovascular disease 
in the mother (no further specification) and neonatal congenital defects ( cardiac 0.41%; 
non-cardiac 2.38%).16
Anticoagulation therapy administered in our institution to mechanical valve re-
cipients was according to our local protocol and initiated in close collaboration with 
the hematologist.17 As soon as pregnancy was confirmed, acenocoumarol was changed 
to a weight adjusted therapeutic dose of low molecular weight heparin (LMWH) until 
the end of the first trimester and when necessary monitored with anti-Xa levels. Aceno-
coumarol was then restarted until 36 weeks of gestation. Hereafter a therapeutic dose 
of LMWH was given until spontaneous onset of labor or the day before induction of 
labor or elective cesarean section. After delivery, LMWH was initiated again, along with 
acenocoumarol until 2 consecutive appropriate INR levels were reached.
Normality of the distribution of continuous data was tested with the Kolmogorov-
Smirnov test with Lilliefors correction. Continuous data are displayed as means with 
standard deviations or in case of a skewed distribution, as medians with interquartile 
ranges and were compared using the one-way analysis of variance test or the Kruskal-
Wallis test. Discrete data are presented as absolute numbers and percentages and 
compared using the Pearson’s Chi-Square test or Fisher’s exact test.
Univariable logistic regression analysis was performed to identify possible factors 
associated with the incidence of pregnancy-related complications. Missing values were 
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imputed by the mean. Age at surgery, maternal age at first pregnancy, valve type, time 
from surgery until first pregnancy, duration of pregnancy, caesarean section, precon-
ceptional LVF, Vmax, and PAP were considered as co-variables in the univariable model 
for cardiac and obstetric events. For comparison of the event incidence with the general 
Dutch population the Chi squared test was used. All statistical tests were two-sided and 
a p-value ≤ 0.05 was considered significant. For data analysis SPSS 17.0 for Windows 
(SPSS, Chicago, Illinois) was used.
ResUlTs
Forty patients experienced at least 1 pregnancy after AVR in our institution (Table 1). 
There were 67 singleton pregnancies in these 40 women. Fifty-five pregnancies contin-
ued beyond 20 weeks (47% males) in 35 women. All 6 spontaneous miscarriages were 
<14 weeks of gestation. Six pregnancies were terminated (Table 1). The only termination 
of pregnancy for maternal cardiac reason was performed in a mechanical valve recipi-
ent with pulmonary hypertension, tricuspid insufficiency, and moderate stenosis of the 
mechanical prosthesis in aortic position of 3.3 m/s. One termination was performed in a 
fetus with spina bifida. There were no acenocoumarol associated embryopathies. Table 
2 displays the mode of delivery for the 55 completed pregnancies differentiated by type 
of valve substitute; Figure 1 illustrates the modes of delivery in comparison to the Dutch 
general population. There was no maternal mortality.
Heart failure was the most common cardiac complication with a persistent NYHA de-
terioration in 3 patients (Table 3). One mechanical valve recipient with permanent atrial 
fibrillation developed prosthetic valve thrombosis and subsequent heart failure at 33 
weeks gestation. Anticoagulation was converted to intravenous heparin and the woman 
underwent a caesarean section at 36 weeks. A girl of 2,150 g was born. Five weeks later 
she underwent a re-AVR with another mechanical valve.
The most common obstetric complications concerned hypertension-related disor-
ders, preterm delivery, and small-for-gestational-age infants (Table 3; Figure 2). Five of 
the 13 pregnancies which ended prematurely were induced before 37 weeks for cardiac 
indication: congestive heart failure in 2 patients (1 mechanical valve prosthesis; 1 pul-
monary autograft), prosthetic valve thrombosis (mechanical valve prosthesis), Marfan 
syndrome (homograft), and dilated aortic root with aortic and pulmonary regurgitation 
(pulmonary autograft).
There was 1 fetal death in a mechanical valve recipient at 20 weeks and 4 days which 
presented with absent heart rate, growth restriction, and fetal hydrops on ultrasound. 
A macerated male infant (190 gram) with a placenta of 30 gram was born. Fetal autopsy 
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Table 1 Patient characteristics
Pregnancy was deﬁned as positive human chorionic
gonadotropin test or obstetric ultrasoundﬁndings.Miscarriage
was deﬁned as spontaneous loss of pregnancy at<20weeks of
gestation. Information about each completed pregnancy
(duration >20 weeks of gestation) included New York Heart
Association (NYHA) functional class, medication, physical
examination, pregnancy duration, and mode of delivery. For
each infant, the gender, birth weight, and Apgar score were
registered.
The registered cardiac complications were arrhythmia
(symptomatic, sustained, documented arrhythmia), heart
failure (requiring treatment), persistent NYHA functional class
deterioration (�1 year postpartum), syncope, thromboembolic
complications, aortic dissection, and/or endocarditis. Obstetric
complications included pregnancy-induced hypertension
(de novo onset of hypertension after�20 weeks of gestation),
preeclampsia (hypertension and proteinuria), eclampsia
(preeclampsia with grand mal seizures), HELLP (hemolysis,
elevated liver enzymes, low platelets) syndrome, preterm,
premature rupture of membranes (membrane rupture
<37 weeks’ gestation), premature labor (spontaneous onset
of labor <37 weeks’ gestation), postpartum hemorrhage
(>1,000 ml), placental abruption, premature delivery
(<37 weeks’ gestation), small-for-gestational-age (birth
weight<10th percentile), fetal death (�20 weeks’ gestation),
and neonatal death (<30 days postpartum).15 The incidence
of complications and mode of delivery in the present study
was compared to data derived from the 2008 Dutch Perinatal
Registry.16 In that registry, the maternal and fetal data of all
deliveries occurring in the Netherlands are recorded (about
Table 1
Patient characteristics
Variable All (n ¼ 40) Autograft (n ¼ 18) Homograft (n ¼ 13) MP (n ¼ 9) p Value
Intervention or surgery before aortic valve replacement
0 23 (58%) 10 (56%) 9 (69%) 4 (44%) 0.46
1 8 (20%) 2 (11%) 4 (31%) 2 (22%) 0.46
>1 9 (23%) 6 (33%) 0 3 (33%) 0.07
Diagnosis
Aortic stenosis 15 (38%) 10 (56%) 4 (31%) 0 0.02
Aortic regurgitation 13 (33%) 3 (17%) 6 (46%) 5 (55%) 0.10
Mixed 12 (30%) 5 (28%) 3 (23%) 4 (44%) 0.61
Etiology
Congenital 26 (65%) 16 (89%) 8 (62%) 2 (22%) <0.01
Rheumatic 12 (30%) 2 (11%) 4 (31%) 6 (67%) 0.01
Aneurysm or dissection 2 (5%) 0 1 (8%) 1 (11%) 0.49
Age at last surgery (yrs) 25.4 � 7.7 21.5 � 6.6 26.9 � 5.0 31.2 � 9.0 <0.01
Concomitant procedures
None 28 (70%) 16 (89%) 8 (62%) 4 (44%) 0.04
Coronary bypass 3 (8%) 1 (6%) 0 2 (22%) 0.23
Mitral valve surgery 6 (15%) 0 3 (23%) 3 (33%) 0.04
Prosthesis size (mm) — — 22 (21e22) 21 (21e23)
Interval from surgery to ﬁrst pregnancy (yrs)* 3.1 (1.6e6.1) 5.5 (1.8e9.4) 2.3 (1.4e4.6) 2.1 (1.5e4.6) 0.14
Total pregnancies 67 33 22 12 0.39
1 40 (60%) 18 (55%) 13 (59%) 9 (75%) 0.46
2 20 (30%) 11 (33%) 6 (27%) 3 (25%) 0.83
3 7 (10%) 4 (12%) 3 (14%) 0 0.46
Pregnancy age (yrs)*
First (n ¼ 40) 30.0 � 5.7 27.0 � 4.1 30.2 � 4.6 35.7 � 5.9 <0.01
Second (n ¼ 20) 30.9 � 4.7 30.0 � 3.9 31.9 � 5.0 32.1 � 8.0 0.75
Third (n ¼ 7) 32.1 � 5.5 32.7 � 7.0 31.3 � 4.0 — 0.86
Preconceptional left ventricular function (n ¼ 66)
Good 64% 61% 77% 50% 0.18
Moderate 36% 39% 23% 50% 0.18
Preconceptional pulmonary artery pressure (mm Hg) (n ¼ 62) 6 (3e15) 13 (9e18) 3 (2e3) 4 (1e11) <0.01
Preconceptional maximum aortic jet velocity (m/s)*
First pregnancy (n ¼ 38) 1.78 � 0.69 1.36 � 0.42 1.85 � 0.60 2.60 � 0.55 <0.01
Second pregnancy (n ¼ 19) 1.70 � 0.54 1.41 � 0.46 2.01 � 0.36 2.23 � 0.38 0.01
Third pregnancy (n ¼ 7) 1.83 � 0.80 1.41 � 0.48 2.39 � 0.87 — 0.23
Completed pregnancies 55 (82%) 28 (85%) 20 (91%) 7 (58%) 0.05
Miscarriage 6 (9%) 3 (9%) 0 3 (25%) 0.05
Pregnancy terminated 6 (9%) 2 (6%) 2 (9%) 2 (17%) 0.64
Social reasons 4 (6%) 2 (6%) 2 (9%) 0 0.70
Maternal cardiac indication 1 (1%) 0 0 1 (17%) 0.18
Fetal spina biﬁda 1 (1%) 0 0 1 (8%) 0.18
Data are presented as n (%), mean � SD (continuous variables), or median (interquartile range; continuous variables).
MP ¼ mechanical aortic valve prosthesis.
* All 67 pregnancies, including miscarriages and terminations.
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variables).
MP = mechanical aortic valve prosthesis.
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Table 2 Mode of delivery for 55 completed pregnancies in 35 women
180,000; 96% complete). It included both home and hospital
deliveries and contained information on the presence of
cardiovascular disease in the mother (no additional speciﬁ-
cation) and neonatal congenital defects (cardiac 0.41%;
noncardiac 2.38%).16
The anticoagulation therapy administered in our institu-
tion to mechanical valve recipients was according to our
local protocol and was initiated in close collaboration with
the hematologist.17 As soon as a pregnancy was conﬁrmed,
acenocoumarol was changed to a weight-adjusted thera-
Table 2
Mode of delivery for 55 c mpl t d pregnancies in 35 women
Variable All (n ¼ 55) Autograft (n ¼ 28) Homograft (n ¼ 20) MP (n ¼ 7) p Value
Vaginal delivery* 42 (76%) 19 (68%) 17 (85%) 6 (86%) 0.32
Spontaneous 11 (20%) 3 (11%) 5 (25%) 3 (43%) 0.25
Assisted delivery 13 (24%) 7 (25%) 5 (25%) 1 (14%) 0.67
Epidural anesthesia 11 (20%) 4 (14%) 5 (25%) 2 (29%) 0.80
Induction of labor 20 (36%) 11 (39%) 7 (35%) 2 (29%) 0.53
Elective cesarean section 8 (15%) 5 (18%) 2 (10%) 1 (14%) 0.89
Maternal cardiovascular risk 5 (9%) 3 (11%) 2 (10%) 0 0.72
Prosthetic valve thrombosis 1 (2%) 0 0 1 (14%) 0.13
Fetal presentation 1 (2%) 1 (4%) 0 0 1.00
Fetopelvic disproportion 1 (2%) 1 (4%) 0 0 1.00
Emergency cesarean section 5 (9%) 4 (14%) 1 (5%) 0 0.42
Fetal distress† 2 (4%) 1 (4%) 1 (5%) 0 1.00
Placental abruption 1 (2%) 1 (4%) 0 0 1.00
Fetopelvic disproportion 2 (4%) 2 (7%) 0 0 0.62
Data are presented as n (%).
* Overlapping categories.
† Deceleration on cardiotocography.
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Data are pres nt d as n (%).
* overlapping categories.
† Deceleration on cardiotocography.
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was declined by the parents. Placental pathology showed severe placental insufficiency. 
One postnatal death occurred in a pulmonary autograft recipient who was on oral 
anticoagulation therapy because of a protein C deficiency and prior deep venous throm-
bosis. At 19 weeks, she had preterm premature rupture of membranes and fetal growth 
restriction. Despite the poor prognosis the woman opted for expectant management. At 
30 weeks, she spontaneously delivered a 600 g boy who died on the first postnatal day 
due to lung hypoplasia.
ﬁ-
ﬁrmed,
’
� SDor
’s exact test.
ﬁrst
ﬁrst preg-
signiﬁcant. For data analysis, SPSS, version 17.0, for
Windows (SPSS, Chicago, Illinois) was used.
Results
A total of 40 patients experienced �1 pregnancy after
AVR in our institution (Table 1), with 67 singleton preg-
nancies. Of these 67 pregnancies, 55 continued >20 weeks
(47% male infants) in 35 women. All 6 spontaneous
miscarriages were <14 weeks of gestation. Six pregnancies
were terminated (Table 1). The only termination of preg-
nancy for maternal cardiac reason was performed in
a mechanical valve recipient with pulmonary hyperten-
sion, tricuspid insufﬁciency, and moderate stenosis of the
mechanical prosthesis in the aortic position of 3.3 m/s. One
termination was performed in a fetus with spina biﬁda. No
acenocoumarol-associated embryopathies developed. The
mode of delivery for the 55 completed pregnancies, differ-
entiated by type of valve substitute, is listed in Table 2.
Figure 1 illustrates the modes of delivery compared to the
Dutch general population. No maternal mortality occurred.
Heart failure was the most common cardiac complica-
tion, with persistent NYHA deterioration in 3 patients
(Table 3). One mechanical valve recipient with permanent
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Figure 1. Mode of delivery of 55 completed pregnancies compared to Dutch
Perinatal Registry. CS ¼ cesarean section.
figure 1 Mode of delivery of 55 compl ted pregnancies com ared to Dutch
Perinatal Registry. CS = cesarean section.
Table 3 Outcome of 55 completed pregnancies in 35 women
atrial ﬁbrillation developed prosthetic valve thrombosis and
subsequent heart failure at 33 weeks’ gestation. Anti-
coagulation was converted to intravenous heparin, and the
woman underwent cesarean section at 36 weeks. A female
infant of 2,150 g was born. Five weeks later, she underwent
Of the 13 pregnancies that ended prematurely, 5 were
induced before 37 weeks because of a cardiac indication:
congestive heart failure in 2 patients (1 mechanical valve
prosthesis, 1 pulmonary autograft), prosthetic valve throm-
bosis (mechanical valve prosthesis), Marfan syndrome
Table 3
Outcome of 55 completed pregnancies in 35 women
Variable All (n ¼ 55) Autograft (n ¼ 28) Homograft (n ¼ 20) MP (n ¼ 7) p Value
Pregnancy duration (weeks) 38 (36e40) 38 (35e40) 39 (38e40) 36 (31e39) 0.20
Birth weight (kg) (n ¼ 54) 3.0 (2.5e3.3) 3.0 (2.4e3.3) 3.1 (2.9e3.3) 2.7 (1.9e3.0) 0.11
Birth weight percentile (n ¼ 54)* 31 (14e54) 30 (11e54) 34 (21e54) 16 (11e80) 0.47
APGAR score �8 at 5 minutes 94% 96% 95% 86% 0.55
Cardiac complications† 7 (13%) 4 (14%) 1 (5%) 2 (29%) 0.21
Heart failure 5 (9%) 2 (7%) 1 (5%) 2 (29%) 0.20
Supraventricular arrhythmia 4 (7%) 1 (4%) 1 (5%) 2 (29%) 0.09
Persistent New York Heart Association deterioration 3 (5%) 1 (4%) 1 (5%) 1 (14%) 0.71
Valve thrombosis 1 (2%) 0 0 1 (14%) 0.13
Obstetric complications† 21 (38%) 11 (39%) 6 (30%) 4 (57%) 0.50
Hypertension-related disorders 4 (7%) 0 4 (20%) 0 0.02
Pregnancy-induced hypertension 2 (4%) 0 2 (10%) 0 0.14
Preeclampsia 2 (4%) 0 2 (10%) 0 0.14
Premature labor 4 (7%) 3 (11%) 0 1 (14%) 0.33
Preterm premature rupture of membranes 3 (5%) 3 (11%) 0 0 0.26
Placental abruption 1 (2%) 1 (4%) 0 0 1.00
Preterm delivery 13 (24%) 8 (29%) 2 (10%) 3 (43%) 0.14
Spontaneous 5 (9%) 4 (14%) 0 1 (14%) 0.24
Cardiac maternal indication 5 (9%) 2 (7%) 1 (5%) 2 (29%) 0.20
Obstetric indication 3 (5%) 2 (7%) 1 (5%) 0 1.00
Small-for-gestational age 8 (15%) 5 (18%) 3 (15%) 0 0.67
Fetal death 1 (2%) 0 0 1 (14%) 0.13
Postpartum hemorrhage 2 (4%) 2 (7%) 0 0 0.36
Postpartum blood loss (ml) 300 (200e425) 300 (200e650) 350 (300e400) 200 (200e500) 0.48
Neonatal death 1 (2%) 1 (4%) 0 0 1.00
Data are presented as number of pregnancies (%) or median (interquartile range; continuous variables).
* Adjusted for gestational age, etal gender, and parity.
† Overlapping categories.
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Figure 2. Incidence of obstetric and perinatal complications of 55 completed pregnancies compared to Dutch Perinatal Registry.16 PIH ¼ pregnancy-induced
hypertension.
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Data ar  presented as number of pregnancies (%) or median (interquartile range; continuous variables).
* adjusted for gestational age, fetal gender, and parity.
† overlapping categories.
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No potential predictors of cardiac complications could be identified. Obstetric com-
plications were more common in patients with cardiac complications during pregnancy 
(OR 13.2; 95% CI 1.5-119.5; p=0.02). There was no correlation between preconceptional 
Vmax over the aortic valve and birth weight (r -0.01; p=0.95).
Two women with a completed pregnancy were not treated according to the current 
ESC guidelines for the use of anticoagulation in pregnant mechanical valve patients.17 
One patient received an insufficient dose of oral anticoagulation therapy and developed 
a prosthetic valve thrombosis. The other patient was treated with a combination of 
acenocoumarol and LMWH until a healthy girl was born by spontaneous vaginal delivery 
at 40 weeks.
DIsCUssIon
Pregnancy in patients after AVR with a human tissue valve or a mechanical valve substi-
tute was associated with serious maternal cardiac and obstetric complications in half of 
the patients in our study. However, all patients survived pregnancy. Human tissue valve 
recipients had a lower incidence of cardiac maternal and obstetric complications than 
patients with mechanical valve prostheses. Mechanical valve recipients were at risk for 
miscarriage, supraventricular arrhythmias, heart failure, and preterm delivery.
Pregnancy elicits major hemodynamic changes.18, 19 In addition, pregnancy induces 
alterations in the maternal coagulation cascade which makes it difficult to provide suffi-
cient anticoagulation therapy in mechanical valve recipients and is therefore associated 
with maternal morbidity and mortality.1, 9, 10 However, more intensive anticoagulation 
atrial ﬁbrillation developed prosthetic valve thrombosis and
subsequent heart failure at 33 weeks’ gestation. Anti-
coagulation was converted to intravenous heparin, and the
woman underwent cesarean section at 36 weeks. A female
infant of 2,150 g was born. Five weeks later, she underwent
repeat AVR with another mechanical valve.
The most common obstetric complications concerned
hypertension-related disorders, preterm delivery, and
small-for-gestational-age infants (Table 3 and Figure 2).
Of the 13 pregnancies that ended prematurely, 5 were
induced before 37 weeks because of a cardiac indication:
congestive heart failure in 2 patients (1 mechanical valve
prosthesis, 1 pulmonary autograft), prosthetic valve throm-
bosis (mechanical valve prosthesis), M rfan syndrome
(homograft), and dilated aortic root with aortic and pulmo-
nary regurgitation (pulmonary autograft).
One fetal death occurred in a mechanical valve recipient
at 20 weeks and 4 days that presented with an absent heart
Postpartum hemorrhage 2 (4%) 2 (7%) 0 0 0.36
Postpartum blood loss (ml) 300 (200e425) 300 (200e650) 350 (300e400) 200 (200e500) 0.48
Neonatal death 1 (2%) 1 (4%) 0 0 1.00
Data are presented as number of pregnancies (%) or median (interquartile range; continuous variables).
* Adjusted for gestational age, fetal gender, and parity.
† Overlapping categories.
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may lead to hemorrhage. A recent review of maternal mortality considers care as sub-
optimal when there has been inappropriate management of anticoagulation, which 
can contribute to maternal cardiac death.20 A Danish cohort study describes 2 maternal 
deaths in 107 mechanical valve recipients of which 1 was anticoagulation related.1 The 
mechanical valve patient in our cohort who developed a prosthetic valve thrombosis 
failed to comply with het anticoagulation therapy leading to inadequate anticoagula-
tion. While appropriate dosing of oral anticoagulation can be challenging in pregnancy, 
patient compliance has also to be taken into account.
Another important cardiac complication in our study population was symptomatic 
heart failure during pregnancy which occurred in 5 patients, of whom 3 experienced 
a persistent New York Heart Association (NYHA) deterioration after 1 year. Heart failure 
is described as a serious complication in pregnant patients who underwent prior valve 
replacement.1, 21-23 It has been the cause of maternal death,1 but also an indication for 
termination of pregnancy.22 Two of the 5 patients with heart failure in our study were 
advised against pregnancy prior to conception; both had persistent NYHA deterioration 
after pregnancy. Although preconceptional counseling has the intention to reduce the 
risk on severe maternal cardiac events during pregnancy, it is the patient and her family 
who finally decides to pursue or decline a pregnancy based on the informed wishes and 
expectations.
In the present study, hypertensive related disorders occurred significantly more 
often in homograft recipients. Of the reports on pregnancy outcomes in homograft 
patients,2, 10, 21, 24, 25 only 1 study describes a case of pre-eclampsia.24 The aortic gradient 
increases significantly in homograft patients during pregnancy, but this is also seen 
in mechanical valve recipients,21 and probably reflects the increased cardiac output 
(increased stroke volume) and decrease in systemic vascular resistance. Unfortunately, 
we could not identify a specific reason for the increase in hypertensive related disorders 
among homograft patients.
Almost all newborns of mechanical recipients were vaginally delivered without ex-
cessive maternal hemorrhage during labor or caesarean section (Figure 2). The Danish 
cohort on the other hand reports a postpartum bleeding incidence of 12% and reported 
1 fatal bleeding.1 This underlines the importance of careful anticoagulation monitoring 
during delivery. Our study illustrates that through careful anticoagulation monitoring 
during delivery it is possible for mechanical valve recipients to deliver a baby without 
extensive bleeding.
There was 1 fetal death and 1 postnatal death, both in patients on oral anticoagulation 
therapy. Although the risks appears to be decreasing in the last few decades, mechanical 
valve recipients still have up to 9% fetal death risk.1, 9, 26 Perinatal death risk is reported 
to be up to 6% in mechanical valve recipients,9, 26, 27 and up to 8% in the mostly small co-
horts of human tissue valve recipients.10-12, 21, 24, 25 Dore and Somerville report 1 perinatal 
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death among 14 pregnancies in pulmonary autograft patients, although not directly 
related to cardiac reasons.11
Preterm delivery occurred more often (24%) in our study population as compared to 
the general Dutch population, especially in mechanical valve recipients. This high rate 
of preterm delivery was also found in the Danish cohort which found a rate of 49%.1 
Of the 13 cases of preterm delivery in the current study, 8 were induced on medical 
indication of which 5 due to cardiac reasons. As preterm delivery is the leading cause 
of infant mortality and morbidity, it is crucial to understand which risk factors are as-
sociated with preterm delivery.28 Maybe the treating physicians are too cautious with 
this particular patient group and therefore it is mainly a doctors decision’ to intervene 
earlier as compared to the normal Dutch population. Perhaps with good advice how to 
guide the anticoagulant management during delivery (new ESC guidelines) and some 
reinsurance, based on our findings, less preterm deliveries could be reached.
The counseling of young female patients who require AVR and may contemplate 
pregnancy, requires a multidisciplinary discussion including several important issues. 
These patients should be individually informed about the (dis)advantages of the dif-
ferent available valve substitutes and corresponding potential pregnancy-associated 
maternal and fetal complications.3 The high incidence of preterm delivery and valve 
thrombosis in mechanical valve recipients illustrates that these valves are far from ideal 
in patients during pregnancy. On the other hand, the curious finding of a high incidence 
of hypertension related disorders in homograft recipients calls for further studies and 
indeed careful monitoring of the last stage of pregnancy in this patient group. Although 
human tissue valves needs careful obstetric monitoring, they provide female patients a 
biological solution that eliminates the daily burden of anticoagulation, in particular dur-
ing pregnancy, and their durability is not influenced by pregnancy.29 Therefore, human 
tissue valves should be considered as aortic valve substitute of choice in young patients 
with severe aortic valve disease who are planning to start a family.
Just as with most studies on this topic, patient numbers in the present study are 
relatively small and treatment took place in a tertiary hospital, necessitating careful 
interpretation of the results.
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absTRaCT
background
Many women with structural heart disease reach reproductive age and contemplate 
motherhood. Pregnancy induces and requires major hemodynamic changes. Pregnant 
women with structural heart disease may have a reduced cardiac reserve. There are no 
longitudinal data on cardiovascular adaptation throughout pregnancy in women with 
structural heart disease.
Methods
Thirty-five women with structural heart disease were included in a prospective observa-
tional trial. Maternal hemodynamics were assessed before conception, during pregnancy 
and 6 months postpartum by transthoracic echocardiography. Uteroplacental perfusion 
was analyzed by obstetric Dopplers. Longitudinal evolution over time was analyzed as 
well as the long term influence of pregnancy on cardiac function.
Results
Cardiac output (CO), stroke volume (SV), left ventricular mass (LV mass) and E/E′ ratio sig-
nificantly increased and ejection fraction (EF) and fractional shortening (FS) decreased 
during pregnancy. There was a statistically significant difference in EF, FS and E/E′ ratio 
before and after pregnancy.
Conclusions
The characteristic pattern of hemodynamic adaptation to pregnancy is attenuated in 
women with structural heart disease. The pregnancy related volume load induces pro-
gression of diastolic dysfunction. Our data suggest a persistent reduction in systolic and 
diastolic cardiac functions after pregnancy in women with structural heart disease.
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1. InTRoDUCTIon
Normal pregnancy induces and requires a major cardiac adaptation. An initial arterial 
vasodilatation, early in pregnancy, triggers a rapid increase in blood volume, cardiac 
output and ventricular mass 1,2. Most of these changes are reversed 6 months after 
pregnancy 3.
Advances in medical and surgical care of patients with structural heart disease have 
led to improved survival and outcome, especially in women with congenital and valvu-
lar heart disease. Many of these women reach reproductive age and experience their 
quality of life to be sufficient to consider pregnancy and motherhood. However, they are 
at increased risk for cardiac and obstetric complications 4-6. The hemodynamic changes 
can put a strain on their circulatory system and may induce cardiac complications such 
as heart failure or arrhythmia. Alternatively, their reduced cardiac reserve could prevent 
adequate adaptation, possibly leading to hypertensive disorders of pregnancy, fetal 
growth restriction or adverse fetal outcome.
Timely counseling and specialized follow up by a dedicated team of cardiologists, 
obstetricians and anesthesiologists, with knowledge of the implications of structural 
heart defects as well as adaptive requirements of pregnancy, are therefore advised 7,8.
While cardiac (mal)adaptation to pregnancy has mostly been studied in healthy 
women, women with hypertensive disorders or with growth restricted fetuses, there is 
hardly any longitudinal data on women with structural heart disease 9. As such most 
information comes from extrapolation of other patient groups 10–17.
Also, little is known on the degree of reversibility of hemodynamic adaptation and its 
effects on cardiac function after pregnancy 18,19.
We therefore aimed to prospectively study longitudinal hemodynamic adaptation to 
pregnancy in women with structural heart disease and asses the influence of this cardiac 
adaptation on postpartum cardiac function.
2. MeTHoDs
The prospective single center observational study was conducted from 2007 until 2010 
in a joint collaboration by the departments of Cardiology and Obstetrics at the Erasmus 
MC. Women with inherited or acquired structural heart disease visiting the outpatient 
clinic of cardiology and/or obstetrics for preconceptional counseling or pregnancy 
during the study period were invited to participate. Women received an individualized, 
standard management by a multidisciplinary team consisting of dedicated cardiologists, 
obstetricians and anesthesiologists according to international guidelines.
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Maternal and uteroplacental hemodynamics were assessed by transthoracic echocar-
diography and obstetric Dopplers. Maternal and pregnancy outcomes were assessed. 
Cardiac measurements were performed before pregnancy, in each trimester of preg-
nancy and six months postpartum. Obstetric Doppler measurements of the uterine and 
umbilical artery were performed in the second and third trimesters. Preconceptional 
hemodynamics were investigated at inclusion or retrieved from a recent previous echo-
cardiographic exam. Pre and post pregnancy measurements were performed irrespec-
tive of the menstrual cycle, method of anticonception and breast feeding status. The 
study was approved by the medical ethical committee of the Erasmus MC University 
Medical Centre of Rotterdam and all participants gave written informed consent. The 
authors of this manuscript have certified that they comply with the Principles of Ethical 
Publishing in the International Journal of Cardiology.
2.1. general outcomes
Demographics, cardiac diagnoses, obstetric outcomes and both maternal and obstetric 
complications were prospectively recorded. Post-partum hemorrhage (PPH) was defined 
as blood loss above 500 ml after vaginal delivery and 1000 ml after cesarean section 20.
Birthweight centiles, corrected for gestational age, maternal race, parity and fetal sex 
were derived from the Dutch national reference curves 21. A birthweight less than the 10th 
percentile, was considered as small for gestational age (SGA). Hypertension (HT) during 
pregnancy was classified as either pre-existent (occurring before 20 weeks of gestation), 
gestational hypertension (de novo hypertension without proteinuria occurring after 20 
weeks of gestation) or pre-eclampsia (hypertension in combination with proteinuria) 22.
Preterm delivery was defined as a delivery occurring before 37 weeks of gestation. 
Pregnancy loss was defined as a miscarriage before and intrauterine death from 20 
weeks of gestation.
2.1.1. Echography
Transthoracic echocardiography was performed using commercially available devices 
with sector transducers (SONOS 7500, Philips Medical Systems, Best, The Netherlands or 
iE33, Philips Medical Systems, Best, The Netherlands), according to the guidelines of the 
American Society of Echocardiography and, when necessary, adapted to the structural 
abnormality 23.
Diastolic and systolic volumes were computed from the left ventricular end systolic 
and end diastolic diameters (LVESD, LVEDD) using the Teicholz formula and fractional 
shortening (FS) and ejection fraction (EF) were calculated accordingly 24. Left ventricular 
mass (LVmass) was calculated using the Devereux formula 25. Left ventricular outflow 
tract diameter was obtained from the parasternal long access view and left ventricular 
outflow tract velocity time integral from the apical five chamber view. Stroke volume 
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(SV) was calculated by multiplying left ventricular outflow area with left ventricular 
velocity time integral, cardiac output (CO) by multiplying stroke volume with heart rate. 
Diastolic function was assessed by pulsed wave Doppler of the mitral inflow (E/A ratio) 
and tissue Doppler of the septal mitral annulus (E/E′ ratio).
Obstetric Dopplers were obtained with commercially available ultrasound devices 
with curved array transducers (iU22, Philips Ultrasound Bothell, WA, USA and Voluson 
730 Expert G.E, Medical systems, Zimpf, Austria).
Pulsatility index of the umbilical artery (Umb PI) and mean pulsatility index of both 
uterine arteries (Uter PI) were obtained by color directed pulsed wave Doppler.
2.2. statistical analysis
Continuous variables are displayed as means with a standard deviation (SD) and range, 
discrete variables are displayed as counts and proportions. To investigate the longitudinal 
evolution over time of the individual cardiac and obstetric Doppler parameters and to 
account for the correlation in the measurements taken from the same patients, a repeated 
measurement analysis using linear mixed effect models was performed 26. As the evolution 
of each parameter during pregnancy may not be linear, we used in our model specifica-
tion second degree polynomials for both the fixed and random effects parts. The models' 
assumptions were validated using residual plots. The analysis was performed in the R 
statistical software (version 2.14.0, 2011-10-31) using package nlme (version 3.1-102). The 
significance level was set at 5% and no multiple testing corrections were applied.
Differences between pre-and post-pregnancy values were analyzed with an F-test. To 
assess whether the evolution during pregnancy predicted this pre–post pregnancy dif-
ference, the area under the longitudinal trajectory during pregnancy using linear mixed 
effect models was computed and subsequently the association between this area and 
pre–post pregnancy difference was tested.
To investigate the association between fetal growth and cardiac adaptation, these 
areas were also correlated with adjusted birthweight centiles and evolution in uterine 
artery flow.
To assess the influence of the severity of cardiac condition and the occurrence of 
pregnancy complications on the longitudinal evolution of the parameters, the popula-
tion was divided in two groups. For the severity of cardiac condition, the division was 
based on the WHO cardiac function classification (WHO classes 1–2 versus WHO classes 
3–4) 27. For the occurrence of pregnancy complications, only those associated with mal-
adaptation to hemodynamic changes were taken into account. As such the population 
was divided based on the occurrence of hypertension and/or small for gestational age 
fetuses (HT/SGA).
The same types of analysis as for the whole population were performed, allowing for 
differences in the average longitudinal evolutions per risk group. Likelihood ratio tests 
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for differences in average longitudinal evolutions between both groups were calculated 
as well as differences between the pre–post pregnancy values. The effect of the severity 
of cardiac condition on adjusted birthweight centiles and occurrence of complications 
was analyzed with a Wilcoxon test and Fisher's exact test respectively.
3. ResUlTs
Thirty-five women with structural heart disease were invited to participate into the 
study. Thirty-two of them became pregnant and 29 reached a gestational age beyond 
the limits of viability (24 weeks). One woman had a spontaneous first trimester miscar-
riage, one woman miscarried after a septic episode following a first trimester reduction 
of a spontaneous triplet to a singleton pregnancy and one woman had an intrauterine 
death with signs of severe placental insufficiency at 20 weeks gestation.
Fig. 1 represents an organogram of the study population. Table 1 offers details on diag-
nosis, previous cardiac interventions, the cardiac condition before pregnancy as well as 
figure 1 Organogram of the study population with details on cardiac diagnosis. * Five women with me-
chanical aortic and/or mitral valve. ** One woman after previous chemotherapy and one woman with a 
dilated cardiomyopathy.
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the WHO risk group classification for each women individually. Of the 32 included women, 
85% had a congenital structural heart defect and 82% had a prior cardiac intervention. 
Fifty-six percent of women were nulliparous at inclusion. Mean age at delivery was 32 
years (SD: 4.3 years, Range: 24 to 41 years) and mean BMI was 25 (SD: 3.9, Range: 18 to 34).
Major maternal (both cardiac and non-cardiac) and/or obstetric (miscarriage, fetal 
death, gestational hypertension, pre-eclampsia, SGA, PPH and major congenital ab-
normality) complications occurred in 62.5% of pregnancies. There was no significant 
Table 1 Detailed information on type of structural heart disease, previous interventions, preconceptional 
cardiac condition and WHO group of the study population. Abbreviations in order of appearance: WHO: 
WHO group, RHD: rheumatic heart disease, AVR: aortic valve replacement, MVR: mitral valve replacement, 
//: subsequent intervention, TV: tricuspid valve, AF: atrial fibrillation, AS: aortic valve stenosis, bicus AV: 
bicuspid aortic valve, MS: mitral valve stenosis, LV: left ventricle, MV: mitral valve, ACS: acute coronary syn-
drome, Ao asc: aorta ascendens, PS: pulmonary valve stenosis, MI: mitral valve insufficiency, LA: left atrium, 
DM: diabetes mellitus, RF: renal failure, Coarct: aortic coarctation, HT: hypertension, APVD: anomalous pul-
monary venous drainage, ASD I: atrium septum defect type 1, Le–Ri shunt: left to right shunt, RV: right 
ventricle, TI: tricuspid valve insufficiency, VSD: ventricular septum defect, PODB: persistent open ductus 
of Botalli, PA: pulmonary artery, PV: pulmonary valve, TOF: tetralogy of Fallot, RA: right atrium, RV: right 
ventricle, PI: pulmonary valve insufficiency, AI: aortic valve insufficiency, ASD II: atrium septum defect type 
2, DCM: dilated cardiomyopathy, CM: cardiomyopathy, TGA: transposition of the great arteries: pAVSD: 
partial atrioventricular septum defect, AMI: acute myocardial infarction, PTCA: percutaneous transluminal 
coronary angioplasty, RCA: right coronary artery, LAD: left anterior descendens coronary artery, RCX: ramus 
circumflexus.
To investigate the longitudinal evolution over time of the individual cardiac and
obstetric Doppler parameters and to account for the correlation in the measurements
taken from the same patients, a repeated measurement analysis using linear mixed ef-
fect models was performed [26]. As the evolution of each parameter during pregnancy
may not be linear, we used in our model speciﬁcation second degree polynomials for
both the ﬁxed and random effects parts. The models' assumptions were validated
using residual plots. The analysis was performed in the R statistical software (version
2.14.0, 2011-10-31) using package nlme (version 3.1-102). The signiﬁcance level was
set at 5% and no multiple testing corrections were applied.
population was divided based on the occurrence of hypertension and/or small for ges-
tational age fetuses (HT/SGA).
The same types of analysis as for the whole population were performed, allowing
for differences in the average longitudinal evolutions per risk group. Likelihood ratio
tests for differences in average longitudinal evolutions between both groups were cal-
culated as well as differences between the pre–post pregnancy values. The effect of the
severity of cardiac condition on adjusted birthweight centiles and occurrence of com-
plications was analyzed with a Wilcoxon test and Fisher's exact test respectively.
Table 1
Detailed information on type of structural heart disease, previous interventions, preconceptional cardiac condition and WHO group of the study population. Abbreviations in order
of appearance: WHO: WHO group, RHD: rheumatic heart disease, AVR: aortic valve replacement, MVR: mitral valve replacement, //: subsequent intervention, TV: tricuspid valve,
AF: atrial ﬁbrillation, AS: aortic valve stenosis, bicus AV: bicuspid aortic valve, MS: mitral valve stenosis, LV: left ventricle, MV: mitral valve, ACS: cute coronary yndrome, Ao asc:
aorta ascendens, PS: pulmonary valve stenosis, MI: mitral valve insufﬁciency, LA: left atrium, DM: diabetes mellitus, RF: renal failure, Coarct: aortic coarctation, HT: hypertension,
APVD: anom lous pulmonary venous drainage, ASD I: atrium septum defect type 1, Le–Ri shunt: left to right shunt, RV: right ventricl , TI: tricuspid valve insufﬁciency, VSD: ven-
tricular septum defect, PODB: persistent open ductus of Botalli, PA: pulmonary artery, PV: pulmonary valve, TOF: tetralogy of Fallot, RA: right atrium, RV: right ventricle, PI: pul-
monary valve insufﬁciency, AI: aortic valve insufﬁciency, ASD II: atrium septum defect type 2, DCM: dilated cardiomyopathy, CM: cardiomyopathy, TGA: transposition of the
great arteries: pAVSD: partial atrioventricular septum defect, AMI: acute myocardial infarction, PTCA: percutaneous transluminal coronary angioplasty, RCA: right coronary artery,
LAD: left anterior descendens coronary artery, RCX: ramus circumﬂexus.
Diagnosis Interventions prior to
pregnancy
Condition prior to
pregnancy
WHO
RHD St Judes AVR (2×), St Judes MVR//TV plasty (2×) AF 3
RHD St Judes MVR//St Judes AVR AF 3
AS (bicus AV) St Judes AVR Aortic root dilatation 48 mm 3
MS (congenital) St-Judes MVR Good LV and MV function after previous valve thrombo-
sis with ACS
3
AS (bicus AV) Homograft Ao asc 43 mm 2
PS balloon dilatation Mild PS 1
MI No Severe MI, dilated LA with DM and RF 1
Coarct, bicus AV Patch//valvulotomy//Ross//stent recoarctation//Bentall No rest coarct, no HT 3
Coarct, bicus AV End to end anastomosis Mild AS, no rest coarct, Ao asc 40 mm, no HT 2
Coarct, APVD Subclavian ﬂap Mild rest coarct, no HT 2
Coarct, ASD I End to end anastomosis//balloon dilatation Mild rest coarct, HT, Le-Ri shunt over ASD and elevated
RV ﬁlling pressures
3
Coarct, bicus AV, cervi-
cal arch
End to end anastomosis Mild rest coarct, no HT, Ao asc 44 mm 3
Coarct End to end anastomosis No rest coarct, no HT, moderate MI and TI 2
Coarct End to end anastomosis Mild rest coarct, HT 2
Coarct, bicus AV End to end anastomosis//balloon dilatation Mild rest coarct, HT, Ao asc 37 mm 2
Coarct, VSD,
PODB
Subclavian ﬂap, PA banding, closure PODB//PA debanding, PV plasty (2×), balloon
dilatation recoarctation
Mild rest coarct, mild PS, no HT 2
VSD, subvalvular
aortic membrane
Closure VSD (2×), resection subvalvular aortic membrane Ao asc 41 mm 2
TOF Closure VSD, transannular patch Dilated RA and RV, mild PS and severe PI 3
TOF, atresia left
PA
Closure VSD and PODB, transannular patch Mild PS 2
TOF Closure VSD, transannular patch//homograft for severe PI Moderate PI 2
TOF, atresia PA Waterston//Rastelli//plasty for PS, closure VSD Severe AI and moderate PI 3
TOF Closure VSD, transannular patch//homograft Mild PI 2
TOF Blalock-Taussig//closure VSD, infundibulectomy 2×//balloon dilatation PV Moderate PI 2
VSD No Mild Le-Ri shunt 2
VSD, ASD II No Mild Le-Ri shunt 2
VSD, double
oriﬁce MV
PA banding//PA debanding, closure VSD//MV plasty Mild MI and PS 2
DCM (familial) No Mild LV impairment 2
CM (chemotherapy) No Dilated LV, mild LV impairment, mild MI 2
TGA Senning Mild RV impairment 3
TGA Mustard Mild RV impairment 3
pAVSD Closure ASD, VSD, MV plasty Moderate MI 2
pAVSD Closure ASD (2×), VSD (2×), MV plasty (2×) and TV plasty Moderate MI, dilated LA 2
AMI (inferioposterior) PTCA RCA, stent LAD and RCX//PTCA LAD for restenosis Mild LV impairment 3
Marfan syndrome No Aorta 39 mm 2
Ebstein anomaly RV and TV plasty (Chauvaud), partial cavopulmonary shunt AF, severe TI, RV impairment 3
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difference in complication rate between the low risk (WHO 1–2) and high risk (WHO 
3–4) groups.
Three women had pre-existent atrial fibrillation and 3 other women reported transient 
episodes of palpitations. There were no new arrhythmic complications during the study 
period. One woman developed a thrombosis of her prosthetic aortic valve (St-Judes) at 
32 weeks, leading to heart failure and requiring postpartum valve replacement.
Details of maternal and obstetric complications as well as obstetric outcomes are 
represented in Table 2.
The longitudinal profiles over time of the echocardiographic and uteroplacental pa-
rameters, starting before pregnancy until six months postpartum, are presented in Fig. 
2 and estimated regression coefficients in Table 3.
A statistically significant linear evolution was observed towards a larger LVESD 
(P=0.001) and smaller FS (P=0.001) and EF (P≤0.001). E/E′ ratio (P=0.008), SV (P=0.045), 
CO (P=0.028), LVmass (P= 0.005) as well as uterine and umbilical artery PI (P≤0.001, 
P≤0.001 respectively) showed a statistically significant parabolic evolution (quadratic 
effect) with increase during pregnancy for the cardiac parameters and decrease for the 
obstetric Doppler indices.
Table 2 Details of maternal and obstetric complications and outcomes.
Fig. 1 represents an organogram of the study population. Table 1 of-
fers details on diagnosis, previous cardiac interventions, the cardiac
condition before pregnancy aswell as theWHO risk group classiﬁcation
for eachwomen individually. Of the 32 includedwomen, 85% had a con-
genital structural heart defect and 82% had a prior cardiac intervention.
Fifty-six percent of women were nulliparous at inclusion. Mean age at
delivery was 32 years (SD: 4.3 years, Range: 24 to 41 years) and mean
There was a statistically signiﬁcant increase in LVESD (P=0.001)
and E/E′ ratio (P=0.006) and decrease in FS (P=0.001) and EF
(P=0.001) after pregnancy as compared to before pregnancy, how-
ever evolution during pregnancy was not predictive for this differ-
ence. Neither was it related to evolution in uterine artery ﬂow nor
with adjusted birthweight.
The inﬂuence of severity of cardiac structural defect based on
Table 2
Det ils of maternal and obstetric complications nd outcomes.
Complications N % WHO 1–2 (n) WHO 3–4 (n) Remarks
Cardiac 21 11
Valve thrombosis 1 3% – 1 Aortic valve thrombosis leading to heart
failure
Heart failure 1 3% – 1
Non-cardiac
Kidney transplant 1 3% 1 – Kidney failure during pregnancy in diabetic
women with pre-existent kidney dysfunc-
tion necessitating postpartum dialysis and
transplant
Sepsis 1 3% 1 After early reduction of a triplet pregnancy
Suicide attempt 1 3% – 1
Post partum
depression
2 6% 1 1
Pyelonefritis 1 3% 1
Obstetric
Pre-existent hypertension 3 9% 2 1
Gestational hypertension 3 9% 3 –
Pre-eclampsia 1 3% 1 –
Preterm delivery 3 9% 1 2 343/7, 351/7, 356/7 weeks
Postpartum hemorrhage 8 25% 5 3
Cesarean section 7 22% 6 1
early miscarriage 2 6% 1 1
Fetal-neonatal
Intrauterine death 1 3% – 1 At 21 weeks
Major congenital
abnormality
1 3% 1 – Trisomy 21 with duodenal atresia
NICU admission 3 9% 1 2
SGA 6 18% 2 4
Pregnancy outcomes Mean SD WHO 1–2 (mean) WHO 3–4 (mean) Median Min Max
Gestational age
(weeks)
39 2 39.175 38.011 39 343/7 416/7
Birthweight (g) 3156 587 3319 2792 3255 1810 4100
Apgar 5 minute 9 1 9.40 9.56 10 8⁎ 10
* Excluding the intrauterine death at 21 weeks.
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figure 2 Fitted longitudinal profiles of each parameters for the whole population. The dashed lines denote 
95% point-wise confidence intervals. The symbol ‘&’ denotes parameters for which there was a significant 
time effect, and the symbol ‘*’ parameters for which there was a significant difference between pre and post 
pregnancy measurements.
Table 3 Estimated regression coefficients per parameter for the whole population.
We observed the characteristic signiﬁcant increase in SV and CO,
with steep rise in the ﬁrst half and a mor gradual plateau-like hase
in th s ond half of pregnancy.
However, the magnitude of increase seems lower than in previ-
ously described normal pregnant populations and more comparable
striction and pregnancies at high altitude [10,11,13–
increase in LVmass during pregnancy.
crease in LVESD, similar to normal pregnancy [17]
months postpartum leading to a statistically signiﬁ
tween pre- and post-pregnancy measurements.
These ﬁndings suggest a negative inﬂ
are in contrast to Uebing's ﬁ
ous effect pregnancy on left ventricular function [19]
reﬂ
function is necessary to conﬁrm our ﬁndings.
portance of atrial contribution to ventricular ﬁ
with HR towards the end of pregnancy [13,17,29]
pregnancy in our population.
However, E/E′
our population, showed a further signiﬁ
clearly in the pathological range [11–13].
Our ﬁ
lead to elevation of ﬁlling pressures, as reﬂ
The signiﬁcant difference in pre–
cates a persistent negative inﬂ
Fig. 2. Fitted longitudinal proﬁles of each parameters for the whole population. The dashed lines denote 95% point-wise conﬁdence intervals. The symbol ‘&’
which there was a signiﬁcant time effect, and the symbol ‘*’ parameters for which there was a signiﬁ
Table 3
Estimated regression coefﬁcients per parameter for the whole population.
Parameter Coef Value Std. error t-Value P-Value
HR Intercept 75.78 1.39 54.48 b0.001
Time 0.01 0.02 0.76 0.447
Time2 −0.00 0.00 −2.02 0.046
LVEDD Intercept 49.11 0.82 59.93 b0.001
Time 0.01 0.01 0.91 O.366
Time2 −0.00 0.00 −0.43 0.667
LVESD Intercept 32.63 0.88 37.02 b0.001
Time 0.02 0.01 2.50 0.014
Time2 0.00 0.00 0.08 0.939
E/A Intercept 1.69 0.10 16.98 b0.001
Time 0.00 0.00 0.06 0.954
Time2 −0.00 0.00 −1.22 0.225
E/E′ Intercept 10.52 0.60 17.63 b0.001
Time 0.02 0.01 3.10 0.003
Time2 −0.00 0.00 −2.96 0.004
FS Intercept 33.84 1.23 27.56 b0.001
Time −0.04 0.02 −2.15 0.034
Time2 −0.00 0.00 −0.76 0.452
EF Intercept 56.61 1.71 33.08 b0.001
Time −0.05 0.02 −2.22 0.029
Time2 −0.00 0.00 −0.74 0.460
SV Intercept 75.03 3.68 20.38 b0.001
Time 0.08 0.05 1.75 0.084
Time2 −0.00 0.00 −2.55 0.013
CO Intercept 5.67 0.30 18.95 b0.001
Time 0.01 0.00 2.17 0.034
Time2 −0.00 0.00 −2.73 0.008
LVmass Intercept 155.01 6.55 23.65 b0.001
Time 0.14 0.08 1.84 0.069
Time2 −0.00 0.00 −3.25 0.002
UterPI Intercept 3.81 0.45 8.48 b0.001
Time −0.21 0.04 −4.83 b0.001
Time2 0.00 0.00 3.69 0.001
UAPI Intercept 1.84 0.13 14.71 b0.001
Time −0.03 0.00 −5.68 b0.001
Chapter 5.3
176
There was a statistically significant increase in LVESD (P=0.001) and E/E′ ratio (P=0.006) 
and decrease in FS (P=0.001) and EF (P=0.001) after pregnancy as compared to before 
pregnancy, however evolution during pregnancy was not predictive for this difference. 
Neither was it related to evolution in uterine artery flow nor with adjusted birthweight.
The influence of severity of cardiac structural defect based on WHO class on longi-
tudinal evolution of the parameters is illustrated in Fig. 3. There were no significant 
differences in average evolution over time between groups except for heart rate (LRT 
9.78, P=0.021). Severity of structural heart defects only influenced heart rate on pre–
post pregnancy difference. Adjusted birthweight centiles were significantly higher in 
the low risk group (WHO1–2) (median=38: IQR 35.6) as compared to the high risk group 
(WHO3–4) (median=14: IQR 24) (P=0.04).
Thirteen women presented with pregnancy complications associated with hemo-
dynamic maladaptation (HT/SGA). There were no significant differences in average 
longitudinal evolution of the parameters between patients with and without HT/SGA. 
The corresponding fitted average longitudinal evolutions are illustrated in Fig. 4. There 
was a significant pre–post pregnancy difference for the LVEDD (mean diff=−2.97 mm, 
P=0.031) between patients with and without HT/SGA.
figure 3 Fitted longitudinal profiles for each parameter divided according to the severity of the cardiac 
condition. The dark gray area surrounding the dashed red line and lighter gray area surrounding the full 
blue line denote the 95% pointwise confidence intervals for the WHO1–2 group and WHO3–4 group re-
spectively. The symbol ‘&’ denotes parameters for which there was a significant difference in the average 
evolutions in time, and the symbol ‘*’ parameters for which there was a significant difference between pre 
and post pregnancy measurements between groups.
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4. DIsCUssIon
Our results offer an insight on both hemodynamic adaptation to pregnancy and long 
term influence of pregnancy on cardiac function in a population of women with struc-
tural heart disease. They show an attenuated cardiovascular adaptation with reduction 
in systolic function and progression of diastolic dysfunction during pregnancy, which 
persist 6 months after pregnancy. We observed the characteristic significant increase in 
SV and CO, with steep rise in the first half and a more gradual plateau-like phase in the 
second half of pregnancy.
However, the magnitude of increase seems lower than in previously described normal 
pregnant populations and more comparable to the pattern observed in pregnancies 
complicated by growth restriction and pregnancies at high altitude 10,11,13-15,28.
The pre-pregnancy LVmass was already elevated in our population, comparable to 
third trimester levels for normal healthy women 17. While somewhat attenuated, we still 
observed a statistically significant increase in LVmass during pregnancy.
Our data also showed a gradual decline in FS and EF due to an increase in LVESD, 
similar to normal pregnancy 17.While the absolute values persisted within normal ranges, 
the decline continued until six months postpartum leading to a statistically significant 
difference between pre- and post-pregnancy measurements.
figure 4 Fitted longitudinal profiles for each parameter divided according to the occurrence of hyperten-
sion and/or small for gestational age fetus. The dark gray area surrounding the dashed red line and lighter 
gray area surrounding the full blue line denote the 95% pointwise confidence intervals for the group with 
and the group without hypertension and/or small for gestational age fetus respectively. The symbol ‘*’ pa-
rameters for which there was a significant difference between pre and post pregnancy measurements.
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These findings suggest a negative influence of pregnancy on systolic function in 
women with structural cardiac disease. Our data are in contrast to Uebing's findings who 
could not observe a deleterious effect pregnancy on left ventricular function 19. One 
could question the accuracy of EF and FS derived from the Teicholz formula in reflecting 
systolic function in pregnant women with structural heart disease. As most other echo-
cardiographic volume estimations equally have intrinsic limitations, we believe that MRI 
analysis of systolic function is necessary to confirm our findings.
Normally the E/A ratio decreases with gestational age, as the importance of atrial 
contribution to ventricular filling increases along with HR towards the end of pregnancy 
13,17,29. We observed a relatively constant E/A ratio and HR within normal ranges through-
out pregnancy in our population.
However, E/E′ ratio, which was already elevated before pregnancy in our population, 
showed a further significant increase with gestational age. While the pattern is similar to 
normal pregnancy the absolute values were far above both normal and pre-eclamptic 
pregnancy values, clearly in the pathological range 11-13.
Our findings suggest a progressive diastolic dysfunction in women with structural 
heart disease with advancing gestational age. In normal pregnancy, increased load is 
compensated by myocardial hypertrophy. Due to elevated baseline levels, the capacity 
for further expansion in LVmass seems reduced in our population. Increments in load 
therefore lead to elevation of filling pressures, as reflected by the E/E′ ratio.
The significant difference in pre–post-pregnancy E/E′ ratio, indicates a persistent 
negative influence of pregnancy on diastolic function in women with structural heart 
disease 6 months postpartum.
Future studies should consider a longer postpartum follow-up to evaluate the tran-
sient or permanent nature of these changes.
To our knowledge this is the first study assessing diastolic function during and after 
pregnancy in women with structural heart disease. Our observations also highlight the 
importance of tissue Doppler in the longitudinal assessment of diastolic dysfunction 
during pregnancy. As important volume- and loading shifts occur along with gestational 
age, changes are best evaluated by a combined assessment of the pulsed wave mitral 
inflow Doppler and load independent tissue Doppler of the mitral annulus.
Not surprisingly, all these findings suggest a mildly reduced cardiac potential for ad-
aptation to the normal requisites of pregnancy in women with structural heart disease. 
The maladaptation is partly comparable to that observed in women with growth restric-
tion and gestational hypertension, however diastolic dysfunction is more severe 11,30.
When assessing the influence of severity of cardiac disease on cardiac adaptation 
we observed a similar pattern between WHO1–2 and WHO3–4 groups. While the trend 
seems visually more pronounced for the severe group (WHO 3–4) in Fig. 3, it failed to 
show statistical significance except for heart rate. Considering the known association 
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between fetal growth restriction and hemodynamic maladaptation, the difference in 
adjusted birthweight centiles nevertheless emphasizes the impression of a reduced car-
diac adaptive potential in high risk groups (Fig. 3) and thus requires further investigation 
in a larger population.
A similar effect is observed for the influence of HT/SGA in Fig. 4. This suggests that the 
reduced cardiac reserve is probably intrinsic to the structural heart disease rather than 
caused by the relatively high prevalence of hypertensive complications and SGA in our 
population (40%).
While the incidence of cardiac complications was relatively low in our population, the 
overall complication rate was high (62.5%). Previous research has demonstrated that 
women with heart disease are also at increased risk for non-cardiac and obstetric pathol-
ogy 4–6. Most hypertensive complications occurred in women with known risk factors 
such as aortic stenosis and coarctation 4. As expected, SGA infants occurred mostly in 
women with atrial repair of transposition of the great arteries and pulmonary stenosis 
spectra 31,32. Of note is the occurrence of post-partum depression in 2 women and a 
suicide attempt during pregnancy in a third woman. One could imagine that the burden 
of cardiac disease adds to the normal psychological challenge which accompanies 
pregnancy and early motherhood.
A higher incidence of depression or psychiatric disturbances has not been described 
in women with structural heart disease. It merits attention in further prospective trials 
as both cardiac disease and suicide are the main causes of maternal mortality in the 
western world 33.
Data on hemodynamic adaptation in pregnancy in women with structural heart 
disease are scarce and have not been described in a longitudinal matter. Therefore com-
parison with other studies is very difficult. Lesniak et al. analyzed the evolution of echo-
cardiographic parameters of various valvular conditions during pregnancy, describing 
slightly different patterns according to the specific valvular pathology 9.
The strength of our study lies in its prospective nature and longitudinal assessment of 
hemodynamic adaptation during pregnancy as well as in the observation of the influ-
ence of pregnancy on long term cardiac outcome.
The main weaknesses of our study are the relatively limited number of patients, the 
heterogeneity of structural heart diseases and the absence of a control group. Future 
prospective research should be multicentric in order to allow pathology specific pattern 
analysis. Where evolutions during pregnancy were compared with previously published 
populations of pregnant women, a matched control group would certainly be prefer-
able, ideally with inclusion of preconceptional measurements.
In conclusion our results show an attenuated cardiovascular adaptation to pregnancy 
in women with structural heart disease. Our data indicate a reduction in systolic func-
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tion and progression diastolic dysfunction during pregnancy, which persist 6 months 
after pregnancy.
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Assessment of the right ventricle in pregnant women
Dear Editor,
We would like to thank the authors for their valuable comments on our manuscript and 
certainly welcome the suggestion for more interest in right ventricular function in preg-
nant women with structural heart disease 1,2.While evaluation of its functioning seems 
evident in lesions with right sided involvement, it is probably essential in all types of 
structural heart disease as it becomes more and more evident that left sided dysfunc-
tion often involves or induces right ventricular dysfunction 3.While the latter is often less 
apparent, it is indeed not less important.
The problem remains that there are no data on normal right ventricular function 
during uncomplicated pregnancy for comparison. It then becomes difficult to discern 
between physiological changes related to pregnancy and pathological changes due to 
the structural defect.
The neglection of right ventricular assessment can largely be attributed to the difficul-
ties in obtaining straightforward representative measurements with ultrasound. Even 
more than for its left counterpart, most parameters only crudely reflect aspects of right 
ventricular function. Interpretation is then highly dependent of underlying structural 
abnormalities and changing loading conditions 4.
Assessment of volume and ejection fraction with 2-D ultrasound is severely hampered 
by the anterior position and complex shape of the right ventricle 4. The gold standard 
remains cardiac magnetic resonance (CMR). 3-D is promising but still remains challeng-
ing in patients with structural heart defects 5,6.
In assessing other parameters of right ventricular systolic function, one has to bear 
in mind that the interplay between intrinsic myocardial performance and loading con-
ditions is even more complex as for the left ventricle. Therefore, development of load 
independent markers of right ventricular function, especially with changing conditions 
during pregnancy, is essential 3.
As suggested, several parameters like tricuspidal annular plane systolic excursion 
(TAPSE), Tissue Doppler velocities as well as strain, strain rate and myocardial accel-
eration during myocardial contraction (IVA), the latter being less load dependent, are 
promising 4,7. Still most of them also have their intrinsic limitations and normal values for 
pregnancy are lacking for comparison.
We performed CMR of the right ventricle in a subgroup of our population and will soon 
submit our data. Unfortunately we did not asses right ventricular function by ultrasound 
in a systematic way 2. We think that more research on normal values of both ventricles 
with the latest ultrasound techniques is primordial in healthy pregnant women and 
agree that parameters of right ventricular function should then be included in studies of 
pregnant women with heart disease. Only then will we be able to truly asses the influ-
ence of pregnancy on global heart function in these women.
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background
Pregnant women with congenital heart disease (CHD) are susceptible to cardiovascular, 
obstetric, and offspring complications. In women with CHD, cardiac dysfunction may 
compromise uteroplacental flow and contribute to the increased incidence of obstetric 
and offspring events.
Methods and Results
We performed a prospective multicenter cohort study of pregnant women with CHD 
and healthy pregnant women. We compared clinical, laboratory, echocardiographic, 
and uteroplacental Doppler flow (UDF) parameters at 20 and 32 weeks gestation, and 
pregnancy outcome. We related cardiovascular parameters to UDF parameters and 
pregnancy outcome in women with CHD. We included 209 women with CHD and 70 
healthy women. Cardiovascular parameters (N-terminal pro-B-type natriuretic peptide, 
left and right ventricular function) differed between both groups. UDF parameters were 
impaired in CHD women (umbilical artery pulsatility and resistance index at 32 weeks 
in CHD versus healthy women, P=0.0085 and P=0.017). The following cardiovascular pa-
rameters prepregnancy and at 20 weeks gestation were associated with UDF (umbilical 
artery resistance index) at 32 weeks at multivariable analysis: (1) right ventricular func-
tion (tricuspid annular plane systolic excursion) (P=0.002), (2) high N-terminal pro-B-
type natriuretic peptide (P=0.085), (3) systemic (P=0.001), and (4) pulmonary (P=0.045) 
atrioventricular valve regurgitation. Women with CHD had more obstetric (58.9% versus 
32.9%, P<0.0001) and offspring events (35.4% versus 18.6%, P=0.008) than healthy 
women. Impaired UDF was associated with adverse obstetric and offspring outcome.
Conclusions
UDF parameters are abnormal in pregnant women with CHD. Cardiovascular function is 
associated with an abnormal pattern of UDF. Compromised UDF may be a key factor in 
the high incidence of offspring and obstetric complications in this population.
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Congenital heart disease (CHD) occurs in ≈1% of newborns, and 50% of these children 
are female. The extensive evolution of cardiac surgery for CHD has resulted in a large 
population of adult women with CHD. Many of them pursue pregnancy. Pregnancy in 
these women is associated with cardiovascular complications, which occur in ≈10% of 
pregnancies. Moreover, obstetric and offspring complications are also more prevalent 
than in healthy pregnant women.1-5 In women with CHD, offspring complications are 
related to maternal cardiac function.5 However, the underlying pathophysiology of this 
relationship is not completely unraveled. In healthy women with intrauterine growth 
restriction or hypertensive disorders of pregnancy, the process of placentation is often 
disturbed, resulting in abnormal uterine and umbilical artery Doppler flow patterns.6 
Such abnormal uteroplacental Doppler flow (UDF) patterns are validated markers of 
adverse offspring outcome. Moreover, coexisting maternal cardiac and vascular func-
tion abnormalities have been demonstrated.7-9 Whether these abnormalities may be ex-
plained by damage caused by circulating angiogenic factors secreted by the placenta, or 
abnormal placentation and offspring outcome are caused by (subtle) underlying cardiac 
and vascular disease, is unknown. In women with CHD, the relation between cardiac 
function (as expressed in N-terminal pro-B-type natriuretic peptide [NT-proBNP] levels 
and echocardiographic parameters), UDF patterns, and offspring complications has not 
been investigated. We hypothesized that preexisting cardiac dysfunction in pregnant 
women with CHD results not only in cardiovascular complications, but also can lead to 
disturbed placentation with abnormal UDF patterns, thus compromising normal growth 
and development of the fetus and contributing to offspring complications in pregnancy. 
To confirm this hypothesis, we performed a prospective study in women with CHD and 
healthy women. The primary objectives of this study are (1) to compare the cardiovascu-
lar clinical, biochemical, and echocardiographic parameters, and UDF patterns, as well, 
of pregnant women with CHD with healthy pregnant women, and (2) to relate maternal 
cardiovascular parameters in women with CHD to UDF patterns. The secondary objec-
tive is to relate UDF patterns to obstetric and offspring outcome. This study will give 
insight in the pathophysiology of offspring complications in women with CHD.
PaTIenTs anD MeTHoDs
Design and setting
This prospective observational multicenter cohort study was conducted between March 
2008 and August 2011. The extensive study design of the Zwangerschap en Aangeboren 
HARtAfwijkingen (ZAHARA) II study was published previously and is summarized below.10
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Patient selection
Female patients with structural CHD (aged ≥18 years) reporting pregnancy with a dura-
tion ≤20 weeks who provided written informed consent and who were followed in 1 
of the 8 participating tertiary hospitals participated in the study. In the Netherlands, 
pregnancies of all healthy women are routinely handled by midwives, regardless of so-
cioeconomic status. Therefore, simultaneously, healthy pregnant women were recruited 
from midwifery practices. Miscarriages or termination before 20 weeks gestation and 
twin pregnancies were excluded, as were women with known illicit drug or alcohol 
abuse. The study was approved by the Medical Ethics Committee of all participating 
hospitals.
sample size Calculation
One of the primary aims of the ZAHARA II study was to compare the UDF, expressed as 
pulsatility and resistance indices in the uterine and umbilical artery, during pregnancy 
between women with CHD and healthy controls. A total sample size of 240 subjects 
(160 patients and 60 [healthy] controls) achieves 80% power to detect a difference of 
0.05 in pulsatility index (25% of the expected standard deviation) among the means 
versus the alternative of equal means by using an independent samples t test with a 
0.05 significance level. The common standard deviation within a group is assumed to be 
0.20. The sample size for comparison of pulsatility index (PI) was based on an effect size 
of 0.25. For resistance index (RI), we would use the same assumption and therefore arrive 
at a similar sample size.
Preconception Characteristics
Baseline data were recorded at the first prenatal visit and included maternal age, ob-
stetric history, cardiovascular history, comorbidity, prepregnancy cardiac status and 
echocardiographic recordings (including systemic and pulmonary ventricular function 
and valvular function), use of medication, and alcohol and smoking history.
evaluation at 20 and 32 weeks
At 20 and 32 weeks gestation, participants underwent clinical and laboratory evalua-
tion (including serum hemoglobin and NT-proBNP), echocardiographic examination, 
and UDF registration (PI and RI of the umbilical artery and of the right and left uterine 
artery, and the presence of early diastolic notching). All echocardiographic recordings 
were made on commercially available Philips or Vingmed General Electric ultrasound 
equipment. Echocardiograms were evaluated off-line by 3 experienced cardiologists 
(each of them reviewed a part of the echocardiograms). A fourth cardiologist checked 
the consistency and accuracy of the echocardiography data. Chamber quantification 
and ventricular and valvular function were assessed according to current guidelines.11–14 
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Because Tricuspid Annular Plane Systolic Excursion (TAPSE) and ejection fraction by 
Simpsons rule are not validated in patients with single ventricles and systemic right 
ventricles, these measurements were not performed in these patient groups.
obstetric and offspring events
Extensive definitions of obstetric and offspring events were published previously and 
are summarized below.10
Obstetric events were noncardiac death, pregnancy-induced hypertension, pre-
eclampsia, eclampsia, gestational diabetes mellitus, HELLP syndrome (hemolysis, 
elevated liver enzymes, low platelet syndrome), hyperemesis gravidarum, assisted deliv-
ery, postpartum hemorrhage, preterm labor, preterm premature rupture of membranes, 
and abruptio placentae.
Offspring events were fetal death, neonatal death, intraventricular hemorrhage, neo-
natal respiratory distress syndrome, infections leading to hospital admission, neonatal 
intensive care unit admission, premature birth, occurrence of CHD, occurrence of other 
congenital disease, small for gestational age, and low birth weight.
statistical analysis
We used SPSS (IBM SPSS Statistics, version 19.0, IBM SPSS Statistics, IBM Corporation, 
Armonk, NY) and STATA (version 12.0, StatCorp LP, College Station, TX) for statistical 
analysis. Continuous variables with normal distribution are presented as mean with 
standard deviation (±standard deviation), nonnormally distributed variables as me-
dian with interquartile ranges, and dichotomous variables are presented as absolute 
numbers with percentages. Cardiovascular parameters and UDF parameters at 20 and 
32 weeks gestation, and pregnancy outcome, were compared between women with 
CHD and healthy women. Comparison of continuous variables between groups was 
performed with the Student t test or Mann-Whitney U test, depending on distribution, 
with and without logarithmic transformation. Longitudinal comparison of continuous 
variables within CHD and healthy pregnancy groups at 2 time points (20 and 32 weeks) 
was performed by using the paired t test. We compared the PI and RI within the groups 
CHD and healthy women and compared these measurements of the CHD group with 
measurements of healthy women at 20 weeks and at 32 weeks, as well. For the compari-
son of dichotomous variables, we used the χ2 test or Fisher exact test, as appropriate. 
A P value of <0.05 was considered statistically significant and all P values are 2-sided. 
Uni- and multivariable linear and logistic regression analyses were performed to assess 
associations between cardiovascular parameters and UDF parameters during pregnancy 
and between UDF parameters and obstetric and offspring outcome, as well, in women 
with CHD. The following predefined variables were assessed in univariable analysis: age, 
disease complexity,15 risk of cardiovascular complications according to modified World 
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Health Organization class,16 body surface area, body mass index, New York Heart As-
sociation functional class, resting heart rate, heart rhythm, mean arterial pressure, smok-
ing during pregnancy, cardiac medication use, prepregnancy hypertension, anemia, 
high NT-proBNP, valve dysfunction (stenosis and regurgitation), left ventricular diastolic 
diameter/body surface area, left ventricular mass/body surface area, left ventricular 
ejection fraction, mean left ventricular systolic tissue velocity (S′) (septal-lateral), left 
atrial volume, left ventricular early to atrial mitral inflow velocity ratio, left ventricular 
mitral inflow deceleration time, mean left ventricular early diastolic tissue velocity (E′) 
(septal-lateral), right ventricular diastolic diameter, right ventricular function (TAPSE), 
and right ventricular systolic tissue velocity (S′).
In addition, variables at 20 weeks gestation were adjusted for prepregnancy values 
that were significantly associated with the studied end points (P<0.05), and variables 
at 32 weeks gestation were adjusted for values that were significantly associated 
with the studied end points prepregnancy and at 20 weeks gestation. Variables that 
were strongly associated with the studied end points (P<0.10) or variables considered 
relevant (P>0.10) entered the multivariable model. The final multivariable model was 
constructed by backward deletion of the least significant characteristic, with a criterion 
for deletion of P≥0.10. When performing the multivariable model, we used pairwise 
deletion of cases to deal with missing values.
ResUlTs
Prepregnancy baseline Characteristics
We recruited 234 pregnant women with CHD. Twenty-five women were excluded 
because of miscarriage (n=11), serious protocol violation (n=6), twin pregnancy (n=4), 
or withdrawal of informed consent (n=4). Simultaneously, 70 healthy, age and parity-
matched pregnant control women with a singleton pregnancy were recruited.
No significant difference was observed between women with CHD and healthy 
pregnant women with respect to maternal age at conception (28.7±4.4 versus 29.2±4.5, 
P=0.44), parity (64.1% versus 62.9% nulliparous, P=0.46), ethnic origin (95.7% versus 
97.1% white, P=0.35), and prepregnancy body mass index (23.5±3.9 versus 23.1±3.9, 
P=0.56). More healthy women smoked prepregnancy than CHD women (33.3% versus 
20.7%, P=0.03). None of the women had impaired glucose tolerance or hypertensive 
disorder of pregnancy at the time of recruitment. Table 1 shows prepregnancy cardiovas-
cular data of the CHD cohort. None of the women had uncorrected cyanotic disease or 
SpO2 <90%; mean oxygen saturation was 98.5±1.5% at 20 weeks gestation. Of patients 
with shunt lesions, 78% had a history of correction of the defect. Cardiac medication was 
used before pregnancy by 15.8% of women with CHD; 7.2% were on anticoagulation 
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Table 1. Maternal Prepregnancy Characteristics in Women With CHD (n=209)
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Table 1. Maternal Prepregnancy Characteristics in Women 
With CHD (n=209)
n %
Underlying CHD
  Left-sided lesions 57 27.3
   Aortic stenosis/bicuspid aortic valve 29 50.9
   Aortic coarctation 26 45.6
   Other 2 3.5
  Right-sided lesions 64 30.6
   Ebstein anomaly 4 6.3
   Pulmonary stenosis 21 32.8
   Tetralogy of Fallot 39 60.9
  Shunt lesions 60 28.7
   Abnormal pulmonary venous return 6 10
   Atrial septal defect 20 33.3
   Atrioventricular septal defect 8 13.3
   Ventricular septal defect 26 43.3
  Connective tissue disease 9 4.3
   Marfan syndrome 8 88.9
   Loeys–Dietz syndrome 1 11.1
  Complex CHD 19 9.1
   Transposition of great arteries  
(Mustard/Senning operation)
11 57.9
   Transposition of great arteries  
(arterial switch operation)
2 10.5
   Congenitally corrected transposition  
of great arteries
1 5.3
   Fontan circulation 3 15.8
   Other complex CHD 2 10.5
Disease complexity*
  Simple 59 28.2
  Moderate complex 131 62.7
  Complex 19 9.1
Modified WHO classification  
(risk of pregnancy)
  Class 1 (low risk) 43 20.6
  Class 2 (moderately high risk) 117 56.0
  Class ≥3 (high risk) 49 23.4
Medical history
  History of heart failure 5 2.4
  History of arrhythmia 19 9.1
  History of hypertension 14 6.7
  History of diabetes mellitus 2 1.0
  Pacemaker 7 3.3
  Mechanical valve prosthesis 11 5.3
  Biological valve prosthesis 20 9.6
Medication use prepregnancy
  Cardiac medication 33 15.8
  β-Blockers 26 12.4
  Other cardiac medication 16 7.7
  Vitamin K-antagonists/heparin 15 7.2
(Continued)
Table 1. Continued
NYHA functional class
  Class I 159 76.1
  Class II 49 23.4
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Table 1. Maternal Prepregnancy Characteristics in Women 
With CHD (n=209)
n %
Underlying CHD
  Left-sided lesions 57 27.3
   Aortic stenosis/bicuspid aortic valve 29 50.9
 Aortic coarctation 26 45 6
Other 2 3 5
Right-sided lesions 64 30
Ebstein anomaly 4 6 3
 Pulmonary te osis 21 2 8
Tetralogy of F lot 39 60 9
Shunt lesions 60 28 7
Abnormal pulmonary venous return 6 10
 Atrial eptal defect 2 33 3
trioventric ar septal defect 8 13.3
Ventricular septal defect 6 4
Connective t ssue disease 9 4
Marfan syndrome 8 88 9
 Lo ys–Dietz syndrome 1 11 1
Complex CHD 19 9 1
Tran position of great arteries  
(Mustard/Senning operation)
1 57 9
   Transposition of great arteries  
(arterial switch operation)
2 10.5
   Congenitally corrected transposition  
of great arteries
1 5.3
   Fontan circulation 3 15.8
   Other complex CHD 2 10.5
Disease complexity*
Simple 59 28 2
  Moderate complex 131 62.7
Complex 1 9 1
Modified WHO classification  
(risk of pregnancy)
  Class 1 (low risk) 43 20.6
  Class 2 (moderately high risk) 117 56.0
≥3 (high risk) 9 3 4
Medical history
History of eart failure 5 2
  History of arrhythmia 19 9.1
ypertension 14 6 7
diabetes mellitus 2 1 0
Pacemaker 7 3 3
Mechanical valv  prosthesis 11 5 3
Biological valve prosthesis 20 9 6
Medicatio  use prepregnancy
Cardia  medication 33 15 8
  β-Blocker 26 12.4
Other ardiac medication 16 7 7
Vitamin K-antagonists/heparin 15 7 2
(Continued)
Table 1. Continued
NYHA functional class
  Class I 159 76.1
  Class II 49 23.4
In underlying heart disease, several groups are mentioned (ie, left sided lesions, right sided lesions, etc). 
The n and % in roman are then a % for such a group. Within each group, subdiagnoses are mentioned (ie, 
aortic stenosis, aortic coarctation, other). The n and % of subdiagnoses are shown in italics. CHD indicates 
congenital heart disease; NYHA, New York Heart Association; and WHO, World Health Organization.
*Disease complexity: according to Warnes et al.15
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therapy and 12.4% used a β-blocker. Sinus rhythm was present in 88% (n=185). Systemic 
ventricular ejection fraction was known in 161 CHD women and was below 45% in 8.1% 
of these women. Prepregnancy right ventricular (RV) function (TAPSE) was known in 138 
CHD women; RV dysfunction (TAPSE < 16 mm) existed in 14.5% of these women. Three 
women conceived through intracytoplasmic sperm injection. Six women had a history of 
thyroid dysfunction; however, thyroid stimulating hormone was normal preconception.
Comparison of Cardiovascular and UDf Parameters between Pregnant women 
with CHD and Healthy Pregnant women
New York Heart Association functional class deterioration >1 class at 32 weeks in com-
parison with prepregnancy occurred only in CHD and not in healthy women: 10.1% 
versus 0%, P=0.003. We compared laboratory, echocardiographic, and UDF parameters 
between CHD and healthy cohorts at 20 and 32 weeks gestation (Table 2). NT-proBNP 
was higher throughout pregnancy in women with CHD and decreased during pregnancy 
in both groups; the decrease was significantly greater in CHD women (P=0.04). Systemic 
ventricular mass corrected for body surface area was higher and increased (P<0.005) 
only in women with CHD. Systemic ventricular ejection fraction did not change signifi-
cantly in both groups. Several diastolic systemic ventricular function parameters were 
significantly worse in CHD women: systemic ventricular annular velocity (E′) was lower 
and diastolic filling pressure (E/E′) higher; change during pregnancy was comparable 
between both groups. RV systolic function (represented by TAPSE and systolic annular 
 Uteroplacental Doppler flow parameters: pulsatility index and resistance index of mean of right and left uterine artery and of 
umbilical artery at 20 and 32 weeks of pregnancy, in women with CHD and healthy women. Mean PI ( ) and mean RI ( ) differed 
significantly between 20 and 32 weeks, in both uterine and umbilical artery and in healthy controls and CHD patients (as represented by 
the horizontal line indicating all  values <0.0001). Significant differences in separate analyses comparing groups at 20 weeks and at 32 
weeks are indicated by vertical lines with  values. CHD indicates congenital heart disease; PI, pulsatility index; and RI, resistance index. 
figure 1 Uteroplacental Dop l r flow parameters: pulsatility index and resistance index of mean of right 
and left uterine artery and of umbilical artery at 20 and 32 weeks of pregnancy, in women with CHD and 
healthy women. Mean PI (left) and mean RI (right) differed significantly between 20 and 32 weeks, in both 
uterine and umbilical artery and in healthy controls and CHD patients (as represented by the horizontal line 
indicating all P values <0.0001). Significant differences in separate analyses comparing groups at 20 weeks 
and at 32 weeks are indicated by vertical lines with P values. CHD indicates congenital heart disease; PI, 
pulsatility index; and RI, resistance index.
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velocity) was worse in CHD and decreased significantly in CHD women only (P=0.017 
and P=0.009, respectively). Figure 1 shows UDF parameters at 20 and 32 weeks. Uterine 
and umbilical artery PI and RI were higher throughout pregnancy in the CHD group and 
decreased in both groups. Uterine artery PI and RI were both measured in 139 women at 
20 weeks, and umbilical artery PI and RI were both measured in 157 women at 32 weeks, 
whereas 51 women did not have any uterine artery UDF measurement at 20 weeks, and 
Table 2. Comparison of Women With CHD (n=209*) With Healthy (n=70*) Women During PregnancyTa le 2. Comparison of W men With CHD (n=209*) With Healthy (n=70*) Women During Pregnancy
Gestational Week 20 Gestational Week 32
CHD Healthy
P Value
CHD Healthy
P Valuen n n n
General parameters
  Smoking during 
pregnancy
10.0% 2.9% 0.077 10.0% 2.9% 0.077
  Cardiac medication 11.0% 0 % 0.002 13.9% 0% <0.0001
  NYHA class I 53.1%
39.7%
7.2%
58.6
41.4%
0 %
0.069 39.6%
46.4%
14.0%
37.1%
62.9%
0%
0.005
  NYHA class II
  NYHA class III
  MAP, mm Hg 81.4±8.7 178 77.8±7.8 69 0.003 83.1±8.0 168 79.7±7.1 65 0.003
Laboratory parameters
  Hb, mmol/L 7.5±0.6 192 7.5±0.5 67 0.59 7.4±0.7 184 7.4±0.5 64 0.62
  NT-proBNP, pg/mL 111.5 
(58.7–171.4)
166 51.0 
(23.5–67.0)
49 <0.0001 64.0 
(47.7–120.0)
159 24.5 
(14.1–41.5)
48 <0.0001
Systemic ventricular size, mass and systolic function†
  Systemic ventricular 
end-diastolic diameter
47.4±5.6 182 48.0±3.8 68 0.29 48.4±6.3 172 48.4±3.6 66 0.83
  Systemic ventricular 
mass/BSA, g/m2
49.7±14.3 177 42.0±7.2 <0.0001 53.9±14.4 166 43.9±8.1 65 <0.0001
  Systemic ventricular 
ejection fraction, %
57.4±8.6 182 61.3±5.9 67 <0.0001 56.9±8.4 167 60.0±6.2 65 0.003
Systemic ventricular diastolic function†
  LA volume, mL‡ 40.2±14.1 157 42.64±10.2 66 0.20 43.3±14.0 153 41.61±11.1 65 0.39
  E/A ratio 1.8 (1.4–2.2) 151 1.7 (1.4–2.2) 64 0.89 1.5 (1.2–1.8) 144 1.5 (1.2–1.7) 62 0.72
  E deceleration time, ms 193.5 
(162.8–237.3)
150 186.5 
(169.5–217.3)
64 0.49 184.0 
(155.5–217.0)
141 191.0 
(159.0–224.0)
59 0.44
  Mean E  (septal- 
lateral), cm/s
11.0 
(10.1–12.5)
133 12.5 
(11.3–13.3)
66 <0.0001 9.96 
(9.06–11.5)
132 11.1 
(9.76–12.5)
58 0.056
  E/E 9.2 (7.7–11.9) 114 7.3 (6.6–8.2) 62 <0.0001 8.8 (7.0–11.3) 113 7.2 (6.1–8.0) 55 <0.0001
Right ventricular size and function†
  Right ventricular 
diastolic diameter, cm
39.0±7.3 161 35.6±4.1 58 <0.0001 39.0±7.0 155 35.7±4.7 53 0.0002
  TAPSE, mm 22.5±5.6 169 26.3±3.4 64 <0.0001 21.4±6.4 164 25.3±3.8 66 <0.0001
  Right ventricular S , cm/s 9.7±2.8 126 11.2±1.9 54 <0.0001 9.3±3.2 135 11.3±2.0 51 <0.0001
BSA indicates body surface area; CHD, congenital heart disease; E, early passive filling velocity of systemic ventricular inflow; E , early diastolic tissue Doppler velocity 
of systemic ventricular annular ring; E/A ratio, early to atrial mitral inflow velocity ratio; Hb, serum hemoglobin; LA, left atrium; MAP, mean arterial pressure; NT-proBNP, 
N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association functional class; Right ventricular S , systolic tissue Doppler velocity of tricuspid annular 
ring; and TAPSE, tricuspid annular plane systolic excursion.
*Numbers different from n=209 or n=70 are shown separately.
†Women with systemic right ventricle heart were only excluded from this specific analysis.
‡LA is the atrium receiving pulmonary venous flow; volume not measured in women with atrial correction of transposition and in Fontan patients.
bsa indicates body surface area; CHD, co genital heart disease; E, early p ssive filling v locity of systemic 
ventricular inflow; E′, early diastolic tissue Doppler velocity of systemic ventricular annular ring; E/A ratio, 
early to atrial mitral inflow velocity ratio; Hb, serum hemoglobin; LA, left atrium; MAP, mean arterial pres-
sure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association functional 
class; Right ventricular S′, systolic tissue Doppler velocity of tricuspid annular ring; and TAPSE, tricuspid 
annular plane systolic excursion.
*numbers different from n=209 or n=70 are shown separately.
†women with systemic right ventricle heart were only excluded from this specific analysis.
‡la is the atrium receiving pulmonary venous flow; volume not measured in women with atrial correction 
of transposition and in Fontan patients.
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23 women did not have any of umbilical artery measurements at 32 weeks. Missing 
measurements were mainly attributable to logistic reasons.
Relation of Cardiovascular Parameters and UDf Indices in women with CHD
We related maternal cardiovascular to UDF parameters. PI and RI were not both mea-
sured in all patients. Because results were comparable, we present RI data, in accordance 
with previous studies presenting data on the relation of UDF parameters with cardiac 
function in healthy women.17 RI was available in 141 women for the uterine artery at 
Table 3. Associations of Preconception and 20 Weeks Variables With Umbilical Artery RI 32 Weeks Entering 
the Multivariable Models
l  .  i ti   re i   0 eeks i l  i  bilical rtery RI 
32 Weeks Entering the Multivariable Models
n* B 95% CI P Value
Association of 20 weeks variables with umbilical artery RI 32 weeks entering model 1
  Age at conception 157 0.003 0.00043 to 0.006 0.025
  Parity 157 0.003 −0.012 to 0.018 0.68
  Smoking during pregnancy 157 0.039 −0.002 to 0.079 0.063
  High NT-proBNP† 129 0.027 −0.001 to 0.054 0.058
  Systemic AV valve 
regurgitation
149 0.059 0.021 to 0.096 0.002
  LVEF, % 139 -0.0002 −0.02 to −0.001 0.77
  TAPSE, mm 131 -0.002 −0.004 to −0.0005 0.124
Association of preconception variables with umbilical artery RI 32 weeks entering model 2
  Disease complexity 157 0.115
  Simple (reference) … … …
  Moderate complex 0.025 −0.004 to 0.053 0.092
  Complex 0.044 −0.004 to 0.093 0.071
  Age at conception 157 0.003 0.00043 to 0.006 0.025
  Parity 157 0.003 −0.012 to 0.018 0.68
  Pacemaker 157 0.046 −0.02 to 0.112 0.174
  Sinus rhythm 134 −0.030 −0.071 to 0.010 0.135
  LVEF, % 118 −0.001 −0.003 to 0.0002 0.091
  TAPSE, mm 100 −0.005 −0.008 to −0.002 <0.001
  Aortic stenosis (moderate/severe) 122 −0.047 −0.103 to 0.009 0.097
  Systemic AV valve regurgitation 127 0.037 −0.004 to 0.078 0.079
  Pulmonary AV valve regurgitation 123 0.040 0.008 to 0.072 0.015
Association of 20 weeks variables with umbilical artery RI 32 weeks entering model 2
  Smoking during pregnancy 157 0.039 −0.002 to 0.079 0.063
  High NT-proBNP* 129 0.027 −0.001 to 0.054 0.058
  LVEF, % 139 −0.0002 −0.02 to −0.001 0.77
For the full list of variables that were assessed in univariable analysis, see Methods. AV indicates atrioventricular; 
CI, confidence interval; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; 
RI, resistance index; and TAPSE, tricuspid annular plane systolic excursion.
*Because the number of measurements of umbilical artery RI at 32 weeks is limited to 157, n cannot exceed this 
number.
†High NT-proBNP: >95th percentile of healthy controls (>128 ng/L).
for the full list of variables that were assessed in univariable analysis, see Methods. AV indicates atrioven-
tricular; CI, confidence interval; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type 
natriuretic peptid ; RI, re istance index; and TAPSE, tricuspid annular plane syst lic excursion.
*because the number of measurements of umbilical artery RI at 32 weeks is limited to 157, n cannot ex-
ceed this number.
†High nT-probnP: >95th percentile of healthy controls (>128 ng/L).
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20 weeks gestation and in 157 women for the umbilical artery at 32 weeks. Univariable 
analysis revealed the following baseline (prepregnancy) variables to be associated with 
uterine artery RI (20 weeks): parity, preconception heart rate, systemic atrioventricular 
valve regurgitation, and left atrial volume. Heart rate, use of cardiac medication, and 
TAPSE at 20 weeks were also associated with uterine artery RI (20 weeks). Hypertension 
was not significantly associated with UDF in our cohort (B=0.028, P=0.28). Multivariable 
analysis rendered parity (B=0.04, P=0.048), resting heart rate at 20 weeks (B=−0.002, 
P=0.006), and use of cardiac medication at 20 weeks (B=0.08, P=0.035) significant. Uni-
variable analysis and multivariable models for the prediction of umbilical artery RI (32 
weeks) are presented in Tables 3 and 4.
Pregnancy outcome in CHD and Healthy women and Relation of outcome to 
UDf
Cardiovascular events occurred in 10.0% in the CHD and 0% in the healthy group. UDF 
parameters were not significantly associated with cardiovascular events.
Obstetric events occurred in 58.9% of CHD and 32.9% of healthy women (P<0.005). 
CHD women had more planned cesarean deliveries (13.4% versus 1.4%, P=0.003) and 
assisted vaginal deliveries (47.4% versus 25.7%, P=0.001). The secondary cesarean de-
livery rate did not differ between both groups (10.0% versus 11.4%). Several obstetric 
events occurred more often in CHD women without the differences reaching statistical 
significance: hypertensive disorders of pregnancy (17.7% versus 11.4%), preeclampsia 
Table 4. Multivariable Regression Analysis for the Prediction of Umbilical Artery RI at 32 Weeks of Gestation
Table 4. Multivariable Regression Analysis for the Prediction of Umbilical Artery RI at 32 
Weeks of Gestation
n* B 95% CI P Value
Model 1: Association of 20 weeks variables with umbilical artery RI 32 weeks (degrees of freedom=128)
  Age at conception 157 0.004 0.001 to 0.008 0.006
  Smoking during pregnancy 157 0.045 −0.000 to 0.090 0.051
  High NT-proBNP† 129 0.024 −0.003 to 0.050 0.085
  Systemic AV valve 
regurgitation
149 0.068 0.027 to 0.109 0.001
Model 2: Association of 20 weeks variables with umbilical artery RI 32 weeks after adjusting for preconception 
variables (degrees of freedom=99)
  Age 157 0.003 0.000 to 0.007 0.040
  Pulmonary AV valve 
regurgitation preconception
127 0.035 0.001 to 0.067 0.045
  TAPSE preconception 100 −0.004 −0.007 to −0.002 0.002
  Systemic AV valve 
regurgitation 20 weeks
149 0.056 −0.011 to 0.101 0.016
AV indicates atrioventricular; CI, confidence interval; NT-proBNP, N-terminal pro B-type natriuretic peptide; RI, 
resistance index; and TAPSE, tricuspid annular plane systolic excursion.
*Because the number of measurements of umbilical artery RI at 32 weeks is limited to 157, n cannot exceed this 
number.
†High NT-proBNP: >95th percentile of healthy controls (>128 ng/L).
aV indicates atrioventricular; CI, confidence interval; NT-proBNP, N-terminal pro B-type natriuretic peptide; 
RI, resistance index; and TAPSE, tricuspid annular plane systolic excursion.
*because the number of measurements of umbilical artery RI at 32 weeks is limited to 157, n cannot ex-
ceed this number.
†High nT-probnP: >95th percentile of healthy controls (>128 ng/L).
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(5.7% versus 1.4%), and preterm premature rupture of membranes (6.7% versus 2.9%). 
Postpartum hemorrhage occurred in both groups in 8.6%. In women with CHD, high 
umbilical artery RI (>90th percentile of healthy group) at 32 weeks was associated with 
obstetric events (P=0.049).
CHD women had shorter gestational age at delivery than healthy women (38.3 ver-
sus 39.7 weeks, P<0.005) and their babies had lower birth weight (3036 versus 3578 
g, P<0.005). More babies of CHD women had an Apgar score of <9 (8.7% versus 0%, 
P=0.009) 10 minutes after birth.
Offspring events occurred more often in CHD women than in healthy women: 35.4% 
versus 18.6% (P=0.008); offspring events excluding the small number of women with 
isolated CHD in the offspring: 34.4% versus 18.6, P=0.012. More children of women 
with CHD were small for gestational age (16.3% versus 4.3%, P=0.008). Congenital heart 
disease occurred in 4.8% of offspring of CHD women versus 0% of healthy women’s 
 Relation of uteroplacental Doppler flow parameters and offspring outcome. , Uterine and umbilical artery PI and offspring 
events. , Uterine and umbilical artery RI and offspring events.  Uterine artery early diastolic notch and offspring events. Reported 
are the percentage of offspring events within, respectively, the groups uterine artery PI and RI at gestational week 20 and the groups 
umbilical artery PI and RI at gestational week 32, and within the groups with and without early diastolic notch. CI indicates confidence 
interval; EDN, early diastolic notch; OR, odds ratio; PI, pulsatility index; RI, resistance index; RR, relative risk; Uma, umbilical artery; and 
Uta, uterine artery.
figure 2 R la ion of uteroplacental Dop ler flow parameters and offspri g outcome. a, Uterine and um-
bilical artery PI and offsprin  events. b, Uterine and umbilical artery RI and offspring events. C, Uterine 
artery early diastolic notch and offspring events. Reported are the percentage of offspring events within, 
respectively, the groups uterine artery PI and RI at gestational week 20 and the groups umbilical artery PI 
and RI at gestational week 32, and within the groups with and without early diastolic notch. CI indicates 
confidence interval; EDN, early diastolic notch; OR, odds ratio; PI, pulsatility index; RI, resistance index; RR, 
relative risk; Uma, umbilical artery; and Uta, uterine artery.
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offspring (P=0.176). Offspring death occurred in 2.9% of the CHD group and 0% of the 
healthy group. Causes of death were pregnancy termination because of spina bifida or 
complex heart disease in 2 pregnancies, intrauterine death in 2 patients because of hy-
drops fetalis and placental insufficiency, and postpartum death because of respiratory 
insufficiency in 2 pregnancies. Premature birth occurred in 12.4% versus 5.7% (P=0.18). 
UDF patterns of women with CHD were associated with offspring events (Figure 2). 
This association was also significant when offspring CHD was excluded from the total 
number of offspring events.
DIsCUssIon
Our study is the first to compare UDF parameters of pregnant women with CHD and 
healthy pregnant women and to relate these to cardiovascular parameters in pregnant 
women with CHD.
Our data show that UDF and cardiovascular parameters differ between women with 
CHD and healthy women. In women with CHD, ventricular function, and valvular func-
tion, is related to UDF. As expected (because this is known in the general pregnant 
population), UDF is associated with obstetric and offspring events.
Adequate uteroplacental blood flow is necessary for normal pregnancy outcome. 
Vascular remodeling of the uteroplacental circulation guarantees sufficient blood flow 
throughout pregnancy. This remodeling is characterized by vascular widening of the 
uterine circulation, which is mediated by endovascular trophoblast invasion of uterine 
spiral arteries, increased shear stress, and angiogenic and humoral factors.18 The remod-
eling process results in a low resistance in the uteroplacental circulation. Abnormalities 
in the placentation process can result in elevated resistance and pulsatility indices, 
which are associated with adverse maternal and offspring outcome, particularly hyper-
tensive disorders and intrauterine growth restriction.5,19 In our study, women with CHD 
had significantly more obstetric and offspring complications than healthy women. This 
included a 4-fold increase in the incidence of preeclampsia and of children born small 
for gestational age. The increased incidence of these complications in women with CHD 
is in line with previous studies.1,3-5,20-22
The association of abnormal UDF patterns and obstetric and offspring outcome, 
which is well established in the general population, was also present in our women 
with CHD. More important, UDF indices indicated a higher resistance in the uteropla-
cental circulation throughout pregnancy in women with CHD than in healthy women. 
We demonstrated that UDF abnormalities in women with CHD were related to cardiac 
function, both before and during pregnancy. Cardiac parameters associated with UDF 
in the multivariable model included preconception RV function but not left ventricu-
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lar function. The likely explanation is the higher prevalence of RV dysfunction in our 
population. We used the TAPSE as a measure of RV function, because it is a reproducible 
simple measurement that is associated with RV function and symptoms in patients with 
CHD.23,24
Healthy pregnant women demonstrated a relatively high New York Heart Association 
functional class during pregnancy, reflecting the normal symptoms of pregnancy that 
can resemble heart failure. Functional class deteriorated more in women with CHD than 
in healthy women, which may indicate a less favorable adaptation of women with CHD 
to the hemodynamic changes of pregnancy.
Not surprisingly, NT-proBNP was higher throughout pregnancy in women with CHD 
than in healthy women. NT-proBNP decreased during pregnancy in both groups, as 
has been demonstrated previously in healthy women,25 and as can be explained by an 
increasing glomerular filtration rate during pregnancy. We found elevated NT-proBNP 
to be weakly associated with abnormal UDF. NT-proBNP and BNP are well-established 
biomarkers of heart failure, and BNP is a predictor of maternal cardiovascular pregnancy 
complications.26 NT-proBNP or BNP have not previously been investigated in relation 
to UDF in women with heart disease. Prepregnancy NT-proBNP was unfortunately not 
available. NT-proBNP may become a useful tool in pregnancy risk estimation in women 
with heart disease, but its role needs further investigation.
Cardiac medication was related to uterine artery RI. The use of cardiac medication is 
also a predictor of maternal cardiac complications and is probably a marker of disease 
severity.5 Most medications were β-blockers, which are known to be associated with 
lower birth weight, which may be mediated by a negative effect on placental blood flow. 
Interestingly, both systemic and pulmonary atrioventricular valve regurgitation were 
associated with UDF parameters. Atrioventricular valve regurgitation is regarded as 
relatively harmless for the mother and her child, because the decrease in vascular resis-
tance that accompanies pregnancy may reduce regurgitation. However, recent research 
indicates that mitral regurgitation does predict maternal cardiovascular complications 
and induces unfavorable cardiac remodeling.5,27 A recent study demonstrated that mitral 
prolapse is associated with preterm delivery.28 Therefore, atrioventricular valve regurgi-
tation cannot be regarded as completely innocent. Our results indicate that placental 
flow may be compromised by atrioventricular valve regurgitation. This association may 
be caused by a direct hemodynamic effect or by a common developmental disorder. 
Valve stenosis did not predict UDF, which might be explained by a lower prevalence 
than regurgitant lesions. In addition to cardiac parameters, parity, age, and smoking 
were also associated with UDF.
Our results support the hypothesis that prepregnancy cardiac dysfunction is related to 
UDF abnormalities, which are indicative of abnormal placentation. This finding is linked 
to the increased incidence of obstetric and offspring complications in women with CHD.
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Evidence from the literature indicates a relationship in the general population be-
tween previous hypertension during pregnancy, preeclampsia, or intrauterine growth 
restriction and the later occurrence of acquired cardiovascular disease in the mother.29-31 
A recent study revealed an association of uterine artery RI during pregnancy with pre-
pregnancy uterine artery blood flow.32 Based on these data, it has been hypothesized 
that pregnancy complications, particularly preeclampsia and intrauterine growth re-
striction, reveal latent cardiovascular abnormalities that may already be present before 
pregnancy. Our study adds evidence to support this hypothesis, because, in our women 
with CHD, cardiac function prepregnancy is related to abnormal UDF and adverse off-
spring outcome.
strengths and limitations
Our study is the first to investigate UDF in pregnant women with cardiac disease. Several 
limitations must be considered. We designed our study to include pregnant women with 
various underlying congenital cardiac diseases. The heterogeneity of our population 
may have caused underrepresentation not only of individual diseases, but also of specific 
cardiac dysfunctions. This may have impacted the robustness of our prediction models. 
Moreover, because the study included women when they were already pregnant, collec-
tion of prepregnancy data was retrospective, and missing data were inevitable (mainly 
prepregnancy echocardiography data).
Additionally, in this multicenter study, deviation from the protocol sometimes oc-
curred, whereas complex disease often prevented accurate measurements of chamber 
size and function. Cardiac output could therefore not be measured reliably, and not all 
data were available in all patients. Technical limitations prevented the digital storage of 
UDF patterns, which were therefore measured by the different caregivers. Our compos-
ite outcome variable combined all offspring events. Because some offspring events (eg, 
CHD) may not be influenced by UDF or may be influenced through a different mecha-
nism, we repeated the analysis without offspring CHD, which did not significantly alter 
outcome. We did not have data available on the course of intrauterine growth and could 
not report on intrauterine growth restriction. Therefore, we used small for gestational 
age as a parameter of offspring growth. There might be some inclusion bias because 
we did not include patients from regional hospitals. Because the composition of our 
population is comparable with the Dutch national congenital database (CONCOR), this 
bias can be regarded unimportant. Because of the significant number of missing data 
from echocardiography in the preconception period, we chose to make a prediction 
model by using data at 20 weeks gestation. Where possible, we assessed the influence of 
the known prepregnancy data. Despite these limitations, we were able to demonstrate 
that cardiac function in women with CHD is associated with an abnormal pattern of UDF 
and adverse pregnancy outcome. Our study results lead to an improved understanding 
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of the pathophysiology of offspring events in women with CHD, and may also contribute 
to a better insight in the pathophysiology of offspring complications in the general 
population.
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ClInICal PeRsPeCTIVe
Women with congenital heart disease (CHD) are not only at risk of maternal cardio-
vascular complications during their pregnancies, but they also have an increased risk 
of obstetric and offspring complications. Offspring complications such as small for 
gestational age and premature birth are related to maternal cardiac function, but the 
mechanism underlying this relationship is unknown. In this clinical study, in 209 preg-
nant women with CHD and 70 healthy women, we demonstrated that uteroplacental 
Doppler flow parameters (uterine and umbilical artery pulsatility and resistance indices) 
are worse in pregnant women with CHD than in healthy women and are related to 
maternal cardiovascular function parameters, such as right ventricular function, valvular 
regurgitation, heart rate, and prepregnancy need for cardiac medication. Uteroplacental 
flow parameters were related to offspring outcome, as is also known in the general preg-
nant population. Therefore, we concluded that in women with CHD, uteroplacental flow 
may be compromised by maternal cardiac dysfunction and that impaired uteroplacental 
flow may be a key factor in the high incidence of obstetric and offspring complications. 
Our study improves the understanding of the pathophysiology of offspring events in 
women with CHD and may also contribute to a better insight into the pathophysiology 
of offspring complications in the general population. The results of this study are of 
importance for counseling of women with CHD who are contemplating pregnancy and 
will improve risk stratification leading to more adequate monitoring of pregnancies in 
these women.
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absTRaCT
Contraceptive counselling should begin early in females with heart disease, preferably 
directly after the start of menstruation. In coming to a decision about the method of 
contraception, the following issues should be considered: (i) the risk of pregnancy 
for the mother and the consequences of an unplanned pregnancy; (ii) the risks of the 
contraceptive method; (iii) failure rates; (iv) the non-contraceptive benefits; (v) the avail-
ability; (vi) the individual’s preferences; (vii) protection against infection; and (viii) costs. 
In some women with heart disease, the issues may be complex and require the input of 
both a cardiologist and an obstetrician (or other feto-maternal expert) to identify the 
optimal approach. No studies have been performed in women with heart disease to 
investigate the relative risks and benefits of different contraceptive methods.
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InTRoDUCTIon
The success of cardiac surgery and the medical management of women with congenital 
and acquired heart disease means that most will reach puberty and could become 
pregnant, as most become sexually active even with severe heart disease.1,2 However, 
pregnancy is high-risk in at least some of these women and needs careful planning.1 – 3 
In the large international prospective registry of pregnant patients with cardiac disease 
(ROPAC), 38% of 1321 women was defined to be high risk and 4% had a contraindication 
for pregnancy.2 Effective contraception is essential especially in those with a contraindi-
cation for pregnancy. In other women, effective contraception is crucial to allow coun-
selling and optimal timing of pregnancy, improving the chances of an uncomplicated 
pregnancy. In addition, women with cardiac disease may use medication that is terato-
genic (i.e. ACE-inhibitors), consequently, effective contraception is essential. However, 
the provision of contraceptive advice to these women is sporadic. One study reported 
that nearly 35% of 49 women had not been advised on the use of contraceptives, while 
counselling in another 30% had been inappropriate.4 Another study reported the wide-
spread use of oestrogen-containing formulations (33%), despite their association with 
an increased risk of thrombo-embolic disease, even in women with a contraindication 
for oestrogen-use, while the safer progesterone-only alternatives were used relatively 
infrequently (1.3%).5
Large population-based sexual health studies have all reported a decrease in median 
age at first intercourse over the past 50 – 60 years. In the western world, the median 
age of menarche is around 12 – 13 and the age at first sexual intercourse for women 
around 17 years, with 2 – 30% having sexual intercourse before the age of 15.6 The mean 
age at first intercourse of women with heart disease is similar to that of the general 
population.7 Clearly general practitioners, (paediatric) cardiologists, obstetricians, and 
other doctors caring for these women should offer appropriate contraceptive advice 
early, preferably soon after menstruation starts.
Medically, the key issues relate to reliability and the thrombosis- and infection risk of 
each possible method. The most reliable methods are those that are the most straight 
forward to use, the implant and the intrauterine device (IUD). The thrombotic risk is 
greatest with oestrogen-containing compounds and the copper IUD has the greatest 
risk of pelvic infection, while all non-barrier contraceptives at best have a limited benefit 
through thickening of the cervical mucous or not protective benefit at all in preventing 
infection. A good approach is the use of a long-acting reversible form of contraception 
combined with a male condom for prevention of sexually transmitted diseases.
From a health economic perspective, contraception is cost saving to society by prevent-
ing the costs and emotional distress associated with unintended pregnancies and termina-
tions.8 This is even more pronounced in women with medical conditions like heart disease. 
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Subdermal implants, IUDs, and sterilization are more cost effective than other methods.8 
This is related to their contraceptive efficacy, high continuation rate, additional medical ben-
efits (e.g. decreased menstrual bloodloss, low thrombotic risk), and long duration of action.
However, the discussion on contraception should not be limited to the safest and most 
efficient way to avoid pregnancy, but should encompass other issues like menstrual 
regulation, reduction of uterine blood loss and menstrual discomfort, as well as the pos-
sibility of treatment for endometriosis, PCOS, acne, ovarian cysts, and other conditions. 
While these issues might be considered less important, they affect the daily comfort 
and wellbeing of women. The chances of a woman continuing to use contraception are 
much greater if the method used also makes her feel well.3 Given the complexity of each 
request, we prefer an individualized approach where the contraceptive and non-con-
traceptive benefits and the risks of each method are matched with the patient’s desire, 
after appropriate counselling. In this article, we will discuss the relative risks and benefits 
of different contraceptive methods in the context of a woman with heart disease.
TyPe of ConTRaCePTIon
To find the best type of contraception, issues such as risks, failure rates, non-contra-
ceptive benefits, individual preferences, and protection against infection should be 
considered (Figure 1). In some women with heart disease, the issues may be complex 
and require the input of both a cardiologist and an obstetrician to identify the optimal 
approach. The risks and consequences of pregnancy, planned as well as unplanned, can 
be estimated based upon the Modified WHO classification of maternal cardiovascular 
risk.9 For the risks of each contraceptive method, the detailed WHO medical eligibility 
criteria (WHO-MEC) for contraceptive use offer guidance in women with specific medical 
conditions.10 The WHO developed this practical system of recommendations with four 
categories for each contraceptive method and each medical condition including heart 
disease (Table 1). The guidelines are developed and regularly updated by a panel of 
international experts, primarily based on scientific evidence where available and expert 
opinion where it is not. As no studies on contraception have been performed in women 
with heart disease most recommendations are based on extrapolation of data from 
studies in women without heart disease. Several national guidelines are based on this 
system, adapted to the local situation.11,12
The efficacy of a contraceptive method is based on its intrinsic mechanism of action, 
but is also highly dependent on its correct use. It is therefore often expressed as an 
optimal efficacy, reflecting its theoretical efficacy and a typical efficacy, based on what is 
observed in real life. Table 2 shows these efficacies along with the most important risks 
and benefits.
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figure 1 Sketch illustrating different types of contraceptives. (1) Safe period, (2) oral contraceptive (COC 
or POP), (3) injectable (DMPA), (4) implant, (5) patch, (6) hysteroscopic tubal occlusion, (7) intrauterine con-
traceptive device, (8) tubal ligation, (9) diaphragm, (10) vaginal ring, (11) male condom, (12) vasectomy.
Table 1 WHO eligibility criteria for widely used contraceptive methods
Chapter 5.5
214
Ta
bl
e 
2 
Th
e 
pe
rc
en
ta
ge
 o
f w
om
en
 w
ho
 w
ill
 e
xp
er
ie
nc
e 
an
 u
np
la
nn
ed
 p
re
gn
an
cy
 w
ith
in
 th
e 
fir
st
 y
ea
r o
f u
se
 o
f a
 g
iv
en
 c
on
tr
ac
ep
tiv
e 
m
et
ho
d 
(t
yp
ic
al
 a
nd
 o
pt
im
al
 u
s-
ag
e)
, t
og
et
he
r w
ith
 th
e 
pe
rc
en
ta
ge
 o
f c
on
tin
ue
d 
us
e 
af
te
r 1
 y
ea
r, 
th
e 
ris
k 
of
 th
ro
m
bo
si
s 
an
d 
of
 in
fe
ct
io
n 
as
so
ci
at
ed
 w
ith
 th
e 
m
et
ho
ds
 u
se
. M
od
ifi
ed
 fr
om
13
,1
4
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
T
ab
le
2
T
he
pe
rc
en
ta
ge
o
fw
o
m
en
w
ho
w
ill
ex
pe
ri
en
ce
an
un
pl
an
ne
d
pr
eg
na
nc
y
w
it
hi
n
th
e
fi
rs
t
ye
ar
o
fu
se
o
fa
gi
ve
n
co
nt
ra
ce
pt
iv
e
m
et
ho
d
(t
yp
ic
al
an
d
o
pt
im
al
us
ag
e)
,t
o
ge
th
er
w
it
h
th
e
pe
rc
en
ta
ge
o
fc
o
nt
in
ue
d
us
e
af
te
r
1
ye
ar
,t
he
ri
sk
o
ft
hr
o
m
bo
si
s
an
d
o
fi
nf
ec
ti
o
n
as
so
ci
at
ed
w
it
h
th
e
m
et
ho
d’
s
us
e.
M
o
di
fi
ed
fr
o
m
1
3
,1
4
G
ro
up
C
o
nt
ra
ce
pt
iv
e
ty
pe
F
ai
lu
re
(t
yp
ic
al
,%
)
F
ai
lu
re
(o
pt
im
al
,%
)
C
o
nt
in
ue
d
us
e
at
1
ye
ar
(%
)
T
hr
o
m
bo
si
s
ri
sk
In
fe
ct
io
n
ri
sk
H
ig
hl
y
ef
fe
ct
iv
e
(,
1%
)
R
ev
er
si
bl
e
Im
pl
an
t
0.
05
0.
05
84
M
ay
be
sl
ig
ht
ly
in
cr
ea
se
d
ri
sk
M
in
im
al
IU
C
D
0.
2
(L
N
G
)
0.
8
(C
op
pe
r)
0.
2
0.
6
80 78
N
o
in
cr
ea
se
d
ri
sk
T
ra
ns
ie
nt
ba
ct
er
ae
m
ia
at
in
se
rt
io
n,
in
cr
ea
se
d
PI
D
H
ig
hl
y
ef
fe
ct
iv
e
(,
1%
)
Ir
re
ve
rs
ib
le
V
as
ec
to
m
y
0.
15
0.
1
10
0
N
o
in
cr
ea
se
d
ri
sk
Po
st
-o
pe
ra
tiv
e
T
ub
al
O
cc
lu
si
on
0.
5
(a
bd
om
in
al
,l
ap
ar
os
co
pi
c,
or
hy
st
er
os
co
pi
c)
0.
5
10
0
N
o
in
cr
ea
se
d
ri
sk
Po
st
-o
pe
ra
tiv
e
M
od
er
at
el
y
ef
fe
ct
iv
e
(3
–
12
%
)
In
je
ct
ab
le
D
ep
o-
Pr
ov
er
a
3%
C
om
bi
ne
d
in
je
ct
ab
le
3%
D
ep
o-
Pr
ov
er
a
0.
3%
C
om
bi
ne
d
in
je
ct
ab
le
0.
05
%
56
D
ep
o-
pr
ov
er
a:
in
cr
ea
se
d
ri
sk
C
om
bi
ne
d
in
je
ct
ab
le
:
in
cr
ea
se
d
ri
sk
M
in
im
al
,b
ut
no
pr
ot
ec
tio
n
fr
om
PI
D
C
om
bi
ne
d
or
al
co
nt
ra
ce
pt
iv
e
8
0.
3
68
In
cr
ea
se
d
ri
sk
M
in
im
al
,b
ut
no
pr
ot
ec
tio
n
fr
om
PI
D
D
es
og
es
tr
el
co
nt
ai
ni
ng
pr
og
es
te
ro
ne
-o
nl
y
pi
ll
8
0.
3
N
o
in
cr
ea
se
d
ri
sk
M
in
im
al
,b
ut
no
pr
ot
ec
tio
n
fr
om
PI
D
Pa
tc
h
8
0.
3
68
In
cr
ea
se
d
ri
sk
M
in
im
al
,b
ut
no
pr
ot
ec
tio
n
fr
om
PI
D
R
in
g
8
0.
3
68
In
cr
ea
se
d
ri
sk
M
in
im
al
,b
ut
no
pr
ot
ec
tio
n
fr
om
PI
D
Po
or
ly
ef
fe
ct
iv
e
(1
8
–
28
%
)
M
al
e
C
on
do
m
15
2
53
N
o
in
cr
ea
se
d
ri
sk
R
ed
uc
ed
PI
D
D
ia
ph
ra
gm
16
6
57
N
o
in
cr
ea
se
d
ri
sk
R
ed
uc
ed
PI
D
Fe
m
al
e
C
on
do
m
21
5
49
N
o
in
cr
ea
se
d
ri
sk
R
ed
uc
ed
PI
D
Sp
on
ge
16
–
32
(n
ul
lip
ar
ou
s
vs
.p
ar
ou
s)
9
–
20
(n
ul
lip
ar
ou
s
vs
.
pa
ro
us
)
46
–
57
(p
ar
ou
s
vs
.
nu
lli
pa
ro
us
)
N
o
in
cr
ea
se
d
ri
sk
N
o
pr
ot
ec
tio
n
fr
om
PI
D
Sa
fe
Pe
ri
od
25
3
–
5
51
N
o
in
cr
ea
se
d
ri
sk
N
o
pr
ot
ec
tio
n
fr
om
PI
D
W
ith
dr
aw
al
27
4
43
N
o
in
cr
ea
se
d
ri
sk
N
o
pr
ot
ec
tio
n
fr
om
PI
D
Sp
er
m
ic
id
e
29
18
42
N
o
in
cr
ea
se
d
ri
sk
N
o
pr
ot
ec
tio
n
fr
om
PI
D
N
o
co
nt
ra
ce
pt
io
n
85
85
Contraception and cardiovascular disease 1731
 by guest on June 29, 2016
http://eurheartj.oxfordjournals.org/
Downloaded from 
215
Contraception and cardiovascular disease
barrier methods, calendar methods, and withdrawal
Barrier forms of contraception (including condoms, diaphragms, and cervical caps), cal-
endar methods, or withdrawal before ejaculation are usually considered insufficient due 
to their substantial failure rate.13 It consistently seems that humans are not invariably 
rational or practical when passionate. Nevertheless, a male condom protects against 
sexually transmitted diseases in non-monogamous relationships and might prove valu-
able as an additional contraceptive method.
Combined oestrogen and progesterone contraceptives
Combined oestrogen and progesterone contraceptives combine either ethinylestradiol 
or estradiol valerate with various progestins (progestogens). They are mostly used as 
tablets with regular stop periods, but they can be delivered by a vaginal ring, injection, 
or transdermal patch. Combined oral contraceptives are divided in four generations 
depending on the progestin used and the type and dose of the oestrogen component. 
The oestrogen component in combined oral contraceptives significantly increases the 
risk of venous thrombosis (2–7-fold) irrespective of the type of progestin used although 
the risk is small in absolute numbers (8–10/10 000 women-years exposure).15,16 This 
risk of an unplanned pregnancy must be weighed against the risks of the combined 
contraceptives. Besides venous thrombosis, combined oral contraceptives increase the 
risk of arterial thrombosis and hypertension.17,18 Therefore, combined oral contracep-
tives are not recommended (WHO-MEC 3) or even contraindicated (WHO-MEC4) in 
women with cardiac disease (especially those with an increased thrombotic risk, either 
venous or arterial), ischaemic heart disease or hypertension. Combined oral contracep-
tives inhibit ovulation, thicken the cervical mucus, preventing sperm penetration, and 
prevent implantation by altering endometrial receptivity. Theoretically, contraceptive 
efficacy is high, but this is completely dependent on its correct usage.13,19 Some medica-
tion may influence their efficacy. For instance, Bosentan, taken in the management of 
pulmonary hypertension, increases the metabolism of contraceptive steroids, decreas-
ing their efficacy and in this circumstance, a supplementary method, like a condom, 
should be used.11,20,21 Combined oral contraceptives usually improve cycle control by 
making periods regular, less painful, and lighter.22,23 Women often reduce the frequency 
of withdrawal bleeds, by continuous intake for 2 or 3 months.24 Combined oral contra-
ceptives can also be used for the treatment of ovarian cysts, polycystic ovary syndrome, 
and features of mild hyperandrogenism like acne or hirsutism.25
Progesterone-only contraceptives
Progesterone-only methods of contraception come in a variety of formulations. 
Depending on the method used, the contraceptive mechanism of action is a combi-
nation of cervical mucus thickening, preventing sperm penetration, and reduction of 
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endometrial receptivity, preventing implantation. The higher dose formulations also 
inhibit ovulation.19,26-30 Most importantly, progestins probably do not increase the risk of 
thrombosis, although discussion exists, as some papers have reported an increased risk 
of thrombosis in patients using Depo-provera, while others have not.31-34 Progesterone-
only pills, commonly known as ‘mini-pills’ contain various types of progestogens and 
are used daily without a break. Most have a limited efficacy as contraceptive but were 
traditionally used as a contraceptive supplement to lactation.
Desogestrel (Cerazette) containing progesterone-only pill is the only one to effectively 
inhibit ovulation and has a similar safety window (12 h) and contraceptive effectivity as 
the combined oral contraceptives. It is therefore the only progesterone-only pill recom-
mended in women with (severe) cardiac disease.11,20,21,28,35
Depot-medroxyprogesterone acetate (DMPA) can be used for intramuscular or sub-
cutaneous injection and offers contraceptive protection for at least 13 weeks. While 
its effect usually last much longer, adherence to the 13-weekly interval (with a 4-week 
grace period) is recommended in order to be able to rely on its contraceptive efficacy.36
Subdermal implants containing etonogestrel or Levongestrel keep their contraceptive 
efficacy for 3–5 years and are easily inserted after simple local infiltration in the medial 
groove between the biceps and triceps. The rare failures due to unnoticed loss of the 
implant at insertion and problems of implant retrieval at removal with the etonogestrel 
containing implants have largely been overcome by a new inserting device and incor-
poration of a radioactive filament.26,36 A large Danish population study including 1 626 
158 women, suggested a potential slightly increased thrombotic risk with subdermal 
implants (relative risk 1.4).32 However, the study failed to reach statistical significance 
(95% CI 0.6–3.4).and with other studies assessing the influence on haemostatic param-
eters being reassuring, there is little evidence of increased thrombosis risk with their 
use.32,37-39 Prolonged exposure to progestagens induces endometrial atrophic changes. 
This results in an irregular and unpredictable bleeding pattern, often with reduced 
blood loss, duration, and menstrual frequency (occasionally amenorrhea).40-43 However, 
it is also sometimes characterized by continuous spotting.26,44 The exact mechanism 
responsible for this remains to be understood but may be related to vascular fragility of 
the atrophic endometrium. While most women welcome the reduction in vaginal blood 
loss, the unpredictable nature or continuous spotting can be bothersome in others. 
Creating realistic expectations during counselling often greatly contributes to patient 
satisfaction and acceptance of undesirable side effects.29,30,45
Intrauterine contraceptive device and intrauterine system
The two most common forms of reversible intrauterine contraceptives are the banded 
copper containing intrauterine device (copper-IUD) and Levonogestrel-releasing intra-
uterine system (IUS) (Levonogestrel-IUS = Mirena). Copper is toxic to the ova and sperm 
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and the device induces an endometrial inflammation preventing implantation, thereby 
offering safe contraception for 10 years. For the Levonogestrel-IUS, the gradual, local 
release of progesterone induces endometrial atrophy and the formation of a cervical 
mucus plug, which impedes sperm penetration offering safe contraception for 5 years. 
It suppresses ovulation for the 1st two cycles thereafter the cycle returns to normal.46 
Progesterone containing subdermal implants and Levonogestrel-IUS and copper-IUD 
are considered long-acting reversible contraceptives. By eliminating the dependency 
on patient adherence, their efficacy is excellent even exceeding sterilization and fertility 
rapidly returns upon removal.13,26,47
While menstrual blood loss and discomfort might be increased after insertion of a 
copper-IUD, the Levonogestrel-IUS, after a 3–4-month period of irregular light loss, usu-
ally reduces blood loss and, in the majority, results in complete amenorrhea. An IUD can 
be used in both nulli- and parous women and have no effect on thrombogenic risk.48 In-
sertion is facilitated during menstruation, offering immediate contraception , but can be 
performed at any point in the cycle and even postpartum.49 Uterine perforation occurs 
but is rare. The risk of pelvic infection is increased for the 3 months after insertion of IUD 
and women should be warned to report fever or other worrying symptoms promptly. 
Transient bacteraemia has been documented at replacement but is rare during simple 
insertion or removal.50,51 Guidelines for infective endocarditis prophylaxis during place-
ment of these devices has changed considerably over the past decade across Europe 
and Northern America. The most recent recommendations from the American Heart As-
sociation (2008) and the National Institute for Clinical Excellence (2008) no longer advise 
routine use of antibiotic prophylaxis for genito-urinary instrumentation in women with 
cardiac disease (including valvular heart disease, congenital heart disease, and cyanotic 
congenital heart disease) irrespective of their underlying risk of endocarditis, or those 
with a high risk of adverse outcomes associated with endocarditis.52,53 These guidelines 
have been driven by four large randomized trials, which were reviewed in a Cochrane 
collaboration meta-analysis by Grimes et al.54-58 These randomized controlled trials were 
designed to explore the peri-procedural infective risk to the upper genito-urinary tract 
associated with instrumentation during IUD implantation. Pelvic inflammatory disease 
within 90 days was the primary outcomes in all four trials. Other secondary outcomes 
included removal of the IUD (in two of the trials) for reasons apart from ‘spontaneous’ 
expulsion of the device. Unscheduled visits were another secondary outcome mea-
sure. Overall these trials demonstrated that prophylactic doxycycline or azithromycin 
compared with placebo or no treatment conferred additional benefit (OR 0.89 (95% CI 
0.53–1.51).54 Sinei et al.,56 using doxycycline prophylaxis, showed a significant reduction 
in non-scheduled visits following IUD insertion in those having received antiobiotic 
prophylaxis, but failed to show a significant reduction in rates of pelvic inflammatory 
disease following IUD insertion. Ladipo et al.,55 replicating this methodology in a Nige-
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rian population, were unable to demonstrate any difference in unscheduled visits or 
infection following IUD insertion. Walsh et al.57 and Zorlu et al.58 also failed to demon-
strate any significant benefit for prophylactic antibiotics on pelvic inflammatory disease. 
However, a recent retrospective study evaluated the effect on endocarditis prevalence 
associated with the introduction of the new guidelines over the period 2004–13 (i.e. 
before and after introduction of the new guidelines). By March 2013, 35 more cases per 
month of endocarditis were reported than would have been expected.59 These results 
do not establish a causal relationship, but call for further systematic evaluation of the 
specific benefit of antibiotic prophylaxis in high-risk women. Currently, the guidelines 
states that antibiotic prophylaxis for the placement of an IUD or IUS is not recom-
mended, however, the administration of prophylactic antibiotics (ampicillin 2 g and 
gentamicin 80 mg given intravenously 1 h before IUD insertion) prevents bacteraemia 
and may be wise in high-risk women (e.g. with a prosthetic valve) given the increasing 
incidence of endocarditis since introduction of the new guidelines, while endocarditis is 
associated with high morbidity and mortality and the incidence or serious side-effects 
of prophylactic antibiotics is relatively low.60
sterilization
Sterilization in a patient with a contraindication for pregnancy or after a couple has com-
pleted their family is not unreasonable.11,21,61 Vasectomy, is a highly effective approach to 
contraception and poses no risk to a woman with heart disease, but may not be ideal in 
the context of a woman with a high chance of early demise as it compromises the fertil-
ity of the man in eventual future relationships. Laparoscopic or open tubal ligation and 
hysteroscopic insertion of intratubal stents may be the best sterilization option as long 
as the woman understand that such procedures should be considered irreversible. If a 
pregnant woman is to be delivered by caesarean section and has completed her family, 
then the option of a sterilization at the same time should be discussed mentioning that 
the regret and failure rate might be slightly higher and the possibility of reversal lower 
than for the standard laparoscopic approach.62,63 Not unreasonably, many women are 
unwilling to be sterilized as a primary form of contraception, even if they have severe 
heart disease and pregnancy would carry a very high risk.
Some women will struggle to accept the finality of no longer being able to have chil-
dren. There are risks associated with the procedure itself and, although rare, it does have 
a failure rate, and definite adverse effect psychological impact on the patient. Recently, 
the role of sterilization has been reduced by the availability of other highly reliable and 
reversible contraceptive techniques, such as subdermal implants and Levonogestrel-IUS.
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emergency contraception
Emergency contraception can be a valuable back-up in case of unprotected intercourse. 
A single dose of 1.5 mg of Levonogestrel is very efficient with a 1.1% failure rate if taken 
within 72 h after unprotected intercourse.64 Its mechanism of action is mainly through 
delaying ovulation. Therefore, its efficacy is limited once ovulation has occurred.65 A sin-
gle dose of Mifeprostone 25 mg and Ulipristal acetate 30 mg, two progesterone receptor 
modulators, seem to be more effective than Levonogestrel and can be taken up to 120 
h after unprotected intercourse. In addition to the inhibition of ovulation, these agents 
may also prevent implantation and reduce tubal motility.64-66 Besides minor side effects 
like nausea, vomiting, and headache, these methods are generally considered safe, even 
in women with heart disease. Patients should be made aware that menstruation is often 
delayed. The most effective approach remains the insertion of a copper-IUD within 120 
h after intercourse (0.09% failure rate), which, as well as preventing pregnancy, will offer 
long-term contraception.67
Two doses of levonorgestrel (750 mg) have a small effect on blood clotting parameters 
with an increase in fibrinogen at 24 and 48 h and a reduction in anti-thrombin III lasting 
from 2–12 h post treatment (oestrogen-based methods have a more marked effect).68 
However, despite these changes, there was no evidence of an increased risk of throm-
bosis in users of post-coital contraception.69 On the contrary, a case report described 
a potentiation of warfarin by levonorgestrel, perhaps by the displacement of warfarin 
from its main transport protein, α1-acid glycoprotein.70 Indeed, there may exist a strong 
and potentially dangerous interaction between high-dose levonorgestrel and warfarin 
urging the need for extra INR control in the first days. Consequently, it may be better to 
insert a copper IUD for post-coital contraception in a woman taking warfarin.
ConTRaCePTIVe aDVICe In woMen wITH sPeCIfIC CaRDIaC lesIons
There is a paucity of published information and very little evidence about contraception 
in women with all forms of heart disease. These women are a heterogeneous group, 
meaning that risk stratification and contraceptive advice has to be individualized and 
should be based not only on the nature of the cardiac problem, but also on the presence 
of other medical conditions, the age of the woman and her partner, number of previous 
children, cultural and religious beliefs, and individual wishes.
Compromised cardiac function
Pregnancy in women with previously diagnosed idiopathic, familial, or peripartum car-
diomyopathy carries a risk of heart failure and occasionally death. Deterioration of left-
ventricular function is reported in up to 50% of cases in the peripartum period, despite 
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optimal medical therapy.71,72 Maternal mortality figures typically include deaths that 
occur during pregnancy or in the first 42 days after delivery. However, deaths related to 
peripartum cardiomyopathy may occur after this limit and the linkage with the preced-
ing pregnancy lost. The cause of death can be intractable heart failure, sudden death 
due to ventricular arrhythmia or due to a thrombo-embolic event, occurring as a result 
of the poorly contractile left and/or right ventricles.73 Therefore, pregnancy is high-risk 
in women with a left-ventricular ejection fraction (LVEF) below 45% (WHO Class III) and 
is contraindicated if LVEF is below 30% (WHO Class IV).9
In patients with peripartum cardiomyopathy, the occurrence of heart failure has been 
reported even after a termination of pregnancy or stillbirth, further supporting the 
need for reliable contraception to prevent unplanned pregnancies. Therefore, in these 
women, effective contraception is essential and while there is no absolute contraindica-
tion to use of any method, an individualized approach should be taken, which includes 
consideration of the risk of thromboemboli, the use of anticoagulation, and the occur-
rence of arrhythmias. Although some fluid retention may occur, there is no evidence 
that the contraceptive steroid hormones aggravate heart failure. However, combined 
oral contraceptives are contraindicated in women who have a reduced ejection fraction 
after a myocardial infarction, especially when other risk factors, such as smoking and 
hypertension, are present.
Contraception in women with heart disease requiring anticoagulation
Women with mechanical valves, Fontan-circulation, and pulmonary hypertension 
have an increased risk of thrombosis, which is commonly managed using Vitamin K 
antagonists. In these women, the cardiovascular and thrombogenic risks of (unplanned) 
pregnancy often outweigh the inherent risks of most contraceptive methods. However, 
in women on anticoagulation, the incidence of heavy and prolonged menstrual bleed-
ing as well as intermenstrual and postcoital bleeding is increased.7,74,75 They can even 
experience ovarian haemorrhage at ovulation, potentially leading to severe abdominal 
bleeding on a rare occasion.76,77
Both oestrogens and progestins can potentiate the anticoagulative effects of cou-
marines, necessitating a re-evaluation of the INR several weeks after initiation.21,70,78 
Therefore, in the context of a woman taking anticoagulants, a reliable contraceptive 
method without increased thrombotic risk, that reduce menstrual blood loss and inhib-
its ovulation would be most suitable. Progesterone-only methods, especially the long-
acting reversible contraceptives and the Levonogestrel-IUS are therefore the method of 
choice in these women, although being on anticoagulants may increase the tendency 
to irregular bleeding patterns, most women would experience a reduction in vaginal 
blood loss. Indeed, this approach is sometimes used in anticoagulated women solely 
to reduce menstrual blood loss, despite earlier sterilization.40-43 While DMPA injections 
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induces some fluid retention and can be complicated by intramuscular haematoma, it 
rarely seems to be of clinical significance, even in patients on anticoagulation.11,20,21,61 
There are no good data on whether the increased thrombogenic risk of combined oral 
contraceptives is controlled by appropriate anticoagulation.74,79,80 Given this uncertainty, 
and the severe consequences of a thrombotic event in this patient population, most 
guidelines state that combined oral contraceptives are contraindicated (WHO-MEC4) in 
women with a history of thrombosis, a mechanical heart valve (particularly the older 
single leaflet valves like the Bjork Shiley or Starr Edwards), Fontan operation, cyanotic 
heart disease, pulmonary hypertension, coronary artery disease, or atrial fibrillation 
despite appropriate anticoagulation.10-12,21 Nevertheless, there is debate among experts 
about these recommendations as scientific support is lacking and combined oral con-
traceptives offer important non-contraceptive benefits such as improved cycle control, 
particularly in women who wish to discontinue progesterone-only methods due to 
unpredictable bleeding.61,81
While certainly not first choice, we believe that combined oral contraceptives can be 
considered in these women after appropriate counseling.
Contraceptive interventions in high-risk women
The pain and cervical manipulation during insertion and removal of an IUD can elicit 
a vagal reaction in as many as 5% of women.11,20,21,61,79,82 While this is usually benign in 
most women, it is potentially dangerous in those with pulmonary hypertension or a 
Fontan repair. Consequently, we recommend that insertion and removal of an IUD in 
these women occurs in a setting with cardiovascular monitoring, with anaesthetic sup-
port on standby, and using appropriate pain relief, either paracervical block or systemic 
opioids, to prevent a vagal reaction. Taking this into account, Levonogestrel-IUS may 
therefore be less suited in these women when compared with subdermal implants. 
Subdermal implants have a superior contraceptive efficacy to sterilization and are eas-
ily inserted, only requiring local anaesthetic and are a very option for women with a 
mechanical valves, pulmonary hypertension, or Fontan repair.11,20,21,26,29,31,61,83 As in the 
case of desogestrel containings progresterone-only-pills, these subdermal implants 
require an additional contraceptive measures in women taking Bosentan. Sterilization 
through laparoscopic tubal ligation requires the creation of a pneumoperitioneum and 
is therefore contraindicated in women with pulmonary hypertension or Fontan repair. 
If desired, an open or laparoscopic procedure with minimal inflation under general, spi-
nal/epidural, or even local anaesthesia can be considered, but it also requires temporary 
cessation of the anticoagulation and contains a procedure inherent risk of haemorrhage 
and thrombosis.11,21,61,84
The new methods of tubal occlusion, achieved by hysteroscopic insertion of tubal 
stents, have been used successfully in a group of women with severe heart disease and 
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may be a good option. Ultrasound assessment of tubal patency after several months is 
required before effective contraception can be expected.21,61,85-87 As for IUD insertion, 
antibiotic coverage can be considered despite the current guidelines and adequate 
monitoring and pain relief to prevent an eventual vagal reaction should be assured in 
these women. Sterilization does not offer the non-contraceptive benefits (e.g. reduc-
tion in menstrual blood loss) of other methods. With the contraceptive efficacy of 
Levonogestrel-IUS and subdermal implants implants exceeding that of sterilization, the 
indications for the latter is limited in this patient population.
Contraception in women with arrhythmias
Women with arrhythmias often use medication that is teratogenic (i.e. amiodarone), 
consequently, effective contraception is essential. When a change of antiarrhtyhmic 
medication is decided upon, it should be implemented when the mother is still using 
contraception, since this allows time to judge the tolerance and effectiveness of the new 
medication. In the case of anticoagulant medication, the change can be made in early 
pregnancy.
A small increase in heart rate was demonstrated in women using oestrogen-containing 
contraceptives,88 but not with oestradiol alone.89 Theoretically, an increase in heart rate 
could reduce myocardial perfusion and promote cardiac arrhythmias, however, the rise 
in heart rate in these studies was minor and is therefore unlikely to be of clinical signifi-
cance. There is no other evidence that contraception of any kind triggers the occurrence 
of arrhythmias. Therefore, the most important issue is the elevated thrombo-embolic 
risk with use of combined contraceptives in women with an arrhythmia. In women with 
isolated arrhythmias (i.e. isolated supraventricular or ventricular extra beats, AVNT, or 
VT’s in long QT-syndrome), combined contraceptives can be used. However, when atrial 
flutter or fibrillation is present, either paroxysmal or permanent, caution in the use of 
combined hormonal contraceptives is advised, because of elevated risk of thrombo-
embolism (WHO-MEC 3).11,61,90,91
ConClUsIon
Contraception is a delicate, sometimes difficult issue, which carries many ethical, moral, 
and medical dilemmas. Contraceptive counselling should begin early, and the choice of 
method based on the impact of (an unplanned) pregnancy, the risks, and benefits of the 
contraceptive type and the individual’s preferences. Complex cases will require the input 
of both a cardiologist and an obstetrician and the absence of any good quality studies 
mean that the decision is almost always based on expert opinion. In many situations, the 
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ease of use and efficacy of the progestogen-only long-acting reversible contraceptive 
methods make them a good method for patients with cardiovascular disease.
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DIsCUssIon
In this thesis we assessed the potential of non-invasive hemodynamic monitoring in 
pregnant women. Normal pregnancy is accompanied by substantial hemodynamic 
changes which are necessary to permit the normal development of a fetus. In healthy 
pregnant women the cardiovascular system is already intensely challenged 1, 2. It is even 
more so in most pregnancy complications or in women with pre-existent cardiovascular 
disease. In fact, the cardiovascular system is predominantly implicated in all major 
causes of maternal and fetal mortality and severe morbidity being either hypertensive 
disease, fetal growth restriction, cardiac disease, sepsis, hemorrhage or preterm birth 
3-9. While its importance is well acknowledged, the cardiovascular system is not as in-
tensively studied as often assumed. Many beliefs on cardiovascular adaptation which 
are commonly accepted in research and relied on in clinical practice are based on old 
data using dated techniques in small number of subjects. As an example, current ideas 
on changes in cardiac output during labor and delivery are almost exclusively based 
on echocardiographic continuous wave Doppler measurements obtained at the pul-
monary valve in 15 women and published in 1987 10. Also, the level of hemodynamic 
monitoring is usually rather basic in pregnant women, even in complex conditions. In 
mothers, blood pressure and pulse oximetry are currently often used as sole surrogates 
of the cardiovascular condition. In the fetus, monitoring is mostly limited to umbilical 
and middle cerebral artery Dopplers along with fetal heart rate monitoring. While these 
parameters are evidently important, they merely offer a crude reflection of the feto-
maternal cardiovascular condition. This might have contributed to the fact that progress 
in our understanding and management of these complex conditions has been limited 
in the last two decades.
Advances in the care for pre-eclampsia have mainly been achieved by a policy of dam-
age control along with improvements in neonatal care. Maternal complications have 
decreased thanks to stricter blood pressure control, liberal use of magnesium sulphate 
and lower threshold for delivery but no substantial breakthrough has been achieved in 
altering the disease course 11, 12. In growth restriction, advanced fetal monitoring strate-
gies incorporating heart rate variability and venous Dopplers have failed to show their 
superiority and experiences with interventions to improve placental perfusion show 
conflicting results 13. Fluid and transfusion protocols in postpartum hemorrhage and 
puerperal sepsis are still usually based on local tradition or expert opinion at best, but 
are rarely hemodynamically guided according to the individual patient needs.
Pioneer work from the late forties until the seventies of last century using invasive 
catheterization and dye dilution techniques explored the substantial changes in cardiac 
output, stroke volume and vascular resistance that accompany normal pregnancy in 
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experimental settings 14-20. With the availability of Swan-Ganz catheters, invasive moni-
toring of maternal hemodynamics was introduced in clinical obstetrics in the eighties 
and nineties 9, 21-33. These experiences greatly contributed to our current pathophysi-
ological understandings and pointed towards the potential of hemodynamic monitor-
ing in the management of critically ill pregnant women. Hemodynamic guided fluid 
management and treatment showed its benefits in women with severe pre-eclampsia, 
pulmonary edema and oliguria 22, 25. However their invasive nature limited their use to 
only a few severe conditions. After the controversies about increased mortality with 
their use in intensive care settings, the enthusiasm for Swan-Ganz catheters faded in 
obstetrics around the millennium change 34-37. Doppler ultrasound then promised to be 
an non-invasive alternative for hemodynamic monitoring 38-41. While Doppler echog-
raphy of the uteroplacental and fetal vasculature became the cornerstone for both 
scientific and clinical assessment of fetal hemodynamics, maternal echocardiography 
remained a non-invasive research alternative for dedicated aficionados only, but failed 
to reach widespread popularity in clinical obstetrics 42-45. Alternative techniques like 
bio-impedance and pulse contour analysis are not commonly used either as validation 
in pregnancy remained an issue due to a lack of an available comparative gold standard 
46-48. Yet the previous experiences with invasive techniques in severe conditions clearly 
suggest the potential of non-invasive hemodynamic monitoring, which could be used 
in a larger population.
In this thesis we initially validate cardiac output measurements using transthoracic 
echocardiography against the gold standard of pulmonary artery catheterization in 
pregnant women 49. With cardiac output being the most prominent parameter of cardiac 
function, it highlights the feasibility and potential of transthoracic echocardiography for 
non-invasive hemodynamic monitoring. Importantly it also offers a new golden stan-
dard for validation and introduction of newer techniques for hemodynamic monitoring 
in pregnancy. The validation issue in the absence of an applicable gold standard, which 
has too often been the subject of discussion amongst interested can now be resolved. 
The potential of magnetic resonance is addressed for analysis of cardiac function in 
general and of the important but often neglected right heart in particular 50, 51. Detailed 
volume analysis by MRI of both left and right atria and ventricles permits to deduct the 
respective contribution of caval (preload) and aortic (afterload) compression by the 
gravid uterus in dorsal decubitus with advancing pregnancy.
Sidestream Darkfield Imaging ( SDF) is introduced and validated for the assessment 
of the microvascular perfusion in pregnant women 52. The microcirculation is the larg-
est compartment of the cardiovascular system and the site where its ultimate goal, the 
exchange of oxygen, nutrients and fluid for carbon dioxide and waste products with 
cells takes place. In severe pre-eclamptic women, we show that microvascular perfu-
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sion is unaffected despite major macrovascular disturbances. It reflects the complex 
interaction between the micro- and macrocirculation, which is characteristic for hemo-
dynamic unstable conditions. It also revealed microcirculatory perfusion disturbances 
in women with HELLP syndrome which concur with the capricious pathophysiology of 
the condition. The non-invasive macrovascular (transthoracic echocardiography) and 
microvascular (SDF) techniques for maternal cardiovascular evaluation are combined 
and detailed uteroplacental and fetal Dopplers added. As such a hemodynamic profile is 
created. It offers a global picture of the pregnant woman and her products of conception 
in addition to a view on the complex interactions between these individual components 
of the challenged cardiovascular tree. The importance of this concept of non-invasive 
hemodynamic profiling in investigating and managing several pregnancy complica-
tions and its feasibility in both healthy and diseased pregnant women is demonstrated. 
Despite the absence of apparent changes in blood pressure, nifedipine tocolysis induces 
a substantial drop in vascular resistance in normotensive pregnant women 53. A com-
pensatory rise in cardiac output sustains the rest of the cardiovascular function and the 
uteroplacental and fetal perfusion in healthy women. It offers a detailed answer to the 
long debated cardiovascular risks and safety of nifedipine tocolysis . The same concept 
is applied for a detailed investigation of the hemodynamic effects of nicardipine in 
severe pre-eclamptic women with a hypertensive crisis 54. The selective nature of the 
arterial relaxation and compensatory increase in cardiac output allow effective and safe 
blood pressure reduction while maintaining maternal cardiac function as well as uterine, 
microvascular, placental and fetal perfusion.
In women with heart disease, cardiovascular function along with uteroplacental 
perfusion and the interactions between them are investigated in both a single center 
and nationwide cohort 55, 56. Cardiovascular adaptation to pregnancy is attenuated with 
a blunted rise in cardiac output, signs of progressive systolic and diastolic dysfunction 
and decreased uteroplacental perfusion. A relation between reduced cardiac function 
and impaired uteroplacental flow is established which is associated with adverse ob-
stetric and neonatal outcomes. It still remains to be answered which pathophysiological 
mechanisms leads to the impairment in uteroplacental perfusion. Is it either a defective 
placentation occurring early in pregnancy, a mismatch between a failing cardiovas-
cular perfusion potential and increasing placental perfusion requirements that occur 
with advancing gestation or a combination of both? Nevertheless, both studies show 
substantially increased incidences of cardiac, pregnancy or offspring complications in 
women with heart disease. Assessment of pregnancy outcomes in women with aortic 
valve substitutes in particular highlight the increased complication rate with mechani-
cal valves 57. As such, human tissue valves, despite their limited sustainability, should 
strongly be considered when counseling young non-pregnant women for optimal 
aortic valve substitutes. Optimal preconception care in women with heart disease also 
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includes appropriate contraceptive advise. It requires an individual approach taking 
effectivity, safety, the particularities of the specific cardiac condition and the women’s 
preferences into account. It is often complex and is best attended in time by a dedicated 
multidisciplinary specialized team. Our review offers guidance on the subject 58.
All our studies showed that ultrasound is the cornerstone for maternal, uteroplacental 
and fetal hemodynamic assessment. While uteroplacental and fetal ultrasound are well 
integrated into daily obstetric routine, maternal ultrasound is much less so and merits 
specific attention. The available obstetric ultrasound devices can easily be upgraded 
with cardiovascular software and probes. Given the similarities with fetal echocardiogra-
phy, training of feto-maternal specialists is within reach. It would well fulfill with the true 
meaning of this subspecialty name. Along with obstetric anesthesiologists, maternal 
medicine internists, congenital cardiologists and neonatal intensivist they can form a 
dedicated feto-maternal critical care team where one a can further share and exchange 
ones expertise on an equivocal base. It also enables the further development of the field 
of Obstetric Critical Care. Finally maternal cardiovascular ultrasound protocols drafted 
and endorsed by the obstetric cardiovascular and ultrasound societies would further 
help to promote and implement maternal cardiovascular ultrasound into obstetric care.
Our studies in normal pregnant women, pre-eclamptic women and women with 
cardiac disease also showed that that the concept of hemodynamic profiling can help 
to elucidate the complex interactions between the several components of the cardio-
vascular tree.
Therefore it has a potential for permitting breakthroughs in the study and manage-
ment of various pregnancy complications. This approach could be employed to address 
research questions in various domains like comparisons of different hypertensive drugs, 
effects of NO donors in fetal growth restriction or optimal amount of fluids required in 
postpartum hemorrhage and puerperal sepsis.
Still, this profile is neither yet offering a complete overview nor is it easily obtained. 
Cardiac and advanced obstetric ultrasound are operator and hardware dependent. They 
also provide single or intermittent measurements. Despite improvements with succes-
sors (Incident Dark Field (IDF)) of the SDF, analysis of microcirculatory images still remains 
time consuming 59, 60. As such the concept needs further fine tuning and evolution. Dop-
plers from other core organs like the brain, kidneys and liver and venous system could 
relatively easily be obtained with the available systems and incorporated in the concept 
61-63. With evolutions in ultrasound devices probably being comparable to evolutions 
in personal computers, we have by far not employed the full potential offered by the 
newer generation ultrasound systems. Tissue Doppler and speckle tracking can help to 
quantify ventricular function independent of load and to reveal subtle differences 6, 64-67. 
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The former is important considering the continuous changes in loading conditions with 
evolving pregnancy. The relevance of the latter lies in the knowledge that subtle sub-
clinical diastolic dysfunction often precedes later overt failure 68. Epidemiological data 
show that pregnancy complications like pre-eclampsia, despite apparent postpartum 
recovery, remain associated with an increased risk of cardiovascular disease later in life 
69, 70. Recent studies using advanced echocardiography unmasked persistent systolic 
and diastolic dysfunction despite apparent clinical recovery after severe pre-eclampsia 
68, 71. It is still unknown whether pre-eclampsia is a symptomatic expression revealed by 
the cardiovascular stress of pregnancy or the cause of this increased cardiovascular risk. 
Either way, it offers a window of opportunity for screening and targeted interventions 
in these women.
While tissue Doppler and speckle tracking become mainstream in adult cardiology 
they still remain experimental in fetal cardiac assessment 72. Given the clear limitations 
of current uteroplacental and fetal Dopplers and changing loading conditions during 
fetal life, these techniques might have an additional potential in reflecting fetal wellbe-
ing, cardiac adaptation to chronic stress and response to medication 73.
Like women, pregnancy and its complications can be intriguingly complex. Despite 
some apparent similarities, the wide pallet of subtle interactions and interindividual 
variations which make them interesting can also render them difficult to understand and 
unpredictable, even for dedicated professionals. Hoping for simple solutions is therefore 
not realistic or fair. It is unlikely that evident changes in occasional measurements of 
a single parameter will offer a comprehensive answer. However, there could be a role 
for continuous concurrent measurements of several maternal, uteroplacental and fetal 
macro- and microvascular parameters, taking the concept of hemodynamic profiling to 
a next level. Dynamic trends and subtle changes can be observed within the individual. 
Large amounts data can be dredged and analyzed with modern software for apparent 
discrete but significant patterns and interactions. A personalized medicine approach is 
reached by assessing variations within one’s individual profile. Ideally these parameters 
should be obtained with an non-invasive, continuous, easy to use, affordable, validated 
and operator independent method. Collection of basic physiological parameters like 
heart rate, blood pressure and arterial oxygen saturation are already common but physi-
cal connection to a device usually limits the subjects mobility. Continuous registration in 
different settings would allow to assess variability, reactivity and interaction with other 
parameters and rule out white coat interference. This will be facilitated by the explosion 
in the evolution of mobile smart devices and apps in the form of wearables like watches, 
glasses, lenses, clothes and chips. Besides peripheral arterial blood pressure, pulse wave 
analysis of peripheral artery wave form also permits the calculation of central blood 
pressure and markers of vascular stiffness like pulse wave velocity, augmentation index 
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and to estimate cardiac output. For cardiac output measurements the third generation 
bio-impedance devices equally seem promising. Measurements can be obtained with 
minimal discomfort by simple application of chest electrodes. The signal quality and sta-
bility is sufficient for use during intense efforts and a wireless design permits measure-
ments in ambulant subjects. As such, it does not require the presence of a high skilled 
health worker and can be used in a variety of situations and populations like laboring 
women, obstetric critical care settings, standard obstetric wards or healthy pregnant 
women. Validation can now be performed against transthoracic echocardiography in 
pregnant women and facilitated by comparing changes within the individual rather 
than absolute values. Inclusion of continuous cerebral monitoring is possible thanks to 
new devices allowing continuous cortical oximetry using NIRS and simultaneous EEG 
recordings with only a few sensors applied on the forehead. Continuous microvascu-
lar tissue perfusion and oxygen supply can be investigated with the O2C technology 
combining laser Doppler flow and tissue spectrophotometry in a single small probe. 
Rapid progressions also occur in the development of wearable electrodes or chips that 
allow, easy and continuous fetal heart rate monitoring while being mobile (Pure trace®, 
Monica Novii®, Pregsense®, Modoo®,…). By improving filtering techniques, additional 
information on fetal heart rate variability and fetal ECG becomes realistic.
With current smartphones capacities surpassing most older PCs, all these wireless 
measured physiological parameters could be recorded, stored, and integrated on them. 
As such, besides in acutely ill, hospital bed bound patients, continuous hemodynamic 
profiling could soon be employed for less severe conditions and in an ambulatory set-
ting.
In conclusion this thesis shows that ultrasound becomes indispensable for advanced 
and integrated feto-maternal medicine and research. It permits non-invasive hemody-
namic profiling which encompasses both the mothers’, uteroplacental and fetal circula-
tory system and thus offers a complete overview. This concept can be used to unravel 
pathophysiological mechanisms, monitor treatment or to predict outcome. A multitude 
in evolutions of devices for wireless and continuous monitoring offers new perspec-
tives to further integrate hemodynamic profiling in obstetric care, in- and outside the 
hospital. It could take the concept of hemodynamic profiling to a next level.
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Summary
sUMMaRy
This thesis addresses the hemodynamics in several pregnancy complications. After the 
introduction (chapter 1), we start in chapter 2 by providing a general overview of normal 
hemodynamic adaptation to pregnancy. In order to permit a successful pregnancy out-
come for both mother and child, the cardiovascular system must undergo substantial 
changes during pregnancy, labor, delivery and in the postpartum period. In chapter 2.1 
adaptations in the various components of the cardiovascular tree during normal preg-
nancy are described in detail. In chapter 2.2 we further focus on the microcirculation. 
It is the largest albeit a lesser studied component of the cardiovascular system. Here, 
exchange of oxygen and nutrients for carbon dioxide and waste products with tissues 
takes place, which is the ultimate goal of circulation. In this chapter we describe the 
anatomy and physiology of the microcirculation along with the techniques, importance 
and potential of microvascular assessment in pregnant women.
In chapter 3 several techniques of non-invasive cardiovascular monitoring are ad-
dressed. In a meta-analysis of combined data from a prospective trial and systematic 
review, cardiac output measurements using transthoracic echocardiography showed 
excellent agreement with pulmonary artery catheterization in pregnant women (chap-
ter 3.1). These results offer the opportunity to consider transthoracic echocardiography 
as an alternative reference technique. In chapter 3.2, the effects of left lateral and supine 
positioning on maternal cardiac function are described in each trimester of pregnancy. 
By using the ability of cardiac magnetic resonance to accurately assess cardiac volumes, 
the respective contributions of caval obstruction and aortic compression by the gravid 
uterus are determined.
In chapter 4 we address the potential of cardiovascular profiling by combining cardiac 
and obstetric ultrasound for maternal, uteroplacental and fetal hemodynamic monitor-
ing in several pregnancy complications. The profile is further elaborated by including 
sidestream darkfield imaging to assess microvascular perfusion.
In chapter 4.1 we show that nifedipine tocolysis induces profound hemodynamic 
changes. A substantial reduction in systemic vascular resistance is balanced by an op-
posing rise in cardiac output thereby maintaining blood pressure, uteroplacental and 
fetal perfusion (chapter 4.1). In severe pre-eclamptic women with a hypertensive crisis, 
nicardipine effectively reduces blood pressure through selective afterload reduction. A 
compensatory increase in cardiac output assures uteroplacental, fetal and microvascu-
lar perfusion. This hemodynamic response is uniform and predictable (chapter 4.2). In 
chapter 4.3 we validated sidestream darkfield imaging in obstetrics. We did not observe 
major differences in sublingual microcirculatory perfusion between women with severe 
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pre-eclampsia and healthy pregnant controls. However HELLP syndrome is character-
ized by impaired capillary perfusion.
In the fifth chapter we focus on women with cardiac disease. With improvements in 
in medical and surgical care, most women with heart disease reach reproductive age. In 
chapter 5.1, a general overview is provided of pregnancy and delivery management in 
these women. A retrospective study reflecting 25 years of experience showed that car-
diac and obstetric problems frequently complicate pregnancies of women with aortic 
valve replacements. As these complications occur more often with mechanical valves, 
human tissue valves should be considered in young women (chapter 5.2). By using 
obstetric and cardiac ultrasound we show in chapter 5.3 that the characteristic pattern 
of hemodynamic adaptation to pregnancy is attenuated in women with structural heart 
disease. The pregnancy related volume load induces progression of diastolic dysfunc-
tion. Our data also suggest a persistent reduction in systolic and diastolic cardiac func-
tion after pregnancy in women with structural heart disease. Uteroplacental Doppler 
flow is impaired in women with heart disease. This impairment is associated with certain 
parameters of cardiac function. Obstetric and off spring complications frequently oc-
cur in women with heart disease and are often related to uteroplacental dysfunction 
(chapter 5.4). Preventing unintended pregnancies is equally important in women with 
heart disease. Early personalised contraceptive advise by a multidisciplinary team, 
where efficacy, inherent risks and benefits are evaluated in relation to the particularities 
of the cardiac condition and the women`s individual preference should be considered 
as an integral part of standard treatment. In many situations, progestogen-only long-
acting reversible contraceptives are most suited for women with cardiovascular disease 
(chapter 5.5).
In chapter 6 we discuss our findings. With continuous evolutions and innovations in 
techniques for hemodynamic monitoring, we reflect on the potential of hemodynamic 
profiling in the near future. Finally, an English and Dutch summary is provided in chapter 
7.
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Samenvatting
saMenVaTTIng
Dit proefschrift beschrijft de hemodynamiek bij verschillende zwangerschapscomplica-
ties. Na de introductie (hoofdstuk 1) wordt in hoofdstuk twee een algemeen overzicht 
gegeven van de normale hemodynamische adaptatie aan de zwangerschap. Tijdens de 
zwangerschap, durante partu en in het kraambed moet het cardiovasculaire systeem 
substantiële veranderingen ondergaan om een goede uitkomst voor moeder en kind te 
realiseren. In hoofdstuk 2.1 worden aanpassingen in de verschillende componenten van 
het cardiovasculaire systeem gedurende de normale zwangerschap in detail beschre-
ven. In hoofdstuk 2.2 wordt er toegespitst op de microcirculatie. Het is de grootste maar 
minder bestudeerde component van het cardiovasculaire systeem. Ter hoogte van de 
weefsels wordt hier zuurstof en nutriënten uitgewisseld voor koolstofdioxide en afval-
producten; in essentie het ultieme doel van de circulatie. In dit hoofdstuk worden naast 
de anatomie en fysiologie van een microcirculatie ook de verschillende technieken, het 
belang en potentieel van microvasculair onderzoek bij zwangere vrouwen aangekaart.
Hoofdstuk 3 gaat over verschillende technieken voor non-invasieve cardiovasculaire 
monitoring. In een meta-analyse die gegevens combineert van een prospectief onder-
zoek en een systematische review, tonen we aan dat cardiac output bepalingen door 
middel van transthoracale cardiografie zeer goed overeen stemmen met metingen ver-
kregen door catheterisatie van de pulmonaal arterie bij zwangere vrouwen (hoofdstuk 
3.1). Deze resultaten laten ons nu toe om transthoracale echocardiografie als alternatieve 
referentie techniek te beschouwen. In hoofdstuk 3.2 worden de effecten van rugligging 
en linker zijligging op de maternale cardiale functie beschreven in elk trimester van de 
zwangerschap. De eigenschap van cardiale magnetische resonantie om nauwkeurig 
volumes te bepalen wordt aangewend om de respectievelijk contributie van vena cava 
obstructie en aorta compressie door de zwangere uterus in kaart te brengen.
In hoofdstuk vier wordt het potentieel van cardiovasculaire profilering aangekaart. 
Cardiale en obstetrische echografie worden gecombineerd voor maternale, uteropla-
centaire en foetale hemodynamische monitoring bij verschillende zwangerschapscom-
plicaties. Het profiel wordt verder aangevuld met sidestream darkfield imaging voor 
onderzoek van de microvasculaire perfusie.
In hoofdstuk 4.1 tonen we aan dat tocolyse met nifedipine belangrijke hemody-
namische veranderingen induceert. Een substantiële reductie van de systemische 
vasculaire weerstand wordt opgevangen door een stijging in cardiac output waardoor 
de bloeddruk, uteroplacentaire en foetale perfusie behouden blijven. Bij ernstige pre-
eclamptische vrouwen met een hypertensieve crisis wordt de bloeddruk met nicardipine 
effectief verlaagd door selectieve afterload reductie. Een compensatoire toename in 
cardiac output verzekert de uteroplacentaire, foetale en microvasculaire perfusie. Deze 
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hemodynamische respons is uniform en voorspelbaar (hoofdstuk 4.2). In hoofdstuk 4.3 
valideren we sidestream darkfield imaging in de obstetrie. Er werden geen majeure ver-
schillen geobserveerd in de sublinguale microcirculatoire perfusie tussen vrouwen met 
ernstige pre-eclampsie en gezonde zwangere controles. Het HELLP-syndroom wordt 
gekenmerkt door een verstoorde capillairen perfusie.
Het vijfde hoofdstuk gaat over vrouwen met een hartziekte. Door verbetering in 
medische en heelkundige zorg bereiken de meeste vrouwen met een hartziekte de 
vruchtbare leeftijd. In hoofdstuk 5.1 wordt een algemeen overzicht aangeboden over 
het beleid tijdens de zwangerschap en de bevalling bij deze vrouwen. Een retrospectief 
onderzoek over 25 jaar toont aan dat cardiale en obstetrische problemen frequent op-
treden bij zwangere vrouwen met aortaklep vervanging. Aangezien deze complicaties 
vaker voorkomen bij mechanische kleppen, moeten humane weefselkleppen ernstig in 
overweging worden genomen bij jonge vrouwen met potentiële kinderwens (hoofdstuk 
5.2). Aan de hand van obstetrische en cardiale echografie tonen we in hoofdstuk 5.3 aan 
dat het karakteristieke patroon van hemodynamische adaptatie aan de zwangerschap is 
afgevlakt bij vrouwen met structurele hartziekte. De volume belasting door de zwanger-
schap induceert een toename in diastolische dysfunctie. Onze bevindingen suggereren 
ook dat de reductie in systolische en diastolische functie persisteert na de zwanger-
schap. Uteroplacentaire Doppler flow is gestoord bij vrouwen met hartziekte. Deze ver-
storing is geassocieerd met bepaalde cardiale parameters. Obstetrische complicaties en 
complicaties bij de kinderen komen frequenter voor bij vrouwen met hartziekte en zijn 
vaak gerelateerd aan de uteroplacentaire dysfunctie (hoofdstuk 5.4). Het voorkomen 
van een ongeplande zwangerschap is belangrijk bij vrouwen met hartziekte. Het vereist 
een vroeg en gepersonaliseerd contraceptief advies door een multidisciplinair team. 
Hierbij worden effectiviteit, inherente risico’s en voordelen meegenomen evenals de 
bijzonderheden van de cardiale conditie en de persoonlijke voorkeur van de vrouw. Dit 
gewogen contraceptief advies maakt integraal deel van de standaard zorg voor vrouwen 
met een hartziekte. Vaak zijn reversibele, lang werkende contraceptieve methodes die 
enkel progesteron bevatten het meest aangewezen voor vrouwen met een hartziekte.
In hoofdstuk zes worden de bevindingen bediscussieerd. Gezien de continue evolutie 
en innovatie in technieken voor hemodynamische monitoring, reflecteren we op het 
potentieel van hemodynamische profilering in de nabije toekomst. Hoofstuk zeven 
bestaat uit een Engelse en Nederlandse samenvatting.
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